Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9231345,elimination half-lives,IgG elimination half-lives ranged from 5.33 to 8.10 days.,"Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231345/),d,5.33 to 8.10,106,DB00028,Intravenous Immunoglobulin
,1665488,half-lives,"When those conjugates were administered intravenously to mice, the half-lives of SOD activity in the circulation were 29 and 42 h for SOD-(Fc)1 and SOD-(Fc)n, respectively, while free SOD had a half-life of 5 min.",Conjugates of superoxide dismutase with the Fc fragment of immunoglobulin G. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665488/),h,29,2625,DB00028,Intravenous Immunoglobulin
,1665488,half-lives,"When those conjugates were administered intravenously to mice, the half-lives of SOD activity in the circulation were 29 and 42 h for SOD-(Fc)1 and SOD-(Fc)n, respectively, while free SOD had a half-life of 5 min.",Conjugates of superoxide dismutase with the Fc fragment of immunoglobulin G. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665488/),h,42,2626,DB00028,Intravenous Immunoglobulin
,1665488,half-life,"When those conjugates were administered intravenously to mice, the half-lives of SOD activity in the circulation were 29 and 42 h for SOD-(Fc)1 and SOD-(Fc)n, respectively, while free SOD had a half-life of 5 min.",Conjugates of superoxide dismutase with the Fc fragment of immunoglobulin G. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665488/),min,5,2627,DB00028,Intravenous Immunoglobulin
,24892422,duration of response,"Median duration of response was 10.0 days, with an overall reduction in bleeding episodes.",Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892422/),d,10.0,3538,DB00028,Intravenous Immunoglobulin
,24892422,peak concentration (Cmax),"Gammaplex provided supranormal concentrations of total IgG; mean peak concentration (Cmax) of 45.3 g/L (4.53 g/dL), with a mean half-life of 28.5 days.",Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892422/),[g] / [l],45.3,3539,DB00028,Intravenous Immunoglobulin
,24892422,half-life,"Gammaplex provided supranormal concentrations of total IgG; mean peak concentration (Cmax) of 45.3 g/L (4.53 g/dL), with a mean half-life of 28.5 days.",Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892422/),d,28.5,3540,DB00028,Intravenous Immunoglobulin
,25789616,half-life (t1/2),Plasma GSK933776 half-life (t1/2) was 10-15 days after repeat dosing.,"First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25789616/),d,10-15,5814,DB00028,Intravenous Immunoglobulin
≤,25789616,peak:trough ratio,For total Aβ42 the peak:trough ratio was ≤2 at doses ≥3 mg/kg; for total Aβ the ratio was ≤2 at 6 mg/kg.,"First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25789616/),,2,5815,DB00028,Intravenous Immunoglobulin
≤,25789616,ratio,For total Aβ42 the peak:trough ratio was ≤2 at doses ≥3 mg/kg; for total Aβ the ratio was ≤2 at 6 mg/kg.,"First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25789616/),,2,5816,DB00028,Intravenous Immunoglobulin
,25248882,half-life,"The half-life was 4.9 days, and the area under the curve (AUC) and maximum concentration (Cmax) increased proportionally with dose.","A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248882/),d,4.9,7717,DB00028,Intravenous Immunoglobulin
,25200415,terminal half-life,QGE031 had a biexponential pharmacokinetic profile after intravenous administration and a terminal half-life of approximately 20 days.,"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25200415/),d,20,10226,DB00028,Intravenous Immunoglobulin
,31847720,Ctrough levels,Ctrough levels achieved ranged 7.96-10.05 g/L.,Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g] / [l],7.96-10.05,11376,DB00028,Intravenous Immunoglobulin
,31847720,Cmax,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g] / [l],16.60,11377,DB00028,Intravenous Immunoglobulin
,31847720,Cmax,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g] / [l],14.20,11378,DB00028,Intravenous Immunoglobulin
,31847720,Cmin,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g] / [l],10.60,11379,DB00028,Intravenous Immunoglobulin
,31847720,Cmin,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g] / [l],8.53,11380,DB00028,Intravenous Immunoglobulin
,31847720,AUC0-last,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g·h] / [l],5971,11381,DB00028,Intravenous Immunoglobulin
,31847720,AUC0-last,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g·h] / [l],6591,11382,DB00028,Intravenous Immunoglobulin
,31847720,dAUC,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g·h] / [l·mg],0.41,11383,DB00028,Intravenous Immunoglobulin
,31847720,dAUC,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[g·h] / [l·mg],0.46,11384,DB00028,Intravenous Immunoglobulin
,31847720,CL,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[ml] / [h],2.53,11385,DB00028,Intravenous Immunoglobulin
,31847720,CL,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),[ml] / [h],2.53,11386,DB00028,Intravenous Immunoglobulin
,31847720,Tmax,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),h,1.19,11387,DB00028,Intravenous Immunoglobulin
,31847720,Tmax,"Mean (SD [not applicable for 3-weekly data]) PK parameters: Cmax, 16.60 and 14.20 (5.53) g/L; Cmin, 10.60 and 8.53 (3.89) g/L; AUC0-last, 5971 and 6591 (2633) g*h/L; dAUC, 0.41 and 0.46 (0.19) g*h/L/mg; CL, 2.53 and 2.53 (1.00) mL/h and median Tmax was 1.19 and 1.14 h, for 3-/4-weekly dosing regimens, respectively.",Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847720/),h,1.14,11388,DB00028,Intravenous Immunoglobulin
,7714737,Keq,The purified antibodies have been shown to have high affinity (Keq range: 1.8 x 10(8) to 8.75 x 10(9) M-1) and high selectivity for methotrexate.,"High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),1/[M],1.8 x 10(8),14733,DB00028,Intravenous Immunoglobulin
,7714737,Keq,The purified antibodies have been shown to have high affinity (Keq range: 1.8 x 10(8) to 8.75 x 10(9) M-1) and high selectivity for methotrexate.,"High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),1/[M],8.75 x 10(9),14734,DB00028,Intravenous Immunoglobulin
,7714737,steady state volume of distribution,"Preliminary pharmacokinetic studies of the purified antibodies in the rat following a 6 mg/kg intravenous infusion (n = 4) indicate a steady state volume of distribution of 38.0 +/- 11.2 mL kg-1, a systemic clearance of 0.92 +/- 0.67 mL kg-1 h-1 and an elimination half life of 28.9 +/- 7.9 h (mean +/- SD).","High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),[ml] / [kg],38.0,14735,DB00028,Intravenous Immunoglobulin
,7714737,systemic clearance,"Preliminary pharmacokinetic studies of the purified antibodies in the rat following a 6 mg/kg intravenous infusion (n = 4) indicate a steady state volume of distribution of 38.0 +/- 11.2 mL kg-1, a systemic clearance of 0.92 +/- 0.67 mL kg-1 h-1 and an elimination half life of 28.9 +/- 7.9 h (mean +/- SD).","High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),[ml] / [h·kg],0.92,14736,DB00028,Intravenous Immunoglobulin
,7714737,elimination half life,"Preliminary pharmacokinetic studies of the purified antibodies in the rat following a 6 mg/kg intravenous infusion (n = 4) indicate a steady state volume of distribution of 38.0 +/- 11.2 mL kg-1, a systemic clearance of 0.92 +/- 0.67 mL kg-1 h-1 and an elimination half life of 28.9 +/- 7.9 h (mean +/- SD).","High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),h,28.9,14737,DB00028,Intravenous Immunoglobulin
,29334816,AUC0-20,"By contrast, intravenous infusion of 0.25 mg/kg colchicine over 1 h produced reproducible pharmacokinetics (AUC0-20 343 [SD = 21] µg/L/h), acute multi-organ injury, and cardiotoxicity requiring euthanasia a mean of 22.5 (SD = 3.2) h after dosing.",Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334816/),[μg] / [h·l],343,15586,DB00028,Intravenous Immunoglobulin
,29334816,AUC0-20,"A full-neutralising equimolar Fab dose given 6 h after the infusion (50% first hour, 50% next 6 h [to reduce renal-loss of unbound Fab]) produced a 7.35-fold increase in plasma colchicine (AUC0-20 2,522 [SD = 14] µg/L/h), and removed all free plasma colchicine, but did not prevent toxicity (euthanasia at 29.1 [SD = 3.4] h).",Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334816/),[μg] / [h·l],"2,522",15587,DB00028,Intravenous Immunoglobulin
,29334816,AUC0-20,"Earlier administration over 1 h of the full-neutralising dose, 1 or 3 h after the colchicine, produced a 12.9-fold (AUC0-20 4,433 [SD = 607] µg/L/h) and 6.0-fold (AUC0-20 2,047 [SD = 51] µg/L/h) increase in plasma colchicine, respectively, absence of free plasma colchicine until 20 h, and survival to study end without marked cardiotoxicity.",Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334816/),[μg] / [h·l],"4,433",15588,DB00028,Intravenous Immunoglobulin
,29334816,AUC0-20,"Earlier administration over 1 h of the full-neutralising dose, 1 or 3 h after the colchicine, produced a 12.9-fold (AUC0-20 4,433 [SD = 607] µg/L/h) and 6.0-fold (AUC0-20 2,047 [SD = 51] µg/L/h) increase in plasma colchicine, respectively, absence of free plasma colchicine until 20 h, and survival to study end without marked cardiotoxicity.",Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334816/),[μg] / [h·l],"2,047",15589,DB00028,Intravenous Immunoglobulin
,34305948,rate of hospitalizations due,Efficacy was also demonstrated by the low mean annualized rate of hospitalizations due to infection (0.1 day) and the mean annualized duration of hospitalizations (0.1 day).,"Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34305948/),d,0.1,21511,DB00028,Intravenous Immunoglobulin
,34305948,duration of hospitalizations,Efficacy was also demonstrated by the low mean annualized rate of hospitalizations due to infection (0.1 day) and the mean annualized duration of hospitalizations (0.1 day).,"Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34305948/),d,0.1,21512,DB00028,Intravenous Immunoglobulin
,34305948,rate,"The mean rate of intravenous and oral antibiotic use was 0.1 day and 13.2 days, respectively.","Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34305948/),d,0.1,21513,DB00028,Intravenous Immunoglobulin
,34305948,rate,"The mean rate of intravenous and oral antibiotic use was 0.1 day and 13.2 days, respectively.","Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34305948/),d,13.2,21514,DB00028,Intravenous Immunoglobulin
,12670367,Half-lives,"Half-lives which were highly variable among patients were similar for total IgG, IgG1 and IgG2 (35.9 +/- 10.8, 36.3 +/- 9.2, and 37.1 +/- 13.9 days, respectively) and shorter for IgG3 and IgG4 (28.6 +/- 10.4 and 15.6 +/- 4.5 days, respectively).",Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670367/),d,35.9,22416,DB00028,Intravenous Immunoglobulin
,12670367,Half-lives,"Half-lives which were highly variable among patients were similar for total IgG, IgG1 and IgG2 (35.9 +/- 10.8, 36.3 +/- 9.2, and 37.1 +/- 13.9 days, respectively) and shorter for IgG3 and IgG4 (28.6 +/- 10.4 and 15.6 +/- 4.5 days, respectively).",Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670367/),d,36.3,22417,DB00028,Intravenous Immunoglobulin
,12670367,Half-lives,"Half-lives which were highly variable among patients were similar for total IgG, IgG1 and IgG2 (35.9 +/- 10.8, 36.3 +/- 9.2, and 37.1 +/- 13.9 days, respectively) and shorter for IgG3 and IgG4 (28.6 +/- 10.4 and 15.6 +/- 4.5 days, respectively).",Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670367/),d,37.1,22418,DB00028,Intravenous Immunoglobulin
,12670367,Half-lives,"Half-lives which were highly variable among patients were similar for total IgG, IgG1 and IgG2 (35.9 +/- 10.8, 36.3 +/- 9.2, and 37.1 +/- 13.9 days, respectively) and shorter for IgG3 and IgG4 (28.6 +/- 10.4 and 15.6 +/- 4.5 days, respectively).",Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670367/),d,28.6,22419,DB00028,Intravenous Immunoglobulin
,12670367,Half-lives,"Half-lives which were highly variable among patients were similar for total IgG, IgG1 and IgG2 (35.9 +/- 10.8, 36.3 +/- 9.2, and 37.1 +/- 13.9 days, respectively) and shorter for IgG3 and IgG4 (28.6 +/- 10.4 and 15.6 +/- 4.5 days, respectively).",Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670367/),d,15.6,22420,DB00028,Intravenous Immunoglobulin
,24019259,serum half-life,KB001 had an acceptable safety profile and a mean serum half-life of 11.9 days.,Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24019259/),d,11.9,23060,DB00028,Intravenous Immunoglobulin
,19451304,maximum concentrations,"Plasma concentrations of KBPA-101 were detected with mean maximum concentrations of drug in plasma of 1,877, 7,571, 24,923, and 83,197 ng/ml following doses of 0.1, 0.4, 1.2, and 4.0 mg/kg body weight, respectively.",Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451304/),[ng] / [ml],"1,877",23772,DB00028,Intravenous Immunoglobulin
,19451304,maximum concentrations,"Plasma concentrations of KBPA-101 were detected with mean maximum concentrations of drug in plasma of 1,877, 7,571, 24,923, and 83,197 ng/ml following doses of 0.1, 0.4, 1.2, and 4.0 mg/kg body weight, respectively.",Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451304/),[ng] / [ml],"7,571",23773,DB00028,Intravenous Immunoglobulin
,19451304,maximum concentrations,"Plasma concentrations of KBPA-101 were detected with mean maximum concentrations of drug in plasma of 1,877, 7,571, 24,923, and 83,197 ng/ml following doses of 0.1, 0.4, 1.2, and 4.0 mg/kg body weight, respectively.",Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451304/),[ng] / [ml],"24,923",23774,DB00028,Intravenous Immunoglobulin
,19451304,maximum concentrations,"Plasma concentrations of KBPA-101 were detected with mean maximum concentrations of drug in plasma of 1,877, 7,571, 24,923, and 83,197 ng/ml following doses of 0.1, 0.4, 1.2, and 4.0 mg/kg body weight, respectively.",Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451304/),[ng] / [ml],"83,197",23775,DB00028,Intravenous Immunoglobulin
,19451304,elimination half-life,The mean elimination half-life was between 70 and 95 h.,Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451304/),h,70 and 95,23776,DB00028,Intravenous Immunoglobulin
,19451304,volume of distribution,The mean volume of distribution was between 4.76 and 5.47 liters.,Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451304/),l,4.76 and 5.47,23777,DB00028,Intravenous Immunoglobulin
,19451304,Clearance,Clearance ranged between 0.039 and 0.120 liters/h.,Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451304/),[l] / [h],0.039 and 0.120,23778,DB00028,Intravenous Immunoglobulin
,12845386,clearance,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [h·kg],10,24529,DB00028,Intravenous Immunoglobulin
,12845386,volume of distribution at steady state,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [kg],48,24530,DB00028,Intravenous Immunoglobulin
,12845386,volume of distribution at steady state,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [kg],45,24531,DB00028,Intravenous Immunoglobulin
,12845386,elimination rate constant,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),1/[h],0.22,24532,DB00028,Intravenous Immunoglobulin
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],87,25579,DB00028,Intravenous Immunoglobulin
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],900,25580,DB00028,Intravenous Immunoglobulin
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],"164,000",25581,DB00028,Intravenous Immunoglobulin
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],"186,000",25582,DB00028,Intravenous Immunoglobulin
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],392,25583,DB00028,Intravenous Immunoglobulin
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],643,25584,DB00028,Intravenous Immunoglobulin
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],870,25585,DB00028,Intravenous Immunoglobulin
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],67.1,25586,DB00028,Intravenous Immunoglobulin
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],71.6,25587,DB00028,Intravenous Immunoglobulin
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],101,25588,DB00028,Intravenous Immunoglobulin
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,265,25589,DB00028,Intravenous Immunoglobulin
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,394,25590,DB00028,Intravenous Immunoglobulin
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,310,25591,DB00028,Intravenous Immunoglobulin
,27185573,Time to response,"Time to response was 41 d, and progression occurred at 126 d.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),d,41,25592,DB00028,Intravenous Immunoglobulin
,3515530,half life,The half life of the tetanus and HBs antibodies (21.7 to 34.4 and 19.7 to 25.7 days respectively) found in 4 healthy volunteers is within the biological range.,[Tolerability and pharmacokinetics of an intravenous immunoglobulin preparation in immunologically normal subjects and tolerability in patients with hypogammaglobulinemia resulting from chronic lymphatic leukemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515530/),d,21.7 to 34.4,26699,DB00028,Intravenous Immunoglobulin
,3515530,half life,The half life of the tetanus and HBs antibodies (21.7 to 34.4 and 19.7 to 25.7 days respectively) found in 4 healthy volunteers is within the biological range.,[Tolerability and pharmacokinetics of an intravenous immunoglobulin preparation in immunologically normal subjects and tolerability in patients with hypogammaglobulinemia resulting from chronic lymphatic leukemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515530/),d,19.7 to 25.7,26700,DB00028,Intravenous Immunoglobulin
,11034040,half-life,The half-life of CytoGam was approximately 7 days.,Evaluation of the half-life of intravenous human cytomegalovirus immune globulin in patients receiving partially mismatched related donor bone marrow transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034040/),d,7,27322,DB00028,Intravenous Immunoglobulin
,9874717,elimination half-lives,"The elimination half-lives were 52.9 and 81.8 h for cIgG and nIgG, respectively.",Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874717/),h,52.9,27323,DB00028,Intravenous Immunoglobulin
,9874717,elimination half-lives,"The elimination half-lives were 52.9 and 81.8 h for cIgG and nIgG, respectively.",Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874717/),h,81.8,27324,DB00028,Intravenous Immunoglobulin
,25637055,terminal half-life,"The terminal half-life ranged from 5.86 to 8.41 h, the apparent volume of distribution ranged from 101 to 150 mL/kg, and clearance ranged from 8.11 to 16.1 mL/h/kg.",GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637055/),h,5.86 to 8.41,27351,DB00028,Intravenous Immunoglobulin
,25637055,apparent volume of distribution,"The terminal half-life ranged from 5.86 to 8.41 h, the apparent volume of distribution ranged from 101 to 150 mL/kg, and clearance ranged from 8.11 to 16.1 mL/h/kg.",GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637055/),[ml] / [kg],101 to 150,27352,DB00028,Intravenous Immunoglobulin
,25637055,clearance,"The terminal half-life ranged from 5.86 to 8.41 h, the apparent volume of distribution ranged from 101 to 150 mL/kg, and clearance ranged from 8.11 to 16.1 mL/h/kg.",GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637055/),[ml] / [h·kg],8.11 to 16.1,27353,DB00028,Intravenous Immunoglobulin
,21413943,overall infection rate,"During the efficacy evaluation period of both studies, none of the children had a serious bacterial infection; the mean overall infection rate/patient year was 4·7 in Europe/Brazil and 5·6 in North America, concurring with previous reports in adults.",Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21413943/),,4·7,28569,DB00028,Intravenous Immunoglobulin
,21413943,overall infection rate,"During the efficacy evaluation period of both studies, none of the children had a serious bacterial infection; the mean overall infection rate/patient year was 4·7 in Europe/Brazil and 5·6 in North America, concurring with previous reports in adults.",Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21413943/),,5·6,28570,DB00028,Intravenous Immunoglobulin
,24117862,bioavailability,The bioavailability of the single subcutaneous dose of 200 mg belimumab in the subjects was estimated to be 77·5%.,The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117862/),%,77·5,28951,DB00028,Intravenous Immunoglobulin
,24117862,Time to the maximum serum concentration,Time to the maximum serum concentration after subcutaneous injection was 6·5 days (median).,The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117862/),d,6·5,28952,DB00028,Intravenous Immunoglobulin
,24117862,terminal half-life,The geometric mean terminal half-life was comparable between the two administration routes (17·7 days intravenous and 15·9 days subcutaneous).,The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117862/),d,17·7,28953,DB00028,Intravenous Immunoglobulin
,24117862,terminal half-life,The geometric mean terminal half-life was comparable between the two administration routes (17·7 days intravenous and 15·9 days subcutaneous).,The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117862/),d,15·9,28954,DB00028,Intravenous Immunoglobulin
,15610511,terminal half-life,"IV anti-IL-12p40 yielded linear pharmacokinetics, with a mean terminal half-life of approximately 24 d.","A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15610511/),d,24,29241,DB00028,Intravenous Immunoglobulin
,23537711,systemic bioavailability,The systemic bioavailability of the venom antigens injected by intramuscular route was 41.7%.,Toxicokinetics of Naja sputatrix (Javan spitting cobra) venom following intramuscular and intravenous administrations of the venom into rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23537711/),%,41.7,30896,DB00028,Intravenous Immunoglobulin
,9210687,clearance,"The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively.",Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210687/),[ml] / [d·kg],3.02,31417,DB00028,Intravenous Immunoglobulin
,9210687,clearance,"The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively.",Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210687/),[ml] / [d·kg],3.65,31418,DB00028,Intravenous Immunoglobulin
,9210687,trough antibody titers,"The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively.",Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210687/),,"1,442",31419,DB00028,Intravenous Immunoglobulin
,9210687,trough antibody titers,"The mean value for HIVIG clearance was 3.02 ml/kg/day at 50 mg/kg and 3.65 ml/kg/day at 200 mg/kg (P = 0.027); the mean trough antibody titers (reciprocal units) were 1,442 and 4,428, respectively.",Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210687/),,"4,428",31420,DB00028,Intravenous Immunoglobulin
,31931361,clearance,A non-compartmental analysis of IgG from neonates (bodyweight range 0.78-1.38 kg) indicated an average clearance of 3.0 ± 2.1 mL/day and volume of distribution at steady state 68 ± 25 mL.,Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931361/),[ml] / [d],3.0,35571,DB00028,Intravenous Immunoglobulin
,31931361,volume of distribution at steady state,A non-compartmental analysis of IgG from neonates (bodyweight range 0.78-1.38 kg) indicated an average clearance of 3.0 ± 2.1 mL/day and volume of distribution at steady state 68 ± 25 mL.,Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931361/),ml,68,35572,DB00028,Intravenous Immunoglobulin
,31931361,clearance,"The population pharmacokinetic model from extensive sampling adequately described concentration- time data with mean clearance (2.7 mL/day), volume of central compartment (8.7 mL) and peripheral compartment (60 mL).",Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931361/),[ml] / [d],2.7,35573,DB00028,Intravenous Immunoglobulin
,31931361,volume of central compartment,"The population pharmacokinetic model from extensive sampling adequately described concentration- time data with mean clearance (2.7 mL/day), volume of central compartment (8.7 mL) and peripheral compartment (60 mL).",Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931361/),ml,8.7,35574,DB00028,Intravenous Immunoglobulin
,31931361,peripheral compartment,"The population pharmacokinetic model from extensive sampling adequately described concentration- time data with mean clearance (2.7 mL/day), volume of central compartment (8.7 mL) and peripheral compartment (60 mL).",Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931361/),ml,60,35575,DB00028,Intravenous Immunoglobulin
,24045402,elimination rate constant,"Pharmacokinetic analyses evidenced a low elimination rate constant (0.0053 per hour) in the cortex, consistent with accumulation within cerebral tissue.",Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24045402/),1/[h],0.0053,35822,DB00028,Intravenous Immunoglobulin
,21711100,beta half-times,"The pharmacokinetic profile showed beta half-times of 14.1 and 6.3 hours for Groups I and II, respectively.",Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21711100/),h,14.1,36217,DB00028,Intravenous Immunoglobulin
,21711100,beta half-times,"The pharmacokinetic profile showed beta half-times of 14.1 and 6.3 hours for Groups I and II, respectively.",Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21711100/),h,6.3,36218,DB00028,Intravenous Immunoglobulin
,27795368,peak serum concentration,"The MEDI4893 peak serum concentration increased dose proportionally from 77.2 μg/ml (225-mg dose) to 1,784 μg/ml (5,000-mg dose).","Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795368/),[μg] / [ml],77.2,36893,DB00028,Intravenous Immunoglobulin
,27795368,peak serum concentration,"The MEDI4893 peak serum concentration increased dose proportionally from 77.2 μg/ml (225-mg dose) to 1,784 μg/ml (5,000-mg dose).","Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795368/),[μg] / [ml],"1,784",36894,DB00028,Intravenous Immunoglobulin
,27795368,area under the concentration-time curve from 0 to 360 days,"The area under the concentration-time curve from 0 to 360 days also increased dose proportionally, from 4,840 μg · day/ml (225-mg dose) to 91,493 μg · day/ml (5,000-mg dose), indicating linear pharmacokinetics.","Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795368/),[d·μg] / [ml],"4,840",36895,DB00028,Intravenous Immunoglobulin
,27795368,area under the concentration-time curve from 0 to 360 days,"The area under the concentration-time curve from 0 to 360 days also increased dose proportionally, from 4,840 μg · day/ml (225-mg dose) to 91,493 μg · day/ml (5,000-mg dose), indicating linear pharmacokinetics.","Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795368/),[d·μg] / [ml],"91,493",36896,DB00028,Intravenous Immunoglobulin
,27795368,terminal half-life,"MEDI4893's terminal half-life was estimated to be 80 to 112 days, which is approximately 4-fold longer than the half-lives of other human immunoglobulin G antibodies.","Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795368/),d,80 to 112,36897,DB00028,Intravenous Immunoglobulin
,22203368,clearance,The predicted non-specific clearance range in humans was 2.6-4.4 mL/day/kg.,"Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203368/),[ml] / [d·kg],2.6-4.4,37002,DB00028,Intravenous Immunoglobulin
,26242380,IC50(saturation),"Parameter estimates (95 % bootstrap confidence intervals) were: baseline CD25 labeling, 47 % (45-48); DAC HYP IC50(saturation), 0.023 µg/mL (0.005-0.073); IC50(desaturation) 0.86 µg/mL (0.74-0.98); Hill coefficient 5.6 (4.3-6.8).",Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242380/),[μg] / [ml],0.023,39210,DB00028,Intravenous Immunoglobulin
,26242380,IC50(desaturation),"Parameter estimates (95 % bootstrap confidence intervals) were: baseline CD25 labeling, 47 % (45-48); DAC HYP IC50(saturation), 0.023 µg/mL (0.005-0.073); IC50(desaturation) 0.86 µg/mL (0.74-0.98); Hill coefficient 5.6 (4.3-6.8).",Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242380/),[μg] / [ml],0.86,39211,DB00028,Intravenous Immunoglobulin
,26242380,Hill coefficient,"Parameter estimates (95 % bootstrap confidence intervals) were: baseline CD25 labeling, 47 % (45-48); DAC HYP IC50(saturation), 0.023 µg/mL (0.005-0.073); IC50(desaturation) 0.86 µg/mL (0.74-0.98); Hill coefficient 5.6 (4.3-6.8).",Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242380/),,5.6,39212,DB00028,Intravenous Immunoglobulin
,11929319,Volume of distribution,"Volume of distribution ranges from 21 to 87 L, and binding to human plasma proteins is modest at 64%.","Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929319/),l,21 to 87,41192,DB00028,Intravenous Immunoglobulin
,11929319,systemic clearance,"Metabolism in humans is negligible, and most drug is excreted renally with systemic clearance ranging from 4.8 to 25.8 L/h.","Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929319/),[l] / [h],4.8 to 25.8,41193,DB00028,Intravenous Immunoglobulin
,18774636,half life,Pharmacokinetics data shows the half life of this mAb was about 5 days after a single intravenous injection.,Isolation and characterization of human anti-VEGF165 monoclonal antibody with anti-tumor efficacy from transgenic mice expressing human immunoglobulin loci. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18774636/),d,5,42349,DB00028,Intravenous Immunoglobulin
,9867150,uptake,"Antibody uptake in primary tumors, metastatic sites and regional metastatic lymph nodes ranged from 0.4% to 134% injected dose/kg, resulting in estimated 90Y-cT84.66 radiation doses ranging from 0.3 to 193 cGy/mCi.",Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9867150/),%,0.4,43455,DB00028,Intravenous Immunoglobulin
,9867150,uptake,"Antibody uptake in primary tumors, metastatic sites and regional metastatic lymph nodes ranged from 0.4% to 134% injected dose/kg, resulting in estimated 90Y-cT84.66 radiation doses ranging from 0.3 to 193 cGy/mCi.",Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9867150/),[%·dose·injected] / [kg],134,43456,DB00028,Intravenous Immunoglobulin
,30834538,terminal plasma half-life,Mean terminal plasma half-life (each cohort) ranged from 53 to 121 hours.,"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30834538/),h,53 to 121,43883,DB00028,Intravenous Immunoglobulin
,26332605,serum trough concentrations,"Mean 28-day serum trough concentrations after the first infusion were 35 and 57 μg/ml for groups infused with 20 mg/kg (n = 8) and 40 mg/kg (n = 5) doses, respectively.","Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332605/),[μg] / [ml],35,43935,DB00028,Intravenous Immunoglobulin
,26332605,serum trough concentrations,"Mean 28-day serum trough concentrations after the first infusion were 35 and 57 μg/ml for groups infused with 20 mg/kg (n = 8) and 40 mg/kg (n = 5) doses, respectively.","Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332605/),[μg] / [ml],57,43936,DB00028,Intravenous Immunoglobulin
,26332605,trough concentrations,Mean 28-day trough concentrations after the second infusion were 56 and 89 μg/ml for the same two doses.,"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332605/),[μg] / [ml],56,43937,DB00028,Intravenous Immunoglobulin
,26332605,trough concentrations,Mean 28-day trough concentrations after the second infusion were 56 and 89 μg/ml for the same two doses.,"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332605/),[μg] / [ml],89,43938,DB00028,Intravenous Immunoglobulin
,26332605,clearance,"Over the 5-40 mg/kg i.v. dose range (n = 18), the clearance was 0.016 l/h and terminal half-life was 15 days.","Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332605/),[l] / [h],0.016,43939,DB00028,Intravenous Immunoglobulin
,26332605,terminal half-life,"Over the 5-40 mg/kg i.v. dose range (n = 18), the clearance was 0.016 l/h and terminal half-life was 15 days.","Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332605/),d,15,43940,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,12.3,46250,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,12.5,46251,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,15.1,46252,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,39.3,46253,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,28.9,46254,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,42.0,46255,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,225,46256,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,158,46257,DB00028,Intravenous Immunoglobulin
,23018115,Areas under the plasma concentration vs. time curves AUC(0-10 days),"Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),d·nM,204,46258,DB00028,Intravenous Immunoglobulin
,23018115,plasma clearance,"8C2 plasma clearance, distribution clearance, and central compartment volume were 0.00543 L/days/kg, 0.0598 L/days/kg, and 0.057 L/kg.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),[l] / [d·kg],0.00543,46259,DB00028,Intravenous Immunoglobulin
,23018115,distribution clearance,"8C2 plasma clearance, distribution clearance, and central compartment volume were 0.00543 L/days/kg, 0.0598 L/days/kg, and 0.057 L/kg.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),[l] / [d·kg],0.0598,46260,DB00028,Intravenous Immunoglobulin
,23018115,central compartment volume,"8C2 plasma clearance, distribution clearance, and central compartment volume were 0.00543 L/days/kg, 0.0598 L/days/kg, and 0.057 L/kg.","Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018115/),[l] / [kg],0.057,46261,DB00028,Intravenous Immunoglobulin
,8277186,half-life,The half-life was 52 h for a single infusion of TNF alpha MAb.,"Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8277186/),h,52,46313,DB00028,Intravenous Immunoglobulin
,11968154,volume of distribution,"At the doses administered, the volume of distribution approximated the serum volume (range of means: 42 to 58 ml/kg).","Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11968154/),m,42 to,50853,DB00028,Intravenous Immunoglobulin
,11968154,elimination half-life,"At doses of 0.5 to 2.0 mg/kg, the mean elimination half-life ranged from 7.0 to 9.6 hours.","Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11968154/),h,7.0 to 9.6,50854,DB00028,Intravenous Immunoglobulin
,11968154,half-life,"At doses of 0.5 to 2.0 mg/kg, the pharmacokinetics were linear and the half-life ranged from 7.0 to 9.6 hours with a volume of distribution that approximated the serum volume.","Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11968154/),h,7.0 to 9.6,50855,DB00028,Intravenous Immunoglobulin
,19733918,maximum E,ESBA105 efficiently migrated from the nasal cavity to the brain and maximum ESBA105 concentrations (C(max)) in the brain were measured between 1.1 and 12.2microg/mg of the total protein.,"Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733918/),[μg] / [mg],1.1 and 12.2,52106,DB00028,Intravenous Immunoglobulin
>,25924888,bioavailability,SC bioavailability of hIgG in all animal groups was similar (>84%).,Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25924888/),%,84,52620,DB00028,Intravenous Immunoglobulin
,9519157,Affinity constants,Affinity constants of the V. aspis-specific F(ab')2 were determined using biosensor technology and found to be in the range of 10(8) M-1 for the four antigenic fractions of V. aspis toxins and for both F(ab')2 preparations.,Preclinical assessment of immunoreactivity of a new purified equine F(ab')2 against European viper venom. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9519157/),1/[M],10(8),53037,DB00028,Intravenous Immunoglobulin
,9519157,terminal half-life,"Infusion of a stoichiometric molar ratio (i.e., 1 mg kg-1) of the new antivenom induced a 2.3-fold elevation of the plasma venom concentration with a Tmax observed 8 h after F(ab')2 administration and a decline in the terminal half-life from 31.92 +/- 4.49 h to 16.73 +/- 4.34 h, in contrast, for the venom alone.",Preclinical assessment of immunoreactivity of a new purified equine F(ab')2 against European viper venom. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9519157/),h,31.92,53038,DB00028,Intravenous Immunoglobulin
,9519157,terminal half-life,"Infusion of a stoichiometric molar ratio (i.e., 1 mg kg-1) of the new antivenom induced a 2.3-fold elevation of the plasma venom concentration with a Tmax observed 8 h after F(ab')2 administration and a decline in the terminal half-life from 31.92 +/- 4.49 h to 16.73 +/- 4.34 h, in contrast, for the venom alone.",Preclinical assessment of immunoreactivity of a new purified equine F(ab')2 against European viper venom. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9519157/),h,16.73,53039,DB00028,Intravenous Immunoglobulin
,27279130,serious bacterial infection rate,The calculated serious bacterial infection rate was 0.05/subject/year.,Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27279130/),1/[subject·year],0.05,53390,DB00028,Intravenous Immunoglobulin
,19491015,total IgG,Median total IgG serum concentrations increased from 10.2g/l pre-infusion to 23.2g/l at infusion end.,Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),[g] / [l],10.2,54348,DB00028,Intravenous Immunoglobulin
,19491015,total IgG,Median total IgG serum concentrations increased from 10.2g/l pre-infusion to 23.2g/l at infusion end.,Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),[g] / [l],23.2,54349,DB00028,Intravenous Immunoglobulin
,19491015,serum concentrations,Median total IgG serum concentrations increased from 10.2g/l pre-infusion to 23.2g/l at infusion end.,Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),[g] / [l],10.2,54350,DB00028,Intravenous Immunoglobulin
,19491015,serum concentrations,Median total IgG serum concentrations increased from 10.2g/l pre-infusion to 23.2g/l at infusion end.,Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),[g] / [l],23.2,54351,DB00028,Intravenous Immunoglobulin
,19491015,terminal half-life,Serum IgG concentrations decreased in a biphasic manner; median terminal half-life was 36.6 days.,Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),d,36.6,54352,DB00028,Intravenous Immunoglobulin
,19491015,half-lives,"Median half-lives were 33.2 for IgG(1), 36.3 for IgG(2), 25.9 for IgG(3) and 36.4 days for IgG(4).",Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),d,33.2,54353,DB00028,Intravenous Immunoglobulin
,19491015,half-lives,"Median half-lives were 33.2 for IgG(1), 36.3 for IgG(2), 25.9 for IgG(3) and 36.4 days for IgG(4).",Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),d,36.3,54354,DB00028,Intravenous Immunoglobulin
,19491015,half-lives,"Median half-lives were 33.2 for IgG(1), 36.3 for IgG(2), 25.9 for IgG(3) and 36.4 days for IgG(4).",Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),d,25.9,54355,DB00028,Intravenous Immunoglobulin
,19491015,half-lives,"Median half-lives were 33.2 for IgG(1), 36.3 for IgG(2), 25.9 for IgG(3) and 36.4 days for IgG(4).",Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),d,36.4,54356,DB00028,Intravenous Immunoglobulin
,19491015,half-lives,"Specific antibody concentrations (anti-CMV, anti-Hemophilus influenzae type B, anti-tetanus toxoid and anti-Streptococcus pneumoniae) decreased with median half-lives of 22.3-30.5 days.",Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491015/),d,22.3-30.5,54357,DB00028,Intravenous Immunoglobulin
,12394838,duration,The duration of CD25 saturation in patients who experienced a rejection episode after desaturation did not differ from those who remained rejection-free for the full 6-month period: 34+/-6 days (n=6) vs. 35+/-14 days (n=33 patients); P=0.74.,A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394838/),d,34,55751,DB00028,Intravenous Immunoglobulin
,12394838,duration,The duration of CD25 saturation in patients who experienced a rejection episode after desaturation did not differ from those who remained rejection-free for the full 6-month period: 34+/-6 days (n=6) vs. 35+/-14 days (n=33 patients); P=0.74.,A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394838/),d,35,55752,DB00028,Intravenous Immunoglobulin
,12394838,CD25 saturation,The duration of CD25 saturation in patients who experienced a rejection episode after desaturation did not differ from those who remained rejection-free for the full 6-month period: 34+/-6 days (n=6) vs. 35+/-14 days (n=33 patients); P=0.74.,A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394838/),d,34,55753,DB00028,Intravenous Immunoglobulin
,12394838,CD25 saturation,The duration of CD25 saturation in patients who experienced a rejection episode after desaturation did not differ from those who remained rejection-free for the full 6-month period: 34+/-6 days (n=6) vs. 35+/-14 days (n=33 patients); P=0.74.,A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394838/),d,35,55754,DB00028,Intravenous Immunoglobulin
,11300442,percent,"Turbidimetric aggregometry with adenosine diphosphate stimulation yielded similar results, whereas percent inhibition of platelet aggregation after thrombin receptor stimulation was 45.8 +/- 16.8% with abciximab, 51.3 +/- 17.6% with tirofiban and 52.9 +/- 14.8% with eptifibatide (p = 0.37).","Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11300442/),%,45,56199,DB00028,Intravenous Immunoglobulin
,11300442,percent,"Turbidimetric aggregometry with adenosine diphosphate stimulation yielded similar results, whereas percent inhibition of platelet aggregation after thrombin receptor stimulation was 45.8 +/- 16.8% with abciximab, 51.3 +/- 17.6% with tirofiban and 52.9 +/- 14.8% with eptifibatide (p = 0.37).","Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11300442/),%,51,56200,DB00028,Intravenous Immunoglobulin
,32078124,durations,"In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively.",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),,4.3,58493,DB00028,Intravenous Immunoglobulin
,32078124,durations,"In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively.",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),,3.4,58494,DB00028,Intravenous Immunoglobulin
,32078124,Kd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],254.9,58495,DB00028,Intravenous Immunoglobulin
,32078124,D-KRd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],277.2,58496,DB00028,Intravenous Immunoglobulin
,32078124,D-KRd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],256.8,58497,DB00028,Intravenous Immunoglobulin
,32078124,D-Kd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],319.2,58498,DB00028,Intravenous Immunoglobulin
,32078124,D-KRd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],575.1,58499,DB00028,Intravenous Immunoglobulin
,32078124,D-KRd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],639.2,58500,DB00028,Intravenous Immunoglobulin
,32078124,D-Kd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],463.2,58501,DB00028,Intravenous Immunoglobulin
,25654695,serum half-life,"Intravenous administration of human albumin to Tg32-Alb(-/-) mFcRn(-/-) hFcRn(Tg/Tg)) mice results in a remarkably extended human albumin serum half-life of ∼24 days, comparable to that found in humans, and in contrast to half-lives of 2.6-5.8 d observed in B6, B6-Alb(-/-) and Tg32 strains.",Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25654695/),d,∼24,58584,DB00028,Intravenous Immunoglobulin
,25654695,half-lives,"Intravenous administration of human albumin to Tg32-Alb(-/-) mFcRn(-/-) hFcRn(Tg/Tg)) mice results in a remarkably extended human albumin serum half-life of ∼24 days, comparable to that found in humans, and in contrast to half-lives of 2.6-5.8 d observed in B6, B6-Alb(-/-) and Tg32 strains.",Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25654695/),d,2.6-5.8,58585,DB00028,Intravenous Immunoglobulin
,21177764,time on study,Median time on study was 104 days (range 17-300).,Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177764/),d,104,60784,DB00028,Intravenous Immunoglobulin
,20550545,infusion rate,"The average IVIG dose was 0·49 g/kg, with an average infusion rate of 2·4 ml/kg/h.","A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20550545/),[ml] / [h·kg],2·4,63084,DB00028,Intravenous Immunoglobulin
,20550545,elimination half-life,Pharmacokinetic studies after the first infusion revealed a mean elimination half-life of 50·8 ± 30·3 days.,"A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20550545/),d,50·8,63085,DB00028,Intravenous Immunoglobulin
below,20550545,trough levels,"During this study, 19 of 649 (2·9%) IgG trough levels were below 6 g/l, better than that of reference IVIGs during the 6 months before study start (10 of 201).","A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20550545/),[g] / [l],6,63086,DB00028,Intravenous Immunoglobulin
,7656506,volume of distribution,"Digoxin-specific Fab is eliminated via renal and nonrenal routes, having a volume of distribution slightly exceeding extracellular volume (0.40 L/kg) and an elimination half-life of 16 to 20 hours.",Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656506/),l,0,63841,DB00028,Intravenous Immunoglobulin
,7656506,elimination half-life,"Digoxin-specific Fab is eliminated via renal and nonrenal routes, having a volume of distribution slightly exceeding extracellular volume (0.40 L/kg) and an elimination half-life of 16 to 20 hours.",Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656506/),h,16 to 20,63842,DB00028,Intravenous Immunoglobulin
,7656506,Systemic clearance,Systemic clearance of digoxin-specific Fab is approximately 0.32 ml/min/kg in digoxin-toxic patients with preserved renal function.,Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656506/),[ml] / [kg·min],0.32,63843,DB00028,Intravenous Immunoglobulin
,9224812,distribution half-life,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,0.15,64331,DB00028,Intravenous Immunoglobulin
,9224812,distribution half-life,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,4.01,64332,DB00028,Intravenous Immunoglobulin
,9224812,distribution half-life,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,0.02,64333,DB00028,Intravenous Immunoglobulin
,9224812,distribution half-life,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,0.21,64334,DB00028,Intravenous Immunoglobulin
,9224812,elimination half-lives,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,57.17,64335,DB00028,Intravenous Immunoglobulin
,9224812,elimination half-lives,"After intravenous injection of 125I-rR-RAGE, the distribution half-life was longer (p < or = 0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr; p < or = 0.01).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),h,26.02,64336,DB00028,Intravenous Immunoglobulin
,9224812,Distribution volume,"Distribution volume was higher in diabetic than in normal rats (6.94 and 3.24 liter/kg, respectively; p = 0.049).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),[l] / [kg],6.94,64337,DB00028,Intravenous Immunoglobulin
,9224812,Distribution volume,"Distribution volume was higher in diabetic than in normal rats (6.94 and 3.24 liter/kg, respectively; p = 0.049).",Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224812/),[l] / [kg],3.24,64338,DB00028,Intravenous Immunoglobulin
,2576050,elimination half-lives,"However, the elimination half-lives and apparent volumes of distribution were similar in both species (about 140 min and 120 mL kg-1, respectively).",The plasma disposition of sheep antibody (Fab) fragments in the guinea-pig and rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576050/),min,140,64569,DB00028,Intravenous Immunoglobulin
,2576050,apparent volumes of distribution,"However, the elimination half-lives and apparent volumes of distribution were similar in both species (about 140 min and 120 mL kg-1, respectively).",The plasma disposition of sheep antibody (Fab) fragments in the guinea-pig and rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576050/),[ml] / [kg],120,64570,DB00028,Intravenous Immunoglobulin
,2576050,distribution volume,"The distribution of Fab fragments in these two species differs significantly from that in the rat, where our earlier studies have shown that these antibody fragments are confined to the intravascular compartment with a distribution volume approximately equivalent to that of plasma (about 40 mL kg-1).",The plasma disposition of sheep antibody (Fab) fragments in the guinea-pig and rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576050/),[ml] / [kg],40,64571,DB00028,Intravenous Immunoglobulin
,8584483,distribution,"Pharmacokinetic analysis showed that the plasma F(ab')2 concentration followed a biexponential decline after intravenous bolus administration with distribution and elimination half-lives of 2.66 +/- 0.18 hrs and 49.69 +/- 4.13 hrs, respectively.",Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584483/),h,2.66,65137,DB00028,Intravenous Immunoglobulin
,8584483,elimination half-lives,"Pharmacokinetic analysis showed that the plasma F(ab')2 concentration followed a biexponential decline after intravenous bolus administration with distribution and elimination half-lives of 2.66 +/- 0.18 hrs and 49.69 +/- 4.13 hrs, respectively.",Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584483/),h,49.69,65138,DB00028,Intravenous Immunoglobulin
,8584483,total volume of distribution (Vdss,The total volume of distribution (Vdss or Vd beta) was between 209 and 265 ml.,Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584483/),ml,209 and 265,65139,DB00028,Intravenous Immunoglobulin
,8584483,Vd beta),The total volume of distribution (Vdss or Vd beta) was between 209 and 265 ml.,Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584483/),ml,209 and 265,65140,DB00028,Intravenous Immunoglobulin
,8584483,Total body clearance,Total body clearance ranged from 3.33 to 3.96 ml.h-1.kg-1.,Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584483/),[ml] / [h·kg],3.33 to 3.96,65141,DB00028,Intravenous Immunoglobulin
,8584483,Tmax,"After intramuscular administration which was only investigated with SAV, Tmax was 48 hrs and the absolute bioavailability was 42%.",Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584483/),h,48,65142,DB00028,Intravenous Immunoglobulin
,8584483,absolute bioavailability,"After intramuscular administration which was only investigated with SAV, Tmax was 48 hrs and the absolute bioavailability was 42%.",Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584483/),%,42,65143,DB00028,Intravenous Immunoglobulin
,9874714,alpha-,"After single iv administration (2.5 mg/kg), dHGF in serum rapidly decreased (alpha- and beta-phase half-life: 3.2 and 26.5 min, respectively).",Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874714/),min,3.2,65746,DB00028,Intravenous Immunoglobulin
,9874714,beta-phase half-life,"After single iv administration (2.5 mg/kg), dHGF in serum rapidly decreased (alpha- and beta-phase half-life: 3.2 and 26.5 min, respectively).",Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874714/),min,26.5,65747,DB00028,Intravenous Immunoglobulin
,9874714,half-life,"Two to four hours after single sc or im administration (2.5 mg/kg), the serum level of dHGF reached a maximum and then gradually declined (half-life: 2.7 h).",Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874714/),h,2.7,65748,DB00028,Intravenous Immunoglobulin
,10094978,half-life,"Thus, anti-HBs half-life was 22 +/- 1.3 days for OMRI-Hep-B recipients and 13 +/- 1.3 days for Hepatect recipients (P <.001).",Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10094978/),d,22,67252,DB00028,Intravenous Immunoglobulin
,10094978,half-life,"Thus, anti-HBs half-life was 22 +/- 1.3 days for OMRI-Hep-B recipients and 13 +/- 1.3 days for Hepatect recipients (P <.001).",Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10094978/),d,13,67253,DB00028,Intravenous Immunoglobulin
,10094978,Time to reach trough anti-HBs levels,"Time to reach trough anti-HBs levels of 150 mIU/mL was significantly longer after administration of OMRI-Hep-B than after Hepatect (79 +/- 4.5 and 52 +/- 3.8 days, respectively; P <.001).",Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10094978/),d,150,67254,DB00028,Intravenous Immunoglobulin
,10094978,Time to reach trough anti-HBs levels,"Time to reach trough anti-HBs levels of 150 mIU/mL was significantly longer after administration of OMRI-Hep-B than after Hepatect (79 +/- 4.5 and 52 +/- 3.8 days, respectively; P <.001).",Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10094978/),d,79,67255,DB00028,Intravenous Immunoglobulin
,10094978,Time to reach trough anti-HBs levels,"Time to reach trough anti-HBs levels of 150 mIU/mL was significantly longer after administration of OMRI-Hep-B than after Hepatect (79 +/- 4.5 and 52 +/- 3.8 days, respectively; P <.001).",Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10094978/),d,52,67256,DB00028,Intravenous Immunoglobulin
,27140796,clearance,"The results of these analyses confirmed that rFVIIIFc clearance (1.65 dL/h) is much lower than that of rFVIII (2.53 dL/h), while the steady state volumes of distribution were similar.",Population pharmacokinetics of recombinant factor VIII Fc fusion protein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140796/),[dl] / [h],1.65,67765,DB00028,Intravenous Immunoglobulin
,27140796,clearance,"The results of these analyses confirmed that rFVIIIFc clearance (1.65 dL/h) is much lower than that of rFVIII (2.53 dL/h), while the steady state volumes of distribution were similar.",Population pharmacokinetics of recombinant factor VIII Fc fusion protein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140796/),[dl] / [h],2.53,67766,DB00028,Intravenous Immunoglobulin
,14534354,maximum effect (Emax,"The maximum effect (Emax = 83.6%) was achieved rapidly and gradually returned to baseline values, although inhibition could be measured long after abciximab concentrations dropped below the detection limit.",Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534354/),%,83.6,70375,DB00028,Intravenous Immunoglobulin
,27031797,clearance,"In mice, clearance and half-life ranged from 5.77 to 9.98 mL/day/kg and 10.2 to 5.76 days, respectively.","Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27031797/),[ml] / [d·kg],5.77 to 9.98,70700,DB00028,Intravenous Immunoglobulin
,27031797,half-life,"In mice, clearance and half-life ranged from 5.77 to 9.98 mL/day/kg and 10.2 to 5.76 days, respectively.","Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27031797/),d,10.2 to 5.76,70701,DB00028,Intravenous Immunoglobulin
,27031797,clearance,"In cynomolgus monkeys, clearance and half-life ranged from 4.33 to 4.34 mL/day/kg and 11.3 to 11.9 days, respectively.","Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27031797/),[ml] / [d·kg],4.33 to 4.34,70702,DB00028,Intravenous Immunoglobulin
,27031797,half-life,"In cynomolgus monkeys, clearance and half-life ranged from 4.33 to 4.34 mL/day/kg and 11.3 to 11.9 days, respectively.","Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27031797/),d,11.3 to 11.9,70703,DB00028,Intravenous Immunoglobulin
,27031797,clearance,The predicted clearance in humans was ∼2.60 mL/day/kg.,"Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27031797/),[ml] / [d·kg],∼2.60,70704,DB00028,Intravenous Immunoglobulin
,28744796,absolute subcutaneous bioavailability,ABT-122 absolute subcutaneous bioavailability was approximately 50% with maximum serum concentrations observed 3-4 days after dosing.,"Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),%,50,71247,DB00028,Intravenous Immunoglobulin
,28744796,maximum serum concentration-to-trough concentration ratio,"ABT-122 maximum serum concentration-to-trough concentration ratio was 2.6 for every other week dosing and 1.3 for every week dosing, corresponding to an effective half-life of 10-18 days.","Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),,2.6,71248,DB00028,Intravenous Immunoglobulin
,28744796,maximum serum concentration-to-trough concentration ratio,"ABT-122 maximum serum concentration-to-trough concentration ratio was 2.6 for every other week dosing and 1.3 for every week dosing, corresponding to an effective half-life of 10-18 days.","Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),,1.3,71249,DB00028,Intravenous Immunoglobulin
,28744796,half-life,"ABT-122 maximum serum concentration-to-trough concentration ratio was 2.6 for every other week dosing and 1.3 for every week dosing, corresponding to an effective half-life of 10-18 days.","Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),d,10-18,71250,DB00028,Intravenous Immunoglobulin
,28744796,area under the serum concentration-time curve accumulation ratio,ABT-122 median area under the serum concentration-time curve accumulation ratio was 3.8-4.8 with every week dosing.,"Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),,3.8-4.8,71251,DB00028,Intravenous Immunoglobulin
,28744796,time to appearance of antidrug antibodies,Measureable antidrug antibodies were observed in all 48 subjects in Study 1 by day 15 post-dose and 19 of 31 ABT-122-treated patients in Studies 2 and 3 [median time to appearance of antidrug antibodies of 64 days (range 15-92 days)].,"Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),d,64,71252,DB00028,Intravenous Immunoglobulin
,21196896,anti-,Overall mean anti-HBs titer during treatment was 363 IU/mL.,Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21196896/),[iu] / [ml],363,71788,DB00028,Intravenous Immunoglobulin
,21196896,titer,Overall mean anti-HBs titer during treatment was 363 IU/mL.,Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21196896/),[iu] / [ml],363,71789,DB00028,Intravenous Immunoglobulin
,21196896,half-life,"Mean HBIg half-life was 21.4, 27.3 and 26 days with intravenous, diluted or concentrated im-preparations, respectively.",Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21196896/),d,21.4,71790,DB00028,Intravenous Immunoglobulin
,21196896,half-life,"Mean HBIg half-life was 21.4, 27.3 and 26 days with intravenous, diluted or concentrated im-preparations, respectively.",Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21196896/),d,27.3,71791,DB00028,Intravenous Immunoglobulin
,21196896,half-life,"Mean HBIg half-life was 21.4, 27.3 and 26 days with intravenous, diluted or concentrated im-preparations, respectively.",Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21196896/),d,26,71792,DB00028,Intravenous Immunoglobulin
,2424931,trough serum IgG concentration,The mean trough serum IgG concentration was 191 mg/dl on the standard dose and increased to 427 mg/dl at the highest dose.,Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2424931/),[mg] / [dl],191,73003,DB00028,Intravenous Immunoglobulin
,2424931,trough serum IgG concentration,The mean trough serum IgG concentration was 191 mg/dl on the standard dose and increased to 427 mg/dl at the highest dose.,Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2424931/),[mg] / [dl],427,73004,DB00028,Intravenous Immunoglobulin
,2424931,serum half-lives,"The serum half-lives of IgG were highly variable, ranging from 22 to 96 days.",Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2424931/),d,22 to 96,73005,DB00028,Intravenous Immunoglobulin
,2424931,clearances,"The mean decreased from 43 days in the first to 33 days in the third and fourth studies, and the clearances of IgG increased from 1.8339 to 2.4302 mg/kg/day, but the differences were not statistically significant.",Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2424931/),[mg] / [d·kg],1.8339,73006,DB00028,Intravenous Immunoglobulin
,2424931,clearances,"The mean decreased from 43 days in the first to 33 days in the third and fourth studies, and the clearances of IgG increased from 1.8339 to 2.4302 mg/kg/day, but the differences were not statistically significant.",Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2424931/),[mg] / [d·kg],2.4302,73007,DB00028,Intravenous Immunoglobulin
,22392046,serious bacterial infection rate,Two serious bacterial infections (SBIs) were observed resulting in a serious bacterial infection rate of 0.035 per person per year and an upper one-sided 99% confidence limit of ≤0.136 SBI/patient/year.,"Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22392046/),1/[person·year],0.035,73693,DB00028,Intravenous Immunoglobulin
,22392046,school missed,The number of days of work or school missed due to infection were relatively low at 2.28 days/patient/year.,"Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22392046/),[d] / [patient·year],2.28,73694,DB00028,Intravenous Immunoglobulin
,22392046,half-life,The IgG half-life was approximately 30 days with variation among individuals.,"Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22392046/),d,30,73695,DB00028,Intravenous Immunoglobulin
,7552478,peak serum concentrations,"Serum concentrations of CD4-IgG increased linearly with dose, with average peak serum concentrations of 22 micrograms/ml with 1,000 micrograms/kg.","Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7552478/),[μg] / [ml],22,74710,DB00028,Intravenous Immunoglobulin
,7642276,half-life,"Intravenous administration of GXM to rats resulted in persistent serum levels which declined with a half-life of 14.3 h in the first 74 h and 3 h thereafter, coincident with the appearance of serum antibodies to GXM.",Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7642276/),h,14.3,76067,DB00028,Intravenous Immunoglobulin
,7642276,half-life,"Intravenous administration of GXM to rats resulted in persistent serum levels which declined with a half-life of 14.3 h in the first 74 h and 3 h thereafter, coincident with the appearance of serum antibodies to GXM.",Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7642276/),h,3,76068,DB00028,Intravenous Immunoglobulin
,12542733,overall half-life (t1/2),"The overall half-life (t1/2) for total IgG was 33 +/- 17 days in the IVIG-N arm and 25 +/- 16 days in the Sandoglobulin arm; for anti-HBsAg t1/2, values were 17 +/- 7 and 17 +/- 9 days, respectively.","Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542733/),d,33,76657,DB00028,Intravenous Immunoglobulin
,12542733,overall half-life (t1/2),"The overall half-life (t1/2) for total IgG was 33 +/- 17 days in the IVIG-N arm and 25 +/- 16 days in the Sandoglobulin arm; for anti-HBsAg t1/2, values were 17 +/- 7 and 17 +/- 9 days, respectively.","Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542733/),d,25,76658,DB00028,Intravenous Immunoglobulin
,12542733,t1/2,"The overall half-life (t1/2) for total IgG was 33 +/- 17 days in the IVIG-N arm and 25 +/- 16 days in the Sandoglobulin arm; for anti-HBsAg t1/2, values were 17 +/- 7 and 17 +/- 9 days, respectively.","Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542733/),d,17,76659,DB00028,Intravenous Immunoglobulin
,12542733,t1/2,"The overall half-life (t1/2) for total IgG was 33 +/- 17 days in the IVIG-N arm and 25 +/- 16 days in the Sandoglobulin arm; for anti-HBsAg t1/2, values were 17 +/- 7 and 17 +/- 9 days, respectively.","Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12542733/),d,17,76660,DB00028,Intravenous Immunoglobulin
,11497339,Total body clearances,"Total body clearances came to 0.14 +/- 0.08 ml/min (anti-HBs), 0.10 +/- 0.02 ml/ min (anti-CMV) and 0.14 +/- 0.07 ml/min (anti-VZV).",Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497339/),[ml] / [min],0.14,78581,DB00028,Intravenous Immunoglobulin
,11497339,Total body clearances,"Total body clearances came to 0.14 +/- 0.08 ml/min (anti-HBs), 0.10 +/- 0.02 ml/ min (anti-CMV) and 0.14 +/- 0.07 ml/min (anti-VZV).",Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497339/),[ml] / [min],0.10,78582,DB00028,Intravenous Immunoglobulin
,11497339,Total body clearances,"Total body clearances came to 0.14 +/- 0.08 ml/min (anti-HBs), 0.10 +/- 0.02 ml/ min (anti-CMV) and 0.14 +/- 0.07 ml/min (anti-VZV).",Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497339/),[ml] / [min],0.14,78583,DB00028,Intravenous Immunoglobulin
,11497339,terminal elimination half-lives,"The terminal elimination half-lives were determined to be 25.34 +/- 8.34 days (anti-HBs), 24.66 7.28 days (anti-CMV) and 31.79 +/- 12.47 days (anti-VZV).",Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497339/),d,25.34,78584,DB00028,Intravenous Immunoglobulin
,11497339,terminal elimination half-lives,"The terminal elimination half-lives were determined to be 25.34 +/- 8.34 days (anti-HBs), 24.66 7.28 days (anti-CMV) and 31.79 +/- 12.47 days (anti-VZV).",Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497339/),d,24.66,78585,DB00028,Intravenous Immunoglobulin
,11497339,terminal elimination half-lives,"The terminal elimination half-lives were determined to be 25.34 +/- 8.34 days (anti-HBs), 24.66 7.28 days (anti-CMV) and 31.79 +/- 12.47 days (anti-VZV).",Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497339/),d,7.28,78586,DB00028,Intravenous Immunoglobulin
,11497339,terminal elimination half-lives,"The terminal elimination half-lives were determined to be 25.34 +/- 8.34 days (anti-HBs), 24.66 7.28 days (anti-CMV) and 31.79 +/- 12.47 days (anti-VZV).",Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497339/),d,31.79,78587,DB00028,Intravenous Immunoglobulin
,10914906,isolation time,Mean isolation time was 12 d.,Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914906/),d,12,78980,DB00028,Intravenous Immunoglobulin
,10914906,absorbed doses,"Dosimetry showed mean absorbed doses of 163, 380, 276, 338, 781, and 216 cGy, for whole-body, liver, kidney, spleen, lung, and red marrow, respectively.",Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914906/),cgy,163,78981,DB00028,Intravenous Immunoglobulin
,10914906,absorbed doses,"Dosimetry showed mean absorbed doses of 163, 380, 276, 338, 781, and 216 cGy, for whole-body, liver, kidney, spleen, lung, and red marrow, respectively.",Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914906/),cgy,380,78982,DB00028,Intravenous Immunoglobulin
,10914906,absorbed doses,"Dosimetry showed mean absorbed doses of 163, 380, 276, 338, 781, and 216 cGy, for whole-body, liver, kidney, spleen, lung, and red marrow, respectively.",Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914906/),cgy,276,78983,DB00028,Intravenous Immunoglobulin
,10914906,absorbed doses,"Dosimetry showed mean absorbed doses of 163, 380, 276, 338, 781, and 216 cGy, for whole-body, liver, kidney, spleen, lung, and red marrow, respectively.",Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914906/),cgy,338,78984,DB00028,Intravenous Immunoglobulin
,10914906,absorbed doses,"Dosimetry showed mean absorbed doses of 163, 380, 276, 338, 781, and 216 cGy, for whole-body, liver, kidney, spleen, lung, and red marrow, respectively.",Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914906/),cgy,781,78985,DB00028,Intravenous Immunoglobulin
,10914906,absorbed doses,"Dosimetry showed mean absorbed doses of 163, 380, 276, 338, 781, and 216 cGy, for whole-body, liver, kidney, spleen, lung, and red marrow, respectively.",Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914906/),cgy,216,78986,DB00028,Intravenous Immunoglobulin
,10914906,Tumor-absorbed doses,Tumor-absorbed doses ranged from 600 to 3800 cGy.,Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914906/),cgy,600 to 3800,78987,DB00028,Intravenous Immunoglobulin
>,33875433,half-life,NTM-1632 has a favorable PK profile with a half-life of >20 days for the 0.330-mg/kg dose and an approximately linear relationship with respect to maximum concentration and area under the concentration-time curve (AUC0→t).,"Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33875433/),d,20,79956,DB00028,Intravenous Immunoglobulin
,27342758,"AUC0-τ,IV","The adjusted weekly mean AUC0-τ,IV was 216,873.7 h*mg/dL for the IV phase versus a mean AUC0-τ,SC of 230,830.0 h*mg/dL for the SC phase.","Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27342758/),[h·mg] / [dl],"216,873.7",80886,DB00028,Intravenous Immunoglobulin
,27342758,"AUC0-τ,SC","The adjusted weekly mean AUC0-τ,IV was 216,873.7 h*mg/dL for the IV phase versus a mean AUC0-τ,SC of 230,830.0 h*mg/dL for the SC phase.","Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27342758/),[h·mg] / [dl],"230,830.0",80887,DB00028,Intravenous Immunoglobulin
,27342758,C trough,The mean (range) C trough was 997.2 (784-1320) mg/dL in the IV phase and 1325.0 (1077-1690) mg/dL in the SC phase.,"Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27342758/),[mg] / [dl],997.2,80888,DB00028,Intravenous Immunoglobulin
,27342758,C trough,The mean (range) C trough was 997.2 (784-1320) mg/dL in the IV phase and 1325.0 (1077-1690) mg/dL in the SC phase.,"Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27342758/),[mg] / [dl],1325.0,80889,DB00028,Intravenous Immunoglobulin
,21424824,trough IgG level,"Pharmacokinetic equivalence of subcutaneous treatment was achieved at a median dose of 137% of the intravenous dose, with a mean trough IgG level of 1,202 mg/dL at the end of the assessment period.","Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21424824/),[mg] / [dl],"1,202",81120,DB00028,Intravenous Immunoglobulin
,21424824,overall infection rate,The overall infection rate during subcutaneous treatment was 4.1 per subject-year.,"Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21424824/),1/[subject-year],4.1,81121,DB00028,Intravenous Immunoglobulin
,17909953,serious bacterial infection rate,The calculated serious bacterial infection rate was 0.021/subject/year.,"A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909953/),1/[subject·year],0.021,81402,DB00028,Intravenous Immunoglobulin
,17909953,half-life,The half-life in serum of the administered IgG was around 31 days.,"A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909953/),d,31,81403,DB00028,Intravenous Immunoglobulin
,15671306,terminal half-life,"Ranibizumab cleared in parallel from all ocular compartments, with a terminal half-life of approximately 3 days.",Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671306/),d,3,85793,DB00028,Intravenous Immunoglobulin
,15671306,bioavailability (F),"After ITV injection, bioavailability (F) was 50% to 60%.",Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671306/),%,50,85794,DB00028,Intravenous Immunoglobulin
,15671306,bioavailability (F),"After ITV injection, bioavailability (F) was 50% to 60%.",Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671306/),%,60,85795,DB00028,Intravenous Immunoglobulin
,15671306,terminal half-life,"After IV administration, the terminal half-life was approximately 0.5 day.",Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671306/),d,0.5,85796,DB00028,Intravenous Immunoglobulin
,15196130,trough levels,"In vivo: In the pharmacokinetic study, trough levels of ABI (before the next dose) ranged between 190 and 580 microg/ml, and the estimated half-life was 10-15 days.","Initial experience with the human anti-human CD154 monoclonal antibody, ABI793, in pig-to-baboon xenotransplantation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196130/),[μg] / [ml],190 and 580,86072,DB00028,Intravenous Immunoglobulin
,15196130,half-life,"In vivo: In the pharmacokinetic study, trough levels of ABI (before the next dose) ranged between 190 and 580 microg/ml, and the estimated half-life was 10-15 days.","Initial experience with the human anti-human CD154 monoclonal antibody, ABI793, in pig-to-baboon xenotransplantation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196130/),d,10-15,86073,DB00028,Intravenous Immunoglobulin
,28711959,annualized rate of infections,The mean annualized rate of infections was 3.79/patient.,"A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28711959/),1/[patient],3.79,86865,DB00028,Intravenous Immunoglobulin
>,28711959,trough level,A lower risk of infections was associated with an IgG trough level > 8 g/L (p = 0.01).,"A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28711959/),[g] / [l],8,86866,DB00028,Intravenous Immunoglobulin
,28711959,trough level,The mean serum IgG trough level before the 6th infusion was 7.73 g/L after a mean dose of IqYmune® of 0.57 g/kg.,"A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28711959/),[g] / [l],7.73,86867,DB00028,Intravenous Immunoglobulin
≥,24115082,serum trough to,"88% of 162-mg q2w patients and 100% of 162-mg qw patients maintained mean serum trough tocilizumab concentrations of ≥1 µg/mL, and had exposure comparable with the approved intravenous tocilizumab dose of 8 mg/kg; this resulted in normalized C-reactive protein levels and improvement in ACR20/50/70 responses.",Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24115082/),[μg] / [ml],1,87292,DB00028,Intravenous Immunoglobulin
,10669338,half-life,"The half-life of HIVIG, determined by serial p24 antibody titers, was 13-16 days, the volume of distribution was 102-113 mL/kg, and clearance was 5.6-6.0 mL/kg/day.",Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669338/),d,13-16,88100,DB00028,Intravenous Immunoglobulin
,10669338,volume of distribution,"The half-life of HIVIG, determined by serial p24 antibody titers, was 13-16 days, the volume of distribution was 102-113 mL/kg, and clearance was 5.6-6.0 mL/kg/day.",Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669338/),[ml] / [kg],102-113,88101,DB00028,Intravenous Immunoglobulin
,10669338,clearance,"The half-life of HIVIG, determined by serial p24 antibody titers, was 13-16 days, the volume of distribution was 102-113 mL/kg, and clearance was 5.6-6.0 mL/kg/day.",Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669338/),[ml] / [d·kg],5.6-6.0,88102,DB00028,Intravenous Immunoglobulin
,30088423,rate of serious bacterial infections,The rate of serious bacterial infections was 0.04/patient-year.,Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30088423/),1/[patient-year],0.04,89008,DB00028,Intravenous Immunoglobulin
,30088423,maximal infusion rate,A maximal infusion rate of 0.14 ml/kg/min was achieved in 82% of pediatric patients (n = 9).,Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30088423/),[ml] / [kg·min],0.14,89009,DB00028,Intravenous Immunoglobulin
≥,30088423,trough levels,Infusions of immunoglobulin G trough levels between infusions remained ≥5-6 g/l; median half-life was 32.79-36.62 days.,Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30088423/),[g] / [l],5-6,89010,DB00028,Intravenous Immunoglobulin
,30088423,half-life,Infusions of immunoglobulin G trough levels between infusions remained ≥5-6 g/l; median half-life was 32.79-36.62 days.,Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30088423/),d,32.79-36.62,89011,DB00028,Intravenous Immunoglobulin
,20801597,K(d),"B7.1-Fc bound to CD28 and CTLA-4 with K(d) values of 45.1 and 9.58 nM, respectively, which were very closed to the previous reports and the function of Fc moiety of fusion protein was also confirmed by Fc receptor binding assay and IL-8 releasing assay.",Qualitative and quantitative studies on human B7.1-Fc fusion protein and the application in pharmacokinetic study in rhesus monkeys. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20801597/),nM,45.1,89105,DB00028,Intravenous Immunoglobulin
,20801597,K(d),"B7.1-Fc bound to CD28 and CTLA-4 with K(d) values of 45.1 and 9.58 nM, respectively, which were very closed to the previous reports and the function of Fc moiety of fusion protein was also confirmed by Fc receptor binding assay and IL-8 releasing assay.",Qualitative and quantitative studies on human B7.1-Fc fusion protein and the application in pharmacokinetic study in rhesus monkeys. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20801597/),nM,9.58,89106,DB00028,Intravenous Immunoglobulin
,32135491,clearance,"Based on uncorrected baseline concentration-time data, the clearance and half-life of Gammagard were 3.1 ± 0.7 mL/day and 22 ± 6 days, respectively.",Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32135491/),[ml] / [d],3.1,93621,DB00028,Intravenous Immunoglobulin
,32135491,half-life,"Based on uncorrected baseline concentration-time data, the clearance and half-life of Gammagard were 3.1 ± 0.7 mL/day and 22 ± 6 days, respectively.",Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32135491/),d,22,93622,DB00028,Intravenous Immunoglobulin
,32135491,clearance,"Based on corrected baseline concentration-time data, the clearance and half-life of Gammagard were 20.2 ± 7.4 mL/day and 5.3 ± 2.2 days, respectively.",Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32135491/),[ml] / [d],20.2,93623,DB00028,Intravenous Immunoglobulin
,32135491,half-life,"Based on corrected baseline concentration-time data, the clearance and half-life of Gammagard were 20.2 ± 7.4 mL/day and 5.3 ± 2.2 days, respectively.",Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32135491/),d,5.3,93624,DB00028,Intravenous Immunoglobulin
,19446146,t((1/2)),"The mean t((1/2)) after intravenous administration was approximately 26 days (range, 25-28 days); the mean t((1/2)) after subcutaneous administration ranged from 33 to 87 days across doses.","Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446146/),d,26,93937,DB00028,Intravenous Immunoglobulin
,19446146,t((1/2)),"The mean t((1/2)) after intravenous administration was approximately 26 days (range, 25-28 days); the mean t((1/2)) after subcutaneous administration ranged from 33 to 87 days across doses.","Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446146/),d,33 to 87,93938,DB00028,Intravenous Immunoglobulin
,15647331,terminal half-life,The terminal half-life of the anti-IFX IgG antibody immune complex was approximately 38 h compared with 86 h for the nonimmune antibody.,"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15647331/),h,38,94275,DB00028,Intravenous Immunoglobulin
,15647331,terminal half-life,The terminal half-life of the anti-IFX IgG antibody immune complex was approximately 38 h compared with 86 h for the nonimmune antibody.,"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15647331/),h,86,94276,DB00028,Intravenous Immunoglobulin
,7664172,initial,"These concentrations declined slowly, with initial and terminal half-lives (mean +/- standard deviation) of 9.95 +/- 3.23 and 47.6 +/- 22.3 h, respectively.",Transport of recombinant human CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7664172/),h,9.95,94277,DB00028,Intravenous Immunoglobulin
,7664172,terminal half-lives,"These concentrations declined slowly, with initial and terminal half-lives (mean +/- standard deviation) of 9.95 +/- 3.23 and 47.6 +/- 22.3 h, respectively.",Transport of recombinant human CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7664172/),h,47.6,94278,DB00028,Intravenous Immunoglobulin
,7664172,half-life,The half-life of rCD4-IgG in infants ranged from 5 to 29 h.,Transport of recombinant human CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7664172/),h,5 to 29,94279,DB00028,Intravenous Immunoglobulin
∼,22223821,half-life (t(1/2)),"Current factor VIII (FVIII) products display a half-life (t(1/2)) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A.",Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22223821/),h,8-12,96371,DB00028,Intravenous Immunoglobulin
,24412778,t1/2π,"There is a rapid (t1/2π = 0.4 h) and a slow (t1/2α = 0.8 h) distribution phase, followed by a long elimination phase (t1/2β = 19.3 h) with a systemic clearance of 6.8 mL h(-1) kg(-1), consistent with the prolonged abnormal hemostasis reported in H. hypnale envenomation.",Pharmacokinetics of the Sri Lankan hump-nosed pit viper (Hypnale hypnale) venom following intravenous and intramuscular injections of the venom into rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412778/),h,0.4,96821,DB00028,Intravenous Immunoglobulin
,24412778,t1/2α,"There is a rapid (t1/2π = 0.4 h) and a slow (t1/2α = 0.8 h) distribution phase, followed by a long elimination phase (t1/2β = 19.3 h) with a systemic clearance of 6.8 mL h(-1) kg(-1), consistent with the prolonged abnormal hemostasis reported in H. hypnale envenomation.",Pharmacokinetics of the Sri Lankan hump-nosed pit viper (Hypnale hypnale) venom following intravenous and intramuscular injections of the venom into rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412778/),h,0.8,96822,DB00028,Intravenous Immunoglobulin
,24412778,t1/2β,"There is a rapid (t1/2π = 0.4 h) and a slow (t1/2α = 0.8 h) distribution phase, followed by a long elimination phase (t1/2β = 19.3 h) with a systemic clearance of 6.8 mL h(-1) kg(-1), consistent with the prolonged abnormal hemostasis reported in H. hypnale envenomation.",Pharmacokinetics of the Sri Lankan hump-nosed pit viper (Hypnale hypnale) venom following intravenous and intramuscular injections of the venom into rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412778/),h,19.3,96823,DB00028,Intravenous Immunoglobulin
,24412778,systemic clearance,"There is a rapid (t1/2π = 0.4 h) and a slow (t1/2α = 0.8 h) distribution phase, followed by a long elimination phase (t1/2β = 19.3 h) with a systemic clearance of 6.8 mL h(-1) kg(-1), consistent with the prolonged abnormal hemostasis reported in H. hypnale envenomation.",Pharmacokinetics of the Sri Lankan hump-nosed pit viper (Hypnale hypnale) venom following intravenous and intramuscular injections of the venom into rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412778/),[ml] / [h·kg],6.8,96824,DB00028,Intravenous Immunoglobulin
,24412778,in,"The intramuscular bioavailability was exceptionally low (Fi.m. = 4%), accountable for the highly varied median lethal doses between intravenous and intramuscular envenomations in animals.",Pharmacokinetics of the Sri Lankan hump-nosed pit viper (Hypnale hypnale) venom following intravenous and intramuscular injections of the venom into rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412778/),%,4,96825,DB00028,Intravenous Immunoglobulin
,2921838,extrarenal clearance,The extrarenal clearance of Fab fragments was lower (5.6 ml/min) than in patients with normal kidney function (10.9 ml/min).,Digitalis intoxication and treatment with digoxin antibody fragments in renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2921838/),[ml] / [min],5.6,97256,DB00028,Intravenous Immunoglobulin
,2921838,extrarenal clearance,The extrarenal clearance of Fab fragments was lower (5.6 ml/min) than in patients with normal kidney function (10.9 ml/min).,Digitalis intoxication and treatment with digoxin antibody fragments in renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2921838/),[ml] / [min],10.9,97257,DB00028,Intravenous Immunoglobulin
,19725594,half-life,"CNTO 528 exhibits a half-life of 141 hours, or approximately 5.9 days.",Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725594/),h,141,97270,DB00028,Intravenous Immunoglobulin
,19725594,half-life,"CNTO 528 exhibits a half-life of 141 hours, or approximately 5.9 days.",Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725594/),d,5.9,97271,DB00028,Intravenous Immunoglobulin
,19725594,SC(50),"The SC(50) was estimated to be 0.37 mg/L, indicating that low serum CNTO 528 concentration was sufficient to produce pharmacological effects.",Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725594/),[mg] / [l],0.37,97272,DB00028,Intravenous Immunoglobulin
,25212703,clearance,"Daclizumab HYP clearance, inter-compartmental clearance, and central and peripheral volumes of distribution were 10 mL/h, 44 mL/h, 3.89 L, and 2.52 L, respectively, scaled by [bodyweight (kg)/70] with 0.54 and 0.64 exponents for clearance and volume parameters, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),[ml] / [h],10,97308,DB00028,Intravenous Immunoglobulin
,25212703,inter-compartmental clearance,"Daclizumab HYP clearance, inter-compartmental clearance, and central and peripheral volumes of distribution were 10 mL/h, 44 mL/h, 3.89 L, and 2.52 L, respectively, scaled by [bodyweight (kg)/70] with 0.54 and 0.64 exponents for clearance and volume parameters, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),[ml] / [h],44,97309,DB00028,Intravenous Immunoglobulin
,25212703,inter-compartmental clearance,"Daclizumab HYP clearance, inter-compartmental clearance, and central and peripheral volumes of distribution were 10 mL/h, 44 mL/h, 3.89 L, and 2.52 L, respectively, scaled by [bodyweight (kg)/70] with 0.54 and 0.64 exponents for clearance and volume parameters, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),l,3.89,97310,DB00028,Intravenous Immunoglobulin
,25212703,central,"Daclizumab HYP clearance, inter-compartmental clearance, and central and peripheral volumes of distribution were 10 mL/h, 44 mL/h, 3.89 L, and 2.52 L, respectively, scaled by [bodyweight (kg)/70] with 0.54 and 0.64 exponents for clearance and volume parameters, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),[ml] / [h],44,97311,DB00028,Intravenous Immunoglobulin
,25212703,central,"Daclizumab HYP clearance, inter-compartmental clearance, and central and peripheral volumes of distribution were 10 mL/h, 44 mL/h, 3.89 L, and 2.52 L, respectively, scaled by [bodyweight (kg)/70] with 0.54 and 0.64 exponents for clearance and volume parameters, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),l,3.89,97312,DB00028,Intravenous Immunoglobulin
,25212703,peripheral volumes of distribution,"Daclizumab HYP clearance, inter-compartmental clearance, and central and peripheral volumes of distribution were 10 mL/h, 44 mL/h, 3.89 L, and 2.52 L, respectively, scaled by [bodyweight (kg)/70] with 0.54 and 0.64 exponents for clearance and volume parameters, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),l,2.52,97313,DB00028,Intravenous Immunoglobulin
,25212703,Lag-time,"Lag-time, mean absorption time, and absolute bioavailability (100-300 mg) for subcutaneous administration were 2 h, 4.6 days, and 84 %, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),h,2,97314,DB00028,Intravenous Immunoglobulin
,25212703,mean absorption time,"Lag-time, mean absorption time, and absolute bioavailability (100-300 mg) for subcutaneous administration were 2 h, 4.6 days, and 84 %, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),d,4.6,97315,DB00028,Intravenous Immunoglobulin
,25212703,absolute bioavailability,"Lag-time, mean absorption time, and absolute bioavailability (100-300 mg) for subcutaneous administration were 2 h, 4.6 days, and 84 %, respectively.","Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),%,84,97316,DB00028,Intravenous Immunoglobulin
,25212703,effective half-life,The estimated effective half-life was 21-25 days.,"Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212703/),d,21-25,97317,DB00028,Intravenous Immunoglobulin
,27381392,half-life,"MHAA4549A showed linear serum pharmacokinetics, with a mean half-life of 22.5 to 23.7 days.","Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27381392/),d,22.5 to 23.7,98108,DB00028,Intravenous Immunoglobulin
up to,24080653,half-life,"In this first study of an Fc-modified monoclonal antibody in humans, motavizumab-YTE was well tolerated and exhibited an extended half-life of up to 100 days.","A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24080653/),d,100,98563,DB00028,Intravenous Immunoglobulin
,18211620,half-life,"High level of erythrocyte ribavirin (1085 microM; mostly as phosphorylated metabolites) with long half-life (15 days) caused severe anaemia, which required several blood transfusions for 2 weeks after the cessation of the ribavirin treatment.",Blood ribavirin concentration in high-dose ribavirin for adenovirus-induced haemorrhagic cystitis - a case report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18211620/),d,15,101142,DB00028,Intravenous Immunoglobulin
,3520504,half-life,A half-life of 11.3 days for the initial phase and 30.7 days for the terminal phase was observed.,Pharmacokinetics of intravenous immunoglobulin (Sandoglobulin) in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3520504/),d,11.3,101267,DB00028,Intravenous Immunoglobulin
,3520504,half-life,A half-life of 11.3 days for the initial phase and 30.7 days for the terminal phase was observed.,Pharmacokinetics of intravenous immunoglobulin (Sandoglobulin) in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3520504/),d,30.7,101268,DB00028,Intravenous Immunoglobulin
,1361548,volume of distribution,"The plasma disposition was characterized by a volume of distribution of 179 +/- 48 mL kg-1, total body clearance of 1.02 +/- 0.07 mL min-1 kg-1, t1/2 alpha of 0.17 +/- 0.03 h and t1/2 beta of 1.3 +/- 0.3 h.",Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),[ml] / [kg],179,102131,DB00028,Intravenous Immunoglobulin
,1361548,total body clearance,"The plasma disposition was characterized by a volume of distribution of 179 +/- 48 mL kg-1, total body clearance of 1.02 +/- 0.07 mL min-1 kg-1, t1/2 alpha of 0.17 +/- 0.03 h and t1/2 beta of 1.3 +/- 0.3 h.",Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),[ml] / [kg·min],1.02,102132,DB00028,Intravenous Immunoglobulin
,1361548,t1/2 alpha,"The plasma disposition was characterized by a volume of distribution of 179 +/- 48 mL kg-1, total body clearance of 1.02 +/- 0.07 mL min-1 kg-1, t1/2 alpha of 0.17 +/- 0.03 h and t1/2 beta of 1.3 +/- 0.3 h.",Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),h,0.17,102133,DB00028,Intravenous Immunoglobulin
,1361548,t1/2 beta,"The plasma disposition was characterized by a volume of distribution of 179 +/- 48 mL kg-1, total body clearance of 1.02 +/- 0.07 mL min-1 kg-1, t1/2 alpha of 0.17 +/- 0.03 h and t1/2 beta of 1.3 +/- 0.3 h.",Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),h,1.3,102134,DB00028,Intravenous Immunoglobulin
,1361548,fraction of,The fraction of colchicine dose excreted by the urinary route was 38 +/- 6.9 and 9 +/- 0.7% respectively in Fab-colchicine- and colchicine-treated groups (P < 0.01).,Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),%,38,102135,DB00028,Intravenous Immunoglobulin
,1361548,fraction of,The fraction of colchicine dose excreted by the urinary route was 38 +/- 6.9 and 9 +/- 0.7% respectively in Fab-colchicine- and colchicine-treated groups (P < 0.01).,Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),%,9,102136,DB00028,Intravenous Immunoglobulin
,3041358,Serum half-lives,"Serum half-lives of IgG following infusions were remarkably short (means, 47 hours for infusions within 3 days of injury and 154 hours for infusions in the third postburn week); Sandoglobulin has been reported to have approximately a 21-day half-life in normal individuals.",High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3041358/),h,47,105696,DB00028,Intravenous Immunoglobulin
,3041358,Serum half-lives,"Serum half-lives of IgG following infusions were remarkably short (means, 47 hours for infusions within 3 days of injury and 154 hours for infusions in the third postburn week); Sandoglobulin has been reported to have approximately a 21-day half-life in normal individuals.",High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3041358/),h,154,105697,DB00028,Intravenous Immunoglobulin
,3041358,Serum half-lives,"Serum half-lives of IgG following infusions were remarkably short (means, 47 hours for infusions within 3 days of injury and 154 hours for infusions in the third postburn week); Sandoglobulin has been reported to have approximately a 21-day half-life in normal individuals.",High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3041358/),d,21,105698,DB00028,Intravenous Immunoglobulin
,3041358,half-life,"Serum half-lives of IgG following infusions were remarkably short (means, 47 hours for infusions within 3 days of injury and 154 hours for infusions in the third postburn week); Sandoglobulin has been reported to have approximately a 21-day half-life in normal individuals.",High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3041358/),d,21,105699,DB00028,Intravenous Immunoglobulin
,2383479,Serum half-life,Serum half-life was 8 h.,Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383479/),h,8,106390,DB00028,Intravenous Immunoglobulin
,2383479,Maximum tumour uptake,"Maximum tumour uptake was between 1 and 8 h after administration and amounted to, respectively, 3% and 1% of the injected dose g-1 for WiDr and NIH:OVCAR-3 tumours.",Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383479/),h,1 and 8,106391,DB00028,Intravenous Immunoglobulin
,2383479,Maximum tumour uptake,"Maximum tumour uptake was between 1 and 8 h after administration and amounted to, respectively, 3% and 1% of the injected dose g-1 for WiDr and NIH:OVCAR-3 tumours.",Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383479/),%,3,106392,DB00028,Intravenous Immunoglobulin
,2383479,Maximum tumour uptake,"Maximum tumour uptake was between 1 and 8 h after administration and amounted to, respectively, 3% and 1% of the injected dose g-1 for WiDr and NIH:OVCAR-3 tumours.",Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383479/),%,1,106393,DB00028,Intravenous Immunoglobulin
,2383479,Half-lives,Half-lives in these tumours were approximately 24 h.,Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383479/),h,24,106394,DB00028,Intravenous Immunoglobulin
,2383479,uptake ratios,Tumour to normal colon uptake ratios increased from 2.3 at 24 h to 17 at 5 days after injection.,Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383479/),,2.3,106395,DB00028,Intravenous Immunoglobulin
,2383479,uptake ratios,Tumour to normal colon uptake ratios increased from 2.3 at 24 h to 17 at 5 days after injection.,Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383479/),,17,106396,DB00028,Intravenous Immunoglobulin
,2383479,Serum half-life,Serum half-life was 20 h with greater than 90% of the 131I bound to 16.88.,Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383479/),h,20,106397,DB00028,Intravenous Immunoglobulin
,1810192,peak concentrations,"After intravenous administration, peak concentrations of rCD4-IgG in serum (20 to 24 micrograms/ml) that have shown antiviral activity in vitro against more sensitive clinical isolates of human immunodeficiency virus were achieved.",Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810192/),[μg] / [ml],20 to 24,107335,DB00028,Intravenous Immunoglobulin
,34107983,half-life,"Pharmacokinetic analysis showed that IL-15/SuIL-15Rα-dFc had a half-life of 14.26 h while IL-15/SuIL-15Rα-mFc had a half-life of 9.16 h in mice, which were much longer than the 0.7-h half-life of commercial recombinant human IL-15 (rhIL-15).",Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34107983/),h,14.26,107368,DB00028,Intravenous Immunoglobulin
,34107983,half-life,"Pharmacokinetic analysis showed that IL-15/SuIL-15Rα-dFc had a half-life of 14.26 h while IL-15/SuIL-15Rα-mFc had a half-life of 9.16 h in mice, which were much longer than the 0.7-h half-life of commercial recombinant human IL-15 (rhIL-15).",Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34107983/),h,9.16,107369,DB00028,Intravenous Immunoglobulin
,34107983,half-life,"Pharmacokinetic analysis showed that IL-15/SuIL-15Rα-dFc had a half-life of 14.26 h while IL-15/SuIL-15Rα-mFc had a half-life of 9.16 h in mice, which were much longer than the 0.7-h half-life of commercial recombinant human IL-15 (rhIL-15).",Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34107983/),h,0.7,107370,DB00028,Intravenous Immunoglobulin
,9653060,Vdss,"Using these allometric techniques, Vdss, Vd beta, Cltot, and t1/2 beta were calculated as 4.12 liter, 4.78 liter, 19.07 ml/h, and 7.2 days, respectively, for a human subject of 70 kg body wt.",Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653060/),l,4.12,114710,DB00028,Intravenous Immunoglobulin
,9653060,Vd beta,"Using these allometric techniques, Vdss, Vd beta, Cltot, and t1/2 beta were calculated as 4.12 liter, 4.78 liter, 19.07 ml/h, and 7.2 days, respectively, for a human subject of 70 kg body wt.",Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653060/),l,4.78,114711,DB00028,Intravenous Immunoglobulin
,9653060,Vd beta,"Using these allometric techniques, Vdss, Vd beta, Cltot, and t1/2 beta were calculated as 4.12 liter, 4.78 liter, 19.07 ml/h, and 7.2 days, respectively, for a human subject of 70 kg body wt.",Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653060/),[ml] / [h],19.07,114712,DB00028,Intravenous Immunoglobulin
,9653060,Cltot,"Using these allometric techniques, Vdss, Vd beta, Cltot, and t1/2 beta were calculated as 4.12 liter, 4.78 liter, 19.07 ml/h, and 7.2 days, respectively, for a human subject of 70 kg body wt.",Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653060/),l,4.78,114713,DB00028,Intravenous Immunoglobulin
,9653060,Cltot,"Using these allometric techniques, Vdss, Vd beta, Cltot, and t1/2 beta were calculated as 4.12 liter, 4.78 liter, 19.07 ml/h, and 7.2 days, respectively, for a human subject of 70 kg body wt.",Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653060/),[ml] / [h],19.07,114714,DB00028,Intravenous Immunoglobulin
,9653060,t1/2 beta,"Using these allometric techniques, Vdss, Vd beta, Cltot, and t1/2 beta were calculated as 4.12 liter, 4.78 liter, 19.07 ml/h, and 7.2 days, respectively, for a human subject of 70 kg body wt.",Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653060/),d,7.2,114715,DB00028,Intravenous Immunoglobulin
,9653060,clearance,"However, the clearance was six-fold lower than values given by Hnatowich et al. (130 ml/h) and Ho et al.",Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653060/),[ml] / [h],130,114716,DB00028,Intravenous Immunoglobulin
,17698592,serum clearance,"In children, serum clearance was 2.0 to 9.4 mL/min/kg and tended to decrease with increasing age.",Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17698592/),[ml] / [kg·min],2.0 to 9.4,115313,DB00028,Intravenous Immunoglobulin
,17698592,clearance,"The average clearance in children, 3.7 +/- 1.5 mL/min/kg (mean +/- SD), was significantly greater than that measured in 33 adults (2.3 +/- 0.7 mL/min/kg, P < .0001).",Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17698592/),[ml] / [kg·min],3.7,115314,DB00028,Intravenous Immunoglobulin
,17698592,clearance,"The average clearance in children, 3.7 +/- 1.5 mL/min/kg (mean +/- SD), was significantly greater than that measured in 33 adults (2.3 +/- 0.7 mL/min/kg, P < .0001).",Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17698592/),[ml] / [kg·min],2.3,115315,DB00028,Intravenous Immunoglobulin
,17698592,terminal elimination half-life,Mean terminal elimination half-life of agalsidase alpha was prolonged in week 25 compared with baseline (150 vs 66 minutes) in 8 of 19 male children.,Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17698592/),min,150,115316,DB00028,Intravenous Immunoglobulin
,17698592,terminal elimination half-life,Mean terminal elimination half-life of agalsidase alpha was prolonged in week 25 compared with baseline (150 vs 66 minutes) in 8 of 19 male children.,Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17698592/),min,66,115317,DB00028,Intravenous Immunoglobulin
,26177518,half-life,The half-life of IdeS was 4.9 (±2.8) hours at 0.24 mg/kg with the main fraction eliminated during 24 hours.,Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26177518/),h,4.9,115768,DB00028,Intravenous Immunoglobulin
,31600485,half-life,"Drug exposure in choroid and retina was approximately one-quarter and one-twelfth of that in vitreous humor, while its half-life in vitreous and aqueous humor were well-sustained (3.3 and 3.0 days).","In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31600485/),d,3.3,119669,DB00028,Intravenous Immunoglobulin
,31600485,half-life,"Drug exposure in choroid and retina was approximately one-quarter and one-twelfth of that in vitreous humor, while its half-life in vitreous and aqueous humor were well-sustained (3.3 and 3.0 days).","In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31600485/),d,3.0,119670,DB00028,Intravenous Immunoglobulin
,31600485,systemic bioavailability,"Remarkably, RC28-E could cross the blood-ocular barrier, and the systemic bioavailability of RC28-E was ~25%.","In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31600485/),%,25,119671,DB00028,Intravenous Immunoglobulin
,8658517,Vdss,"Using these allometric techniques, Vdss, Vd beta, Cltot and t 1/2 beta were calculated as 10.75 liter, 24.64 liter, 17.9 ml/min, and 16 hr, respectively, for a human subject of 70 kg body weight.",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),l,10.75,121407,DB00028,Intravenous Immunoglobulin
,8658517,Vd beta,"Using these allometric techniques, Vdss, Vd beta, Cltot and t 1/2 beta were calculated as 10.75 liter, 24.64 liter, 17.9 ml/min, and 16 hr, respectively, for a human subject of 70 kg body weight.",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),l,24.64,121408,DB00028,Intravenous Immunoglobulin
,8658517,Vd beta,"Using these allometric techniques, Vdss, Vd beta, Cltot and t 1/2 beta were calculated as 10.75 liter, 24.64 liter, 17.9 ml/min, and 16 hr, respectively, for a human subject of 70 kg body weight.",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),[ml] / [min],17.9,121409,DB00028,Intravenous Immunoglobulin
,8658517,Cltot,"Using these allometric techniques, Vdss, Vd beta, Cltot and t 1/2 beta were calculated as 10.75 liter, 24.64 liter, 17.9 ml/min, and 16 hr, respectively, for a human subject of 70 kg body weight.",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),l,24.64,121410,DB00028,Intravenous Immunoglobulin
,8658517,Cltot,"Using these allometric techniques, Vdss, Vd beta, Cltot and t 1/2 beta were calculated as 10.75 liter, 24.64 liter, 17.9 ml/min, and 16 hr, respectively, for a human subject of 70 kg body weight.",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),[ml] / [min],17.9,121411,DB00028,Intravenous Immunoglobulin
,8658517,t 1/2 beta,"Using these allometric techniques, Vdss, Vd beta, Cltot and t 1/2 beta were calculated as 10.75 liter, 24.64 liter, 17.9 ml/min, and 16 hr, respectively, for a human subject of 70 kg body weight.",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),h,16,121412,DB00028,Intravenous Immunoglobulin
,8658517,Vd beta,"These values are in accordance with those previously described in digoxin-Fab-treated patients (body weight = 61 +/- 3 kg, Vd beta = 24.9 +/- 3. 7 liter; Cltot = 20.8 +/- 2.1 ml/min; t 1/2 beta = 14.3 +/- 1.8 hr).",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),l,24.9,121413,DB00028,Intravenous Immunoglobulin
,8658517,Cltot,"These values are in accordance with those previously described in digoxin-Fab-treated patients (body weight = 61 +/- 3 kg, Vd beta = 24.9 +/- 3. 7 liter; Cltot = 20.8 +/- 2.1 ml/min; t 1/2 beta = 14.3 +/- 1.8 hr).",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),[ml] / [min],20.8,121414,DB00028,Intravenous Immunoglobulin
,8658517,t 1/2 beta,"These values are in accordance with those previously described in digoxin-Fab-treated patients (body weight = 61 +/- 3 kg, Vd beta = 24.9 +/- 3. 7 liter; Cltot = 20.8 +/- 2.1 ml/min; t 1/2 beta = 14.3 +/- 1.8 hr).",Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658517/),h,14.3,121415,DB00028,Intravenous Immunoglobulin
,2555005,Peak titers,Peak titers achieved were comparable to those of the CMV seropositive patients averaging 1:2702 (range 1:596-1:10 514).,Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2555005/),,1,122570,DB00028,Intravenous Immunoglobulin
,2555005,half-life,"After the first dose of IVIg, the half-life of CMV IgG antibody was 3.4 +/- 2.0 (SD) days, although it lengthened to 6.1 +/- 5.1 days after the fifth dose of IVIg.",Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2555005/),d,3.4,122571,DB00028,Intravenous Immunoglobulin
,2555005,half-life,"After the first dose of IVIg, the half-life of CMV IgG antibody was 3.4 +/- 2.0 (SD) days, although it lengthened to 6.1 +/- 5.1 days after the fifth dose of IVIg.",Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2555005/),d,6.1,122572,DB00028,Intravenous Immunoglobulin
,2555005,half-life,"The half-life of total IgG was estimated to be between 5 and 10 days, depending on the assumptions made regarding endogenous production.",Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2555005/),d,5 and 10,122573,DB00028,Intravenous Immunoglobulin
,10551976,half-life,The half-life of endotoxin was half as long when vitamin A was given for prophylaxis (median 35 min) and for treatment (33 min) than in the controls (67 min; p < 0.004).,Acute effects of vitamin A on the kinetics of endotoxin in conscious rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551976/),min,35,122633,DB00028,Intravenous Immunoglobulin
,10551976,half-life,The half-life of endotoxin was half as long when vitamin A was given for prophylaxis (median 35 min) and for treatment (33 min) than in the controls (67 min; p < 0.004).,Acute effects of vitamin A on the kinetics of endotoxin in conscious rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551976/),min,33,122634,DB00028,Intravenous Immunoglobulin
,10551976,half-life,The half-life of endotoxin was half as long when vitamin A was given for prophylaxis (median 35 min) and for treatment (33 min) than in the controls (67 min; p < 0.004).,Acute effects of vitamin A on the kinetics of endotoxin in conscious rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551976/),min,67,122635,DB00028,Intravenous Immunoglobulin
,8306270,Tumor uptake,"Tumor uptake of both antibodies (2.3 +/- 0.53 %ID/kg) was significantly higher than that of normal tissues (0.56 +/- 0.12; P < 0.001), except for blood (2.8 +/- 0.83), resulting in an RI > or = 3.",Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306270/),[%id] / [kg],2.3,125016,DB00028,Intravenous Immunoglobulin
,8306270,Tumor uptake,"Tumor uptake of both antibodies (2.3 +/- 0.53 %ID/kg) was significantly higher than that of normal tissues (0.56 +/- 0.12; P < 0.001), except for blood (2.8 +/- 0.83), resulting in an RI > or = 3.",Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306270/),[%id] / [kg],0.56,125017,DB00028,Intravenous Immunoglobulin
,8306270,Tumor uptake,"Tumor uptake of both antibodies (2.3 +/- 0.53 %ID/kg) was significantly higher than that of normal tissues (0.56 +/- 0.12; P < 0.001), except for blood (2.8 +/- 0.83), resulting in an RI > or = 3.",Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306270/),[%id] / [kg],2.8,125018,DB00028,Intravenous Immunoglobulin
,8306270,uptake,There were no significant differences in uptake (%ID/g) between F(ab')2 and IgG (F[ab']2 = 2.0 +/- 0.57; IgG = 2.6 +/- 0.94).,Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306270/),%,2.0,125019,DB00028,Intravenous Immunoglobulin
,8306270,uptake,There were no significant differences in uptake (%ID/g) between F(ab')2 and IgG (F[ab']2 = 2.0 +/- 0.57; IgG = 2.6 +/- 0.94).,Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306270/),%,2.6,125020,DB00028,Intravenous Immunoglobulin
,8306270,plasma T1/2,The mean +/- SD of plasma T1/2 was slightly shorter for F(ab')2 (28.8 +/- 7.2 hours) than for IgG (45.9 +/- 16.7; P = 0.08).,Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306270/),h,28.8,125021,DB00028,Intravenous Immunoglobulin
,8306270,plasma T1/2,The mean +/- SD of plasma T1/2 was slightly shorter for F(ab')2 (28.8 +/- 7.2 hours) than for IgG (45.9 +/- 16.7; P = 0.08).,Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306270/),,45.9,125022,DB00028,Intravenous Immunoglobulin
,31341417,half-life time,"Its half-life time in vivo is only about 50 minutes, which limits its clinical application.",Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31341417/),min,50,126446,DB00028,Intravenous Immunoglobulin
,31341417,half-life time,The half-life time of PSG4R was 56.270 ± 15.398 h.,Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31341417/),h,56.270,126447,DB00028,Intravenous Immunoglobulin
,1744925,half-life (T1/2 alpha),Blood clearance of the 131I-labeled MAb 16.88 was biphasic with a mean half-life (T1/2 alpha) of 12 hours and T1/2 beta of 45 hours.,Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744925/),h,12,126808,DB00028,Intravenous Immunoglobulin
,1744925,T1/2 beta,Blood clearance of the 131I-labeled MAb 16.88 was biphasic with a mean half-life (T1/2 alpha) of 12 hours and T1/2 beta of 45 hours.,Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744925/),h,45,126809,DB00028,Intravenous Immunoglobulin
,1744925,Clearance rate,Clearance rate was 0.09 L/hour.,Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744925/),[l] / [h],0.09,126810,DB00028,Intravenous Immunoglobulin
,1744925,immunoreactive fraction,"More than 90% of the 131I in serum was protein bound, with an immunoreactive fraction of 80% in the first 48 hours.",Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744925/),%,80,126811,DB00028,Intravenous Immunoglobulin
,1744925,sensitivities,They had sensitivities ranging from 5 ng/mL to 0.5 micrograms/mL for goat or rabbit antihuman IgM.,Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744925/),[ng] / [ml],5,126812,DB00028,Intravenous Immunoglobulin
,1744925,sensitivities,They had sensitivities ranging from 5 ng/mL to 0.5 micrograms/mL for goat or rabbit antihuman IgM.,Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744925/),[μg] / [ml],0.5,126813,DB00028,Intravenous Immunoglobulin
,21749402,half-life,Pharmacokinetic studies resulted in an IgG half-life of 30·9 ± 11·3 days and a mean IgG trough level of 6·8 ± 1·2 g/l.,Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749402/),d,30·9,127477,DB00028,Intravenous Immunoglobulin
,21749402,trough level,Pharmacokinetic studies resulted in an IgG half-life of 30·9 ± 11·3 days and a mean IgG trough level of 6·8 ± 1·2 g/l.,Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749402/),[g] / [l],6·8,127478,DB00028,Intravenous Immunoglobulin
,19997861,Serious bacterial infection rate,Serious bacterial infection rate was 0.025/subject/year.,"Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19997861/),1/[subject·year],0.025,129485,DB00028,Intravenous Immunoglobulin
,19997861,Half-life,Half-life in serum of the administered IgG was approximately 35 days.,"Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19997861/),d,35,129486,DB00028,Intravenous Immunoglobulin
,9336364,serum half-life (,"Antibody serum half-life (and maximum concentration [Cmax]) generally increased between the first and fourth infusions (33.2 hours v 76.6 hours, respectively) following the 375-mg/m2 doses.",IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9336364/),h,33.2,129932,DB00028,Intravenous Immunoglobulin
,9336364,maximum concentration [Cmax],"Antibody serum half-life (and maximum concentration [Cmax]) generally increased between the first and fourth infusions (33.2 hours v 76.6 hours, respectively) following the 375-mg/m2 doses.",IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9336364/),h,76.6,129933,DB00028,Intravenous Immunoglobulin
,9336364,time to disease progression,"Six of 18 assessable patients had a partial remission (PR), with a median time to disease progression of 6.4 months (range, 3 to 21.7).",IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9336364/),month,6.4,129934,DB00028,Intravenous Immunoglobulin
,29623653,clearance,"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),[l] / [d],0.117,130079,DB00028,Intravenous Immunoglobulin
,29623653,volume of distribution of the central (V1),"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),l,0.801,130080,DB00028,Intravenous Immunoglobulin
,29623653,peripheral (V2) compartment,"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),l,0.801,130081,DB00028,Intravenous Immunoglobulin
,29623653,intercompartmental clearance,"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),l,0.962,130082,DB00028,Intravenous Immunoglobulin
,29623653,intercompartmental clearance,"The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091-0.134) L/day, 0.801 (0.545-0.960) L, 0.962 (0.733-1.759) L, and 0.692 (0.482-1.779) L/day, respectively.",Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29623653/),[l] / [d],0.692,130083,DB00028,Intravenous Immunoglobulin
,2760499,peak serum antibody concentrations,"Intravenous bolus infusion of MA-1C1, 1 mg/kg, resulted in peak serum antibody concentrations of 3.8 +/- 0.08 and 3.7 +/- 0.05 micrograms/ml in infected and noninfected animals, respectively.",Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760499/),[μg] / [ml],3.8,130134,DB00028,Intravenous Immunoglobulin
,2760499,peak serum antibody concentrations,"Intravenous bolus infusion of MA-1C1, 1 mg/kg, resulted in peak serum antibody concentrations of 3.8 +/- 0.08 and 3.7 +/- 0.05 micrograms/ml in infected and noninfected animals, respectively.",Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760499/),[μg] / [ml],3.7,130135,DB00028,Intravenous Immunoglobulin
,2760499,Serum half-lives,Serum half-lives were 25 and 22 h in infected and noninfected groups.,Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760499/),h,25,130136,DB00028,Intravenous Immunoglobulin
,2760499,Serum half-lives,Serum half-lives were 25 and 22 h in infected and noninfected groups.,Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760499/),h,22,130137,DB00028,Intravenous Immunoglobulin
,8410279,mean residence time,"After injection, the 111In-DTPA dimer distributed in a large volume (88 ml/kg-180 ml/kg) and cleared through the kidneys (mean residence time in the whole body: 9 hr-16 hr).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),h,9,131532,DB00028,Intravenous Immunoglobulin
,8410279,mean residence time,"After injection, the 111In-DTPA dimer distributed in a large volume (88 ml/kg-180 ml/kg) and cleared through the kidneys (mean residence time in the whole body: 9 hr-16 hr).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),h,16,131533,DB00028,Intravenous Immunoglobulin
,8410279,Uptake,"Uptake of 111In by the tumor using this two-step technique (1.8%-17.5% injected dose ID/kg, measured from surgical samples 48 hr after hapten injection) was not found significantly lower than that achieved with our reference 111In-labeled anti-CEA F(ab)'2 1 to 4 days after injection in six patients with similar clinical status (5.5%-30.2% ID/kg).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),%,1.8,131534,DB00028,Intravenous Immunoglobulin
,8410279,Uptake,"Uptake of 111In by the tumor using this two-step technique (1.8%-17.5% injected dose ID/kg, measured from surgical samples 48 hr after hapten injection) was not found significantly lower than that achieved with our reference 111In-labeled anti-CEA F(ab)'2 1 to 4 days after injection in six patients with similar clinical status (5.5%-30.2% ID/kg).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),%,17.5,131535,DB00028,Intravenous Immunoglobulin
,8410279,Uptake,"Uptake of 111In by the tumor using this two-step technique (1.8%-17.5% injected dose ID/kg, measured from surgical samples 48 hr after hapten injection) was not found significantly lower than that achieved with our reference 111In-labeled anti-CEA F(ab)'2 1 to 4 days after injection in six patients with similar clinical status (5.5%-30.2% ID/kg).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),%,5.5,131536,DB00028,Intravenous Immunoglobulin
,8410279,Uptake,"Uptake of 111In by the tumor using this two-step technique (1.8%-17.5% injected dose ID/kg, measured from surgical samples 48 hr after hapten injection) was not found significantly lower than that achieved with our reference 111In-labeled anti-CEA F(ab)'2 1 to 4 days after injection in six patients with similar clinical status (5.5%-30.2% ID/kg).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),%,30.2,131537,DB00028,Intravenous Immunoglobulin
,8410279,tumor-to-blood,"In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),,7.8,131538,DB00028,Intravenous Immunoglobulin
,8410279,tumor-to-blood,"In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),,4.2,131539,DB00028,Intravenous Immunoglobulin
,8410279,tumor-to-blood,"In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),,2.8,131540,DB00028,Intravenous Immunoglobulin
,8410279,tumor-to-liver uptake ratios,"In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),,4.2,131541,DB00028,Intravenous Immunoglobulin
,8410279,tumor-to-liver uptake ratios,"In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),,2.8,131542,DB00028,Intravenous Immunoglobulin
,8410279,tumor-to-liver uptake ratios,"In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8).","Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410279/),,0.8,131543,DB00028,Intravenous Immunoglobulin
,19743503,Bioavailability,Bioavailability was approximately 30-40% following sc or iv administration and similar doses yielded similar biological activity irrespective of administration route.,Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19743503/),%,30-40,132860,DB00028,Intravenous Immunoglobulin
,19630866,serious bacterial infection rate,The serious bacterial infection rate was 0.021/subject/year.,Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19630866/),1/[subject·year],0.021,134783,DB00028,Intravenous Immunoglobulin
,19630866,half-life,The half-life in serum of the administered IgG was around 31 days.,Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19630866/),d,31,134784,DB00028,Intravenous Immunoglobulin
,8897267,area under the total MTX concentration vs time curve,"Pharmacokinetic studies revealed that intravenous anti-methotrexate immunoglobulin G (anti-MTX IgG) and anti-methotrexate Fab (anti-MTX Fab) administration produced dramatic alterations in the plasma pharmacokinetics of methotrexate (MTX), following intraperitoneal MTX administration (area under the total MTX concentration vs time curve for anti-MTX IgG relative to control, 420 +/- 90 (p < 0.05); for anti-MTX Fab relative to control, 46 +/- 6.1 (p < 0.05); area under the free MTX concentration vs time curve for anti-MTX IgG relative to control, 0.64 +/- 0.16; for anti-MTX Fab relative to control, 0.45 +/- 0.20 (p < 0.05)).",Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897267/),,420,135477,DB00028,Intravenous Immunoglobulin
,8897267,area under the total MTX concentration vs time curve,"Pharmacokinetic studies revealed that intravenous anti-methotrexate immunoglobulin G (anti-MTX IgG) and anti-methotrexate Fab (anti-MTX Fab) administration produced dramatic alterations in the plasma pharmacokinetics of methotrexate (MTX), following intraperitoneal MTX administration (area under the total MTX concentration vs time curve for anti-MTX IgG relative to control, 420 +/- 90 (p < 0.05); for anti-MTX Fab relative to control, 46 +/- 6.1 (p < 0.05); area under the free MTX concentration vs time curve for anti-MTX IgG relative to control, 0.64 +/- 0.16; for anti-MTX Fab relative to control, 0.45 +/- 0.20 (p < 0.05)).",Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897267/),,46,135478,DB00028,Intravenous Immunoglobulin
,8897267,area under the free MTX concentration vs time curve,"Pharmacokinetic studies revealed that intravenous anti-methotrexate immunoglobulin G (anti-MTX IgG) and anti-methotrexate Fab (anti-MTX Fab) administration produced dramatic alterations in the plasma pharmacokinetics of methotrexate (MTX), following intraperitoneal MTX administration (area under the total MTX concentration vs time curve for anti-MTX IgG relative to control, 420 +/- 90 (p < 0.05); for anti-MTX Fab relative to control, 46 +/- 6.1 (p < 0.05); area under the free MTX concentration vs time curve for anti-MTX IgG relative to control, 0.64 +/- 0.16; for anti-MTX Fab relative to control, 0.45 +/- 0.20 (p < 0.05)).",Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897267/),,0.64,135479,DB00028,Intravenous Immunoglobulin
,8897267,area under the free MTX concentration vs time curve,"Pharmacokinetic studies revealed that intravenous anti-methotrexate immunoglobulin G (anti-MTX IgG) and anti-methotrexate Fab (anti-MTX Fab) administration produced dramatic alterations in the plasma pharmacokinetics of methotrexate (MTX), following intraperitoneal MTX administration (area under the total MTX concentration vs time curve for anti-MTX IgG relative to control, 420 +/- 90 (p < 0.05); for anti-MTX Fab relative to control, 46 +/- 6.1 (p < 0.05); area under the free MTX concentration vs time curve for anti-MTX IgG relative to control, 0.64 +/- 0.16; for anti-MTX Fab relative to control, 0.45 +/- 0.20 (p < 0.05)).",Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897267/),,0.45,135480,DB00028,Intravenous Immunoglobulin
,32172489,MTD,"In the dose escalation phase (1-200 mg) involving 37 Caucasian patients, the MTD was 100 mg.",Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32172489/),mg,100,137470,DB00028,Intravenous Immunoglobulin
,31311668,maximal dose,"The maximal dose of 110 mg/kg could be administered, and no antidrug antibodies were induced.",A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31311668/),,110,138954,DB00028,Intravenous Immunoglobulin
,31311668,Cmax,"After administration of 36-110 mg/kg, mean temelimab Cmax increased from 859 to 2450 μg/mL, and AUC values increased from 319,900 to 1,030,000 μg·h/mL.",A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31311668/),[μg] / [ml],85,138955,DB00028,Intravenous Immunoglobulin
,31311668,Cmax,"After administration of 36-110 mg/kg, mean temelimab Cmax increased from 859 to 2450 μg/mL, and AUC values increased from 319,900 to 1,030,000 μg·h/mL.",A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31311668/),[μg] / [ml],245,138956,DB00028,Intravenous Immunoglobulin
,31311668,AUC,"After administration of 36-110 mg/kg, mean temelimab Cmax increased from 859 to 2450 μg/mL, and AUC values increased from 319,900 to 1,030,000 μg·h/mL.",A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31311668/),[h·μg] / [ml],"319,900",138957,DB00028,Intravenous Immunoglobulin
,31311668,AUC,"After administration of 36-110 mg/kg, mean temelimab Cmax increased from 859 to 2450 μg/mL, and AUC values increased from 319,900 to 1,030,000 μg·h/mL.",A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31311668/),[h·μg] / [ml],"1,030,000",138958,DB00028,Intravenous Immunoglobulin
,1662233,half-life,"Compared with the 22-day half-life in normal subjects, the half-life in BMT patients was approximately 6 days for either the 250 mg/kg or 500 mg/kg dose regimen.",Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662233/),d,22,140681,DB00028,Intravenous Immunoglobulin
,1662233,half-life,"Compared with the 22-day half-life in normal subjects, the half-life in BMT patients was approximately 6 days for either the 250 mg/kg or 500 mg/kg dose regimen.",Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662233/),d,6,140682,DB00028,Intravenous Immunoglobulin
,1662233,Peak concentrations,"Peak concentrations were 3.5 +/- 1.4 and 2.6 +/- 0.7 mg/mL of IVIG in week 1 as well as 5.5 +/- 2.6 and 3.4 +/- 1.2 mg/mL in week 3 after the 250 mg/kg and 500 mg/kg, respectively.",Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662233/),[mg] / [ml],3.5,140683,DB00028,Intravenous Immunoglobulin
,1662233,Peak concentrations,"Peak concentrations were 3.5 +/- 1.4 and 2.6 +/- 0.7 mg/mL of IVIG in week 1 as well as 5.5 +/- 2.6 and 3.4 +/- 1.2 mg/mL in week 3 after the 250 mg/kg and 500 mg/kg, respectively.",Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662233/),[mg] / [ml],2.6,140684,DB00028,Intravenous Immunoglobulin
,1662233,Peak concentrations,"Peak concentrations were 3.5 +/- 1.4 and 2.6 +/- 0.7 mg/mL of IVIG in week 1 as well as 5.5 +/- 2.6 and 3.4 +/- 1.2 mg/mL in week 3 after the 250 mg/kg and 500 mg/kg, respectively.",Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662233/),[mg] / [ml],5.5,140685,DB00028,Intravenous Immunoglobulin
,1662233,Peak concentrations,"Peak concentrations were 3.5 +/- 1.4 and 2.6 +/- 0.7 mg/mL of IVIG in week 1 as well as 5.5 +/- 2.6 and 3.4 +/- 1.2 mg/mL in week 3 after the 250 mg/kg and 500 mg/kg, respectively.",Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662233/),[mg] / [ml],3.4,140686,DB00028,Intravenous Immunoglobulin
,1662233,Total body clearance,"Total body clearance of IVIG was 0.61 and 0.46 mL/kg/hr for the 500 mg/kg and 250 mg/kg, respectively.",Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662233/),[ml] / [h·kg],0.61,140687,DB00028,Intravenous Immunoglobulin
,1662233,Total body clearance,"Total body clearance of IVIG was 0.61 and 0.46 mL/kg/hr for the 500 mg/kg and 250 mg/kg, respectively.",Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662233/),[ml] / [h·kg],0.46,140688,DB00028,Intravenous Immunoglobulin
,19938102,increase in serum IgG (DeltaIgG),"The increase in serum IgG (DeltaIgG) 2 weeks after IVIg treatment varied considerably between patients (mean, 7.8g/L; standard deviation, 5.6g/L).",Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19938102/),[g] / [l],7.8,141283,DB00028,Intravenous Immunoglobulin
≥,25196897,steady-state FVIII activity trough levels,Simulated dosing regimens predicted a greater proportion of subjects with steady-state FVIII activity trough levels of ≥ 1 IU dL(-1) (1%) with rFVIIIFc than with equivalent rFVIII regimens.,Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25196897/),[iu] / [dl],1,142030,DB00028,Intravenous Immunoglobulin
≥,25196897,trough levels,"These results suggest that patients on rFVIIIFc prophylaxis can reduce their infusion frequency as compared with their prior FVIII regimen while maintaining low bleeding rates, affording more patients trough levels of ≥ 1 IU dL(-1) than with rFVIII products requiring more frequent dosing regimens.",Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25196897/),[iu] / [dl],1,142031,DB00028,Intravenous Immunoglobulin
,9604285,time needed,"The time needed by the venom and toxin to reach maximum tissue concentration (tmax) ranged between 7 and 15 min and 60 and 180 min for the shallow and deep tissue compartments, respectively.","Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604285/),min,7 and 15,144130,DB00028,Intravenous Immunoglobulin
,9604285,time needed,"The time needed by the venom and toxin to reach maximum tissue concentration (tmax) ranged between 7 and 15 min and 60 and 180 min for the shallow and deep tissue compartments, respectively.","Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604285/),min,60 and 180,144131,DB00028,Intravenous Immunoglobulin
,9604285,bioavailability factor (F),"The bioavailability factor (F) was 0.82 and 0.88 for the venom and toxin, respectively.","Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604285/),,0.82,144132,DB00028,Intravenous Immunoglobulin
,9604285,bioavailability factor (F),"The bioavailability factor (F) was 0.82 and 0.88 for the venom and toxin, respectively.","Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604285/),,0.88,144133,DB00028,Intravenous Immunoglobulin
,9604285,F-,Fab had an F-value of 0.36 and required 4.3 and 47.4-fold the time taken by the venom and toxin to achieve tmax.,"Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604285/),,0.36,144134,DB00028,Intravenous Immunoglobulin
,9604285,F,"The calculated values of F for F(ab')2 and IgG were 0.25 and 0.26, respectively.","Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604285/),,0.25,144135,DB00028,Intravenous Immunoglobulin
,9604285,F,"The calculated values of F for F(ab')2 and IgG were 0.25 and 0.26, respectively.","Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9604285/),,0.26,144136,DB00028,Intravenous Immunoglobulin
,8666001,maximal anti-HBs concentrations,After administration of BT 507 maximal anti-HBs concentrations of 1778 mU.,Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666001/),mu,1778,146012,DB00028,Intravenous Immunoglobulin
,8666001,terminal elimination half-life,"The terminal elimination half-life was 22.4 days, and total clearance and volume of distribution were determined to be 0.122 ml.min-1 and 5.41, respectively.",Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666001/),d,22.4,146013,DB00028,Intravenous Immunoglobulin
,8666001,total clearance,"The terminal elimination half-life was 22.4 days, and total clearance and volume of distribution were determined to be 0.122 ml.min-1 and 5.41, respectively.",Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666001/),[ml] / [min],0.122,146014,DB00028,Intravenous Immunoglobulin
,8666001,volume of distribution,"The terminal elimination half-life was 22.4 days, and total clearance and volume of distribution were determined to be 0.122 ml.min-1 and 5.41, respectively.",Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666001/),,5.41,146015,DB00028,Intravenous Immunoglobulin
,2341860,plasma half-life,Seven of these patients had initial peak serum concentrations greater than 80% of predicted values with plasma disappearance curves fitting a one-compartment system and a plasma half-life of 31.5 h (range of 20.3-44.6 h).,Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341860/),h,31.5,146393,DB00028,Intravenous Immunoglobulin
,2341860,plasma half-life,He achieved 65% of the predicted value for peak serum concentration of HA-1A with a plasma half-life of 12.3 h.,Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341860/),h,12.3,146394,DB00028,Intravenous Immunoglobulin
,9818074,response duration,"The median response duration and time to progression are 11.6 and 13.2 months, respectively.",Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),month,11.6,146564,DB00028,Intravenous Immunoglobulin
,9818074,time to progression,"The median response duration and time to progression are 11.6 and 13.2 months, respectively.",Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),month,13.2,146565,DB00028,Intravenous Immunoglobulin
,9818074,half-life,The half-life of the monoclonal antibody increased from 76.3 hours after the first infusion to 205.8 hours after the fourth infusion and was concomitant with a four-fold decrease in the antibody clearance.,Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),h,76.3,146566,DB00028,Intravenous Immunoglobulin
,9818074,half-life,The half-life of the monoclonal antibody increased from 76.3 hours after the first infusion to 205.8 hours after the fourth infusion and was concomitant with a four-fold decrease in the antibody clearance.,Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),h,205.8,146567,DB00028,Intravenous Immunoglobulin
,9818074,serum levels,"At three months and six months post-treatment, the median Rituximab serum levels were 20.3 micrograms/ml (range 0.0 to 96.8 micrograms/ml in 104 patients) and 1.3 micrograms/ml (range 0.0-28.7 micrograms/ml in 13 patients), respectively.",Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),[μg] / [ml],20.3,146568,DB00028,Intravenous Immunoglobulin
,9818074,serum levels,"At three months and six months post-treatment, the median Rituximab serum levels were 20.3 micrograms/ml (range 0.0 to 96.8 micrograms/ml in 104 patients) and 1.3 micrograms/ml (range 0.0-28.7 micrograms/ml in 13 patients), respectively.",Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818074/),[μg] / [ml],1.3,146569,DB00028,Intravenous Immunoglobulin
,18757508,terminal half-life in circulation,"Compared to its terminal half-life in circulation (7 hours), the vitreal half-life of ESBA105 is significantly enhanced (16-24 hours).","Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757508/),h,7,146800,DB00028,Intravenous Immunoglobulin
,18757508,half-life,"Compared to its terminal half-life in circulation (7 hours), the vitreal half-life of ESBA105 is significantly enhanced (16-24 hours).","Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757508/),h,16-24,146801,DB00028,Intravenous Immunoglobulin
,29670279,T1/2,"F-652 IV dosing resulted in linear increases in Cmax and AUC(0-t), and the T1/2 ranged from 39.4 to 206 h in the cohorts.","Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29670279/),h,39.4 to 206,148618,DB00028,Intravenous Immunoglobulin
,2072295,blood-brain barrier permeability surface area product,The blood-brain barrier permeability surface area product for 3H-cationized IgG was 0.57 +/- 0.04 microliters min-1 g-1.,Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072295/),[μl] / [g·min],0.57,148836,DB00028,Intravenous Immunoglobulin
,10883413,peak concentrations,"In subjects receiving IVIG-L, peak concentrations of the stabilizer nicotinamide ranged from 0.34 to 0.47 mmol/L and of nicotinamide-N-oxide from 0.03 to 0.04 mmol/L, which are below those reported to cause adverse events.","Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883413/),[mM] / [l],0.34 to 0.47,148982,DB00028,Intravenous Immunoglobulin
,10883413,peak concentrations,"In subjects receiving IVIG-L, peak concentrations of the stabilizer nicotinamide ranged from 0.34 to 0.47 mmol/L and of nicotinamide-N-oxide from 0.03 to 0.04 mmol/L, which are below those reported to cause adverse events.","Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883413/),[mM] / [l],0.03 to 0.04,148983,DB00028,Intravenous Immunoglobulin
,1981586,t1/2 alpha,"Using ELISA2, which was generally the more sensitive assay, to compare the plasma disposition of the sheep polyclonal digoxin-specific Fab fragments with rat monoclonal digoxin-specific Fab fragments, it was shown that the rat product had a shorter t1/2 alpha (11 vs 22 min), a t1/2 beta which was not significantly different (253 vs 168 min), but a faster clearance (1.2 vs 0.7 mL kg-1 min-1), associated with a much larger Vdss (321 vs 108 mL kg-1).",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),min,11,151040,DB00028,Intravenous Immunoglobulin
,1981586,t1/2 alpha,"Using ELISA2, which was generally the more sensitive assay, to compare the plasma disposition of the sheep polyclonal digoxin-specific Fab fragments with rat monoclonal digoxin-specific Fab fragments, it was shown that the rat product had a shorter t1/2 alpha (11 vs 22 min), a t1/2 beta which was not significantly different (253 vs 168 min), but a faster clearance (1.2 vs 0.7 mL kg-1 min-1), associated with a much larger Vdss (321 vs 108 mL kg-1).",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),min,22,151041,DB00028,Intravenous Immunoglobulin
,1981586,t1/2 beta,"Using ELISA2, which was generally the more sensitive assay, to compare the plasma disposition of the sheep polyclonal digoxin-specific Fab fragments with rat monoclonal digoxin-specific Fab fragments, it was shown that the rat product had a shorter t1/2 alpha (11 vs 22 min), a t1/2 beta which was not significantly different (253 vs 168 min), but a faster clearance (1.2 vs 0.7 mL kg-1 min-1), associated with a much larger Vdss (321 vs 108 mL kg-1).",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),min,253,151042,DB00028,Intravenous Immunoglobulin
,1981586,t1/2 beta,"Using ELISA2, which was generally the more sensitive assay, to compare the plasma disposition of the sheep polyclonal digoxin-specific Fab fragments with rat monoclonal digoxin-specific Fab fragments, it was shown that the rat product had a shorter t1/2 alpha (11 vs 22 min), a t1/2 beta which was not significantly different (253 vs 168 min), but a faster clearance (1.2 vs 0.7 mL kg-1 min-1), associated with a much larger Vdss (321 vs 108 mL kg-1).",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),min,168,151043,DB00028,Intravenous Immunoglobulin
,1981586,clearance,"Using ELISA2, which was generally the more sensitive assay, to compare the plasma disposition of the sheep polyclonal digoxin-specific Fab fragments with rat monoclonal digoxin-specific Fab fragments, it was shown that the rat product had a shorter t1/2 alpha (11 vs 22 min), a t1/2 beta which was not significantly different (253 vs 168 min), but a faster clearance (1.2 vs 0.7 mL kg-1 min-1), associated with a much larger Vdss (321 vs 108 mL kg-1).",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),[ml] / [kg·min],1.2,151044,DB00028,Intravenous Immunoglobulin
,1981586,clearance,"Using ELISA2, which was generally the more sensitive assay, to compare the plasma disposition of the sheep polyclonal digoxin-specific Fab fragments with rat monoclonal digoxin-specific Fab fragments, it was shown that the rat product had a shorter t1/2 alpha (11 vs 22 min), a t1/2 beta which was not significantly different (253 vs 168 min), but a faster clearance (1.2 vs 0.7 mL kg-1 min-1), associated with a much larger Vdss (321 vs 108 mL kg-1).",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),[ml] / [kg·min],0.7,151045,DB00028,Intravenous Immunoglobulin
,1981586,Vdss,"Using ELISA2, which was generally the more sensitive assay, to compare the plasma disposition of the sheep polyclonal digoxin-specific Fab fragments with rat monoclonal digoxin-specific Fab fragments, it was shown that the rat product had a shorter t1/2 alpha (11 vs 22 min), a t1/2 beta which was not significantly different (253 vs 168 min), but a faster clearance (1.2 vs 0.7 mL kg-1 min-1), associated with a much larger Vdss (321 vs 108 mL kg-1).",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),[ml] / [kg],321,151046,DB00028,Intravenous Immunoglobulin
,1981586,Vdss,"Using ELISA2, which was generally the more sensitive assay, to compare the plasma disposition of the sheep polyclonal digoxin-specific Fab fragments with rat monoclonal digoxin-specific Fab fragments, it was shown that the rat product had a shorter t1/2 alpha (11 vs 22 min), a t1/2 beta which was not significantly different (253 vs 168 min), but a faster clearance (1.2 vs 0.7 mL kg-1 min-1), associated with a much larger Vdss (321 vs 108 mL kg-1).",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),[ml] / [kg],108,151047,DB00028,Intravenous Immunoglobulin
,1981586,extracellular fluid volume,"The extracellular fluid volume, using thiocyanate as a marker, was about 216 mL kg-1 for the nine rabbits used.",The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981586/),[ml] / [kg],216,151048,DB00028,Intravenous Immunoglobulin
,16628126,Terminal elimination half-life,Terminal elimination half-life was 10.9 days.,An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628126/),d,10.9,151759,DB00028,Intravenous Immunoglobulin
,25662592,peak plasma concentrations,Mean peak plasma concentrations were 19·3 μg/mL (SD 3·5) with the one dose schedule and 23·0 μg/mL (4·5) with the five-dose schedule.,"Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25662592/),[μg] / [ml],19·3,152004,DB00028,Intravenous Immunoglobulin
,25662592,peak plasma concentrations,Mean peak plasma concentrations were 19·3 μg/mL (SD 3·5) with the one dose schedule and 23·0 μg/mL (4·5) with the five-dose schedule.,"Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25662592/),[μg] / [ml],23·0,152005,DB00028,Intravenous Immunoglobulin
,9799353,uptake,"Activity in the blood after i.p. administration was described by a bi-exponential curve with a mean uptake and elimination half-life of 6.9+/-3.2 h and 160+/-45 h, respectively.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),h,6.9,152728,DB00028,Intravenous Immunoglobulin
,9799353,elimination half-life,"Activity in the blood after i.p. administration was described by a bi-exponential curve with a mean uptake and elimination half-life of 6.9+/-3.2 h and 160+/-45 h, respectively.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),h,160,152729,DB00028,Intravenous Immunoglobulin
,9799353,half-life for the elimination phase,For i.v. infusion the mean half-life for the elimination phase was 103+/-12 h.,Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),h,103,152730,DB00028,Intravenous Immunoglobulin
,9799353,Cumulative excretion,"Cumulative excretion in the urine was 17%+/-3% ID and 21%+/-7% ID in 96 h for i.p. and i.v. administration, respectively.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),%,17,152731,DB00028,Intravenous Immunoglobulin
,9799353,Cumulative excretion,"Cumulative excretion in the urine was 17%+/-3% ID and 21%+/-7% ID in 96 h for i.p. and i.v. administration, respectively.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),%,21,152732,DB00028,Intravenous Immunoglobulin
,9799353,Tumour uptake,Tumour uptake determined in the ovarian cancer tissue specimens ranged from 3.4% to 12.3% ID/kg for i.p. administration and from 3.6% to 5.4% ID/kg for i.v. administration.,Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),%,3.4,152733,DB00028,Intravenous Immunoglobulin
,9799353,Tumour uptake,Tumour uptake determined in the ovarian cancer tissue specimens ranged from 3.4% to 12.3% ID/kg for i.p. administration and from 3.6% to 5.4% ID/kg for i.v. administration.,Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),%,12.3,152734,DB00028,Intravenous Immunoglobulin
,9799353,Tumour uptake,Tumour uptake determined in the ovarian cancer tissue specimens ranged from 3.4% to 12.3% ID/kg for i.p. administration and from 3.6% to 5.4% ID/kg for i.v. administration.,Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),%,3.6,152735,DB00028,Intravenous Immunoglobulin
,9799353,Tumour uptake,Tumour uptake determined in the ovarian cancer tissue specimens ranged from 3.4% to 12.3% ID/kg for i.p. administration and from 3.6% to 5.4% ID/kg for i.v. administration.,Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),%,5.4,152736,DB00028,Intravenous Immunoglobulin
,9799353,total activity,"Assuming that an absorbed dose to the bone marrow of 2 Gy will be dose limiting, a total activity of 4.1 GBq 131I-cMOv18 IgG can be administered safely via the i.p. route and 3.5 GBq via the i.v. route.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),gbq,4.1,152737,DB00028,Intravenous Immunoglobulin
,9799353,total activity,"Assuming that an absorbed dose to the bone marrow of 2 Gy will be dose limiting, a total activity of 4.1 GBq 131I-cMOv18 IgG can be administered safely via the i.p. route and 3.5 GBq via the i.v. route.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),,3.5,152738,DB00028,Intravenous Immunoglobulin
,9799353,maximum absorbed dose,"At this maximal tolerated dose, a maximum absorbed dose to 1-g tumours in the peritoneal cavity of 18 and 8 Gy can be reached after i.p. and i.v. administration, respectively.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),gy,18,152739,DB00028,Intravenous Immunoglobulin
,9799353,maximum absorbed dose,"At this maximal tolerated dose, a maximum absorbed dose to 1-g tumours in the peritoneal cavity of 18 and 8 Gy can be reached after i.p. and i.v. administration, respectively.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),gy,8,152740,DB00028,Intravenous Immunoglobulin
,9799353,total doses,"For the i. p. route of administration, dose estimates for the tumour are even higher when the electron dose of the peritoneal activity is also taken into account: total doses to the tumour of 30 Gy and 22 Gy will be absorbed at the tumour surface and at 0.2 mm depth, respectively.",Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799353/),,30,152741,DB00028,Intravenous Immunoglobulin
,28378901,peak levels,"Patients received a median IVIg dose of 30 g (range, 15-70 g) every 14 days (range, 7-28 days) resulting in high IgG peak levels (median, 25.9 g/L; range, 16.7-41.0 g/L) and trough levels (median, 16.1 g/L; range, 9.7-23.6 g/L).",Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28378901/),[g] / [l],25.9,158293,DB00028,Intravenous Immunoglobulin
,28378901,trough levels,"Patients received a median IVIg dose of 30 g (range, 15-70 g) every 14 days (range, 7-28 days) resulting in high IgG peak levels (median, 25.9 g/L; range, 16.7-41.0 g/L) and trough levels (median, 16.1 g/L; range, 9.7-23.6 g/L).",Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28378901/),[g] / [l],16.1,158294,DB00028,Intravenous Immunoglobulin
,28378901,half-life,"IgG PK parameters, including half-life (median, 23.1 days; range, 11-60 days), were constant during subsequent courses in the same patients, but varied considerably between patients.",Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28378901/),d,23.1,158295,DB00028,Intravenous Immunoglobulin
,8635863,Tumour uptake,"Tumour uptake ranged from 0.8 to 1.9% ID/kg, resulting in tumour/background ratios of 3 to 8.","Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8635863/),[%·id] / [kg],0.8 to 1.9,158738,DB00028,Intravenous Immunoglobulin
,8635863,tumour/background ratios,"Tumour uptake ranged from 0.8 to 1.9% ID/kg, resulting in tumour/background ratios of 3 to 8.","Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8635863/),,3 to 8,158739,DB00028,Intravenous Immunoglobulin
,3417365,uptake,The observed uptake was 85% injected dose/g for OV-TL3 and 22% injected dose/g for OC125.,Localization of radiolabelled F(ab')2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417365/),%,85,159327,DB00028,Intravenous Immunoglobulin
,3417365,uptake,The observed uptake was 85% injected dose/g for OV-TL3 and 22% injected dose/g for OC125.,Localization of radiolabelled F(ab')2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417365/),%,22,159328,DB00028,Intravenous Immunoglobulin
,3417365,uptake,This compares to the observed antibody uptake of 9% injected dose/g for OV-TL3 and less than 1% injected dose/g for OC125 in solid tumor masses after i.p. injection.,Localization of radiolabelled F(ab')2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417365/),%,9,159329,DB00028,Intravenous Immunoglobulin
less,3417365,uptake,This compares to the observed antibody uptake of 9% injected dose/g for OV-TL3 and less than 1% injected dose/g for OC125 in solid tumor masses after i.p. injection.,Localization of radiolabelled F(ab')2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417365/),%,1,159330,DB00028,Intravenous Immunoglobulin
,17255829,peak level,The peak level (61.0 and 66.3 microg/mL) and half-life (92.3 and 96.3 h) of natalizumab were comparable after the first and third infusions.,Natalizumab therapy for moderate to severe Crohn disease in adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255829/),[μg] / [ml],61.0,159571,DB00028,Intravenous Immunoglobulin
,17255829,peak level,The peak level (61.0 and 66.3 microg/mL) and half-life (92.3 and 96.3 h) of natalizumab were comparable after the first and third infusions.,Natalizumab therapy for moderate to severe Crohn disease in adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255829/),[μg] / [ml],66.3,159572,DB00028,Intravenous Immunoglobulin
,17255829,half-life,The peak level (61.0 and 66.3 microg/mL) and half-life (92.3 and 96.3 h) of natalizumab were comparable after the first and third infusions.,Natalizumab therapy for moderate to severe Crohn disease in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255829/),h,92.3,159573,DB00028,Intravenous Immunoglobulin
,17255829,half-life,The peak level (61.0 and 66.3 microg/mL) and half-life (92.3 and 96.3 h) of natalizumab were comparable after the first and third infusions.,Natalizumab therapy for moderate to severe Crohn disease in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255829/),h,96.3,159574,DB00028,Intravenous Immunoglobulin
,23200102,elimination half-life,"The mean elimination half-life ranged between 19 and 26 days, with therapeutically efficient concentrations maintained over a 4-week periods at doses of 2 and 6 mg/kg.","GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23200102/),d,19 and 26,160598,DB00028,Intravenous Immunoglobulin
,21764796,serum half-time,Pharmacokinetics showed that patients receiving IVIG had a significantly shorter serum half-time (41.6 ± 14.0 h) than those without (65.2 ± 9.8 h).,(124)I-huA33 antibody PET of colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21764796/),h,41.6,160862,DB00028,Intravenous Immunoglobulin
,21764796,serum half-time,Pharmacokinetics showed that patients receiving IVIG had a significantly shorter serum half-time (41.6 ± 14.0 h) than those without (65.2 ± 9.8 h).,(124)I-huA33 antibody PET of colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21764796/),h,65.2,160863,DB00028,Intravenous Immunoglobulin
,12228199,half-life,The overall mean half-life was 10.7 +/- 4.1 hours.,Phase I study of recombinant human endostatin in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228199/),h,10.7,161729,DB00028,Intravenous Immunoglobulin
,16705486,elimination half-life,The median elimination half-life of IgG was 35 days.,"Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16705486/),d,35,164236,DB00028,Intravenous Immunoglobulin
,16705486,trough levels,Median total IgG trough levels varied from 9.6 to 11.2 g/L.,"Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16705486/),[g] / [l],9.6 to 11.2,164237,DB00028,Intravenous Immunoglobulin
,33503289,terminal half-life,ALPN-101 exhibited a dose-dependent increase in exposure with an estimated terminal half-life of 4.3-8.6 days and SC bioavailability of 60.6% at 3 mg/kg.,"First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33503289/),d,4.3-8.6,164805,DB00028,Intravenous Immunoglobulin
,33503289,bioavailability,ALPN-101 exhibited a dose-dependent increase in exposure with an estimated terminal half-life of 4.3-8.6 days and SC bioavailability of 60.6% at 3 mg/kg.,"First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33503289/),%,60.6,164806,DB00028,Intravenous Immunoglobulin
,30952104,bioavailability,The model estimate of bioavailability was 73.9%.,Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952104/),%,73.9,165145,DB00028,Intravenous Immunoglobulin
,30952104,AUC ratios,Mean AUC ratios of Ig20Gly to IVIG with a dose adjustment factor of 1.30:1 were 98.7% for weekly and 97.7% for twice-weekly administration demonstrating comparable exposure.,Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952104/),%,98.7,165146,DB00028,Intravenous Immunoglobulin
,30952104,AUC ratios,Mean AUC ratios of Ig20Gly to IVIG with a dose adjustment factor of 1.30:1 were 98.7% for weekly and 97.7% for twice-weekly administration demonstrating comparable exposure.,Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952104/),%,97.7,165147,DB00028,Intravenous Immunoglobulin
,31117485,serum T1/2 β,"Pharmacokinetics showed a median serum T1/2 β of 198 h, volume of central compartment of 3.54 L (similar to plasma volume), and clearance of 19.7 mL/h.",Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),h,198,165370,DB00028,Intravenous Immunoglobulin
,31117485,volume of central compartment,"Pharmacokinetics showed a median serum T1/2 β of 198 h, volume of central compartment of 3.54 L (similar to plasma volume), and clearance of 19.7 mL/h.",Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),l,3.54,165371,DB00028,Intravenous Immunoglobulin
,31117485,clearance,"Pharmacokinetics showed a median serum T1/2 β of 198 h, volume of central compartment of 3.54 L (similar to plasma volume), and clearance of 19.7 mL/h.",Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),[ml] / [h],19.7,165372,DB00028,Intravenous Immunoglobulin
,31117485,biologic T1/2,The median biologic T1/2 for whole-body retention was 469 h.,Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),h,469,165373,DB00028,Intravenous Immunoglobulin
,31117485,absorbed doses to normal organs,"The highest mean absorbed doses to normal organs (mGy/MBq) were 1.18, 1.11, 0.78, 0.73, and 0.71 for liver, heart wall, lung, kidney, and spleen, respectively.",Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),[mgy] / [Mbq],1.18,165374,DB00028,Intravenous Immunoglobulin
,31117485,absorbed doses to normal organs,"The highest mean absorbed doses to normal organs (mGy/MBq) were 1.18, 1.11, 0.78, 0.73, and 0.71 for liver, heart wall, lung, kidney, and spleen, respectively.",Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),[mgy] / [Mbq],1.11,165375,DB00028,Intravenous Immunoglobulin
,31117485,absorbed doses to normal organs,"The highest mean absorbed doses to normal organs (mGy/MBq) were 1.18, 1.11, 0.78, 0.73, and 0.71 for liver, heart wall, lung, kidney, and spleen, respectively.",Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),[mgy] / [Mbq],0.78,165376,DB00028,Intravenous Immunoglobulin
,31117485,absorbed doses to normal organs,"The highest mean absorbed doses to normal organs (mGy/MBq) were 1.18, 1.11, 0.78, 0.73, and 0.71 for liver, heart wall, lung, kidney, and spleen, respectively.",Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),[mgy] / [Mbq],0.73,165377,DB00028,Intravenous Immunoglobulin
,31117485,absorbed doses to normal organs,"The highest mean absorbed doses to normal organs (mGy/MBq) were 1.18, 1.11, 0.78, 0.73, and 0.71 for liver, heart wall, lung, kidney, and spleen, respectively.",Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31117485/),[mgy] / [Mbq],0.71,165378,DB00028,Intravenous Immunoglobulin
,27129122,plasma Cmax,"Geometric mean values for plasma Cmax (ng/mL) were 4.1, 15.7, 26.5, and 51.2 for doses of 0.15, 0.45, 0.90, and 1.5 µg/kg, respectively.","PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129122/),[ng] / [ml],4.1,166127,DB00028,Intravenous Immunoglobulin
,27129122,plasma Cmax,"Geometric mean values for plasma Cmax (ng/mL) were 4.1, 15.7, 26.5, and 51.2 for doses of 0.15, 0.45, 0.90, and 1.5 µg/kg, respectively.","PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129122/),[ng] / [ml],15.7,166128,DB00028,Intravenous Immunoglobulin
,27129122,plasma Cmax,"Geometric mean values for plasma Cmax (ng/mL) were 4.1, 15.7, 26.5, and 51.2 for doses of 0.15, 0.45, 0.90, and 1.5 µg/kg, respectively.","PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129122/),[ng] / [ml],26.5,166129,DB00028,Intravenous Immunoglobulin
,27129122,plasma Cmax,"Geometric mean values for plasma Cmax (ng/mL) were 4.1, 15.7, 26.5, and 51.2 for doses of 0.15, 0.45, 0.90, and 1.5 µg/kg, respectively.","PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129122/),[ng] / [ml],51.2,166130,DB00028,Intravenous Immunoglobulin
,23754736,clearance (CL),"Following intravenous dosing, the typical clearance (CL) and central volume of distribution (V 1) were estimated to be 176 mL/day and 2.9 L, respectively.","Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23754736/),[ml] / [d],176,167909,DB00028,Intravenous Immunoglobulin
,23754736,central volume of distribution (V 1),"Following intravenous dosing, the typical clearance (CL) and central volume of distribution (V 1) were estimated to be 176 mL/day and 2.9 L, respectively.","Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23754736/),l,2.9,167910,DB00028,Intravenous Immunoglobulin
,8049447,terminal elimination half-life,"The terminal elimination half-life of the antibody was 44 to 363 hours, with a harmonic mean of 79, 88, and 94 hours, respectively, for the three doses studied.",Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8049447/),h,44 to 363,168507,DB00028,Intravenous Immunoglobulin
,8049447,terminal elimination half-life,"The terminal elimination half-life of the antibody was 44 to 363 hours, with a harmonic mean of 79, 88, and 94 hours, respectively, for the three doses studied.",Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8049447/),h,79,168508,DB00028,Intravenous Immunoglobulin
,8049447,terminal elimination half-life,"The terminal elimination half-life of the antibody was 44 to 363 hours, with a harmonic mean of 79, 88, and 94 hours, respectively, for the three doses studied.",Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8049447/),h,88,168509,DB00028,Intravenous Immunoglobulin
,8049447,terminal elimination half-life,"The terminal elimination half-life of the antibody was 44 to 363 hours, with a harmonic mean of 79, 88, and 94 hours, respectively, for the three doses studied.",Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8049447/),h,94,168510,DB00028,Intravenous Immunoglobulin
,33919927,apparent total body clearance,"F(ab')2 fragments given intramuscularly had 25-fold longer apparent total body clearance and 14-fold longer elimination half-time compared to Fab fragments given intravenously (2 weeks vs. 24 h, respectively).",Intravenous Vipera berus Venom-Specific Fab Fragments and Intramuscular Vipera ammodytes Venom-Specific F(ab')2 Fragments in Vipera ammodytes-Envenomed Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33919927/),weeks,2,169174,DB00028,Intravenous Immunoglobulin
,33919927,elimination half-time,"F(ab')2 fragments given intramuscularly had 25-fold longer apparent total body clearance and 14-fold longer elimination half-time compared to Fab fragments given intravenously (2 weeks vs. 24 h, respectively).",Intravenous Vipera berus Venom-Specific Fab Fragments and Intramuscular Vipera ammodytes Venom-Specific F(ab')2 Fragments in Vipera ammodytes-Envenomed Patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33919927/),h,24,169175,DB00028,Intravenous Immunoglobulin
,3339509,peak IgG concentrations,"Mean peak IgG concentrations were 1564 and 1316 mg/dL for the high-dose and low-dose groups, respectively.",Disposition of an immunoglobulin intravenous preparation in very low birth weight neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3339509/),[mg] / [dl],1564,169956,DB00028,Intravenous Immunoglobulin
,3339509,peak IgG concentrations,"Mean peak IgG concentrations were 1564 and 1316 mg/dL for the high-dose and low-dose groups, respectively.",Disposition of an immunoglobulin intravenous preparation in very low birth weight neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3339509/),[mg] / [dl],1316,169957,DB00028,Intravenous Immunoglobulin
,3339509,elimination half-lives,"Mean elimination half-lives were 22.6 and 22.8 days in the high-dose and low-dose groups, respectively.",Disposition of an immunoglobulin intravenous preparation in very low birth weight neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3339509/),d,22.6,169958,DB00028,Intravenous Immunoglobulin
,3339509,elimination half-lives,"Mean elimination half-lives were 22.6 and 22.8 days in the high-dose and low-dose groups, respectively.",Disposition of an immunoglobulin intravenous preparation in very low birth weight neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3339509/),d,22.8,169959,DB00028,Intravenous Immunoglobulin
,22846381,bioavailability,"The bioavailability of IGHy measured by area under the concentration versus time curve was 93.3% of IGIV, which is pharmacokinetically equivalent.",Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22846381/),%,93.3,170105,DB00028,Intravenous Immunoglobulin
,22846381,rate,"Local reactions to IGHy were generally mild to moderate, with a rate of 0.203 per infusion.",Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22846381/),1/[infusion],0.203,170106,DB00028,Intravenous Immunoglobulin
,22846381,acute serious bacterial infection rate,"The acute serious bacterial infection rate per subject-year for IGHy was low (0.025; upper 99% CI limit, 0.046).",Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22846381/),,0.025,170107,DB00028,Intravenous Immunoglobulin
,22846381,Overall infection rates,Overall infection rates per subject-year were 2.97 for IGHy and 4.51 for IGIV.,Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22846381/),,2.97,170108,DB00028,Intravenous Immunoglobulin
,22846381,Overall infection rates,Overall infection rates per subject-year were 2.97 for IGHy and 4.51 for IGIV.,Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22846381/),,4.51,170109,DB00028,Intravenous Immunoglobulin
,12659687,dissociation constant,"The dissociation constant of ING-1(heMAb) for binding to Ep-CAM on HT-29 human colon tumor cells was 2 to 5 nM, similar to chimeric ING-1.",In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659687/),nM,2 to 5,172733,DB00028,Intravenous Immunoglobulin
,12659687,maximum cytolysis,"In antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity assays, ING-1(heMAb) caused a concentration-dependent lysis of BT-20 breast, MCF-7 breast, HT-29 colon, and CACO-2 colon tumor cells, with maximum cytolysis at approximately 1 microg/ml.",In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659687/),[μg] / [ml],1,172734,DB00028,Intravenous Immunoglobulin
,12659687,alpha half-life,"After an intravenous injection in rats, plasma ING-1(heMAb) levels declined with an alpha half-life of 8 to 11 hours, and a beta half-life of 20 days, typical of an IgG in a species without the target for ING-1.",In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659687/),h,8 to 11,172735,DB00028,Intravenous Immunoglobulin
,12659687,beta half-life,"After an intravenous injection in rats, plasma ING-1(heMAb) levels declined with an alpha half-life of 8 to 11 hours, and a beta half-life of 20 days, typical of an IgG in a species without the target for ING-1.",In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659687/),d,20,172736,DB00028,Intravenous Immunoglobulin
,3827946,ED50,"Intramuscular administration of DNP-F (0.027-27 mumol/kg/day) for 4 days to male Wistar rats produced a dose-dependent (ED50 2.7 mumol/kg) IgG anti-DNP antibody response, measured by enzyme-linked immunosorbent assay.","Drug-protein conjugates--XI. Disposition and immunogenicity of dinitrofluorobenzene, a model compound for the investigation of drugs as haptens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3827946/),[μM] / [kg],2.7,173346,DB00028,Intravenous Immunoglobulin
,3827946,half-life,"Formation of circulating (serum) DNP-protein conjugates was determined by radiometric analysis, and found to reach steady state (0.12-0.17% dose/ml) between days 6 and 8 and decline with a half-life of 7.4 days.","Drug-protein conjugates--XI. Disposition and immunogenicity of dinitrofluorobenzene, a model compound for the investigation of drugs as haptens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3827946/),d,7.4,173347,DB00028,Intravenous Immunoglobulin
,10219988,terminal half-life,"After an intravenous injection, fraction II (FII) was rapidly distributed and eliminated from the body (terminal half-life of 1.9 h).",Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219988/),h,1.9,175300,DB00028,Intravenous Immunoglobulin
,10219988,Tmax,"When injected subcutaneously, high concentrations of FII were measured in the vascular space rapidly after the injection (Tmax = 1 h) and FII was eliminated with a terminal half-life of 1.8 h, close to that determined after intravenous injection.",Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219988/),h,1,175301,DB00028,Intravenous Immunoglobulin
,10219988,terminal half-life,"When injected subcutaneously, high concentrations of FII were measured in the vascular space rapidly after the injection (Tmax = 1 h) and FII was eliminated with a terminal half-life of 1.8 h, close to that determined after intravenous injection.",Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219988/),h,1.8,175302,DB00028,Intravenous Immunoglobulin
,10219988,area under the concentration time curve,"Immunotherapy performed 2 h after the experimental envenomation largely increased the area under the concentration time curve of FII compared to that calculated in absence of immunotherapy (13,000 versus 170 ng h ml(-1), respectively).",Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219988/),[h·ng] / [ml],"13,000",175303,DB00028,Intravenous Immunoglobulin
,10219988,area under the concentration time curve,"Immunotherapy performed 2 h after the experimental envenomation largely increased the area under the concentration time curve of FII compared to that calculated in absence of immunotherapy (13,000 versus 170 ng h ml(-1), respectively).",Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219988/),[h·ng] / [ml],170,175304,DB00028,Intravenous Immunoglobulin
,7834398,peak serum rCD4-IgG concentrations,"Mean calculated peak serum rCD4-IgG concentrations were 5.47 micrograms/ml with ZDV and 8.28 micrograms/ml without ZDV, with serum half-lives of 34.2 and 32.0 h, respectively.",Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834398/),[μg] / [ml],5.47,175343,DB00028,Intravenous Immunoglobulin
,7834398,peak serum rCD4-IgG concentrations,"Mean calculated peak serum rCD4-IgG concentrations were 5.47 micrograms/ml with ZDV and 8.28 micrograms/ml without ZDV, with serum half-lives of 34.2 and 32.0 h, respectively.",Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834398/),[μg] / [ml],8.28,175344,DB00028,Intravenous Immunoglobulin
,7834398,serum half-lives,"Mean calculated peak serum rCD4-IgG concentrations were 5.47 micrograms/ml with ZDV and 8.28 micrograms/ml without ZDV, with serum half-lives of 34.2 and 32.0 h, respectively.",Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834398/),h,34.2,175345,DB00028,Intravenous Immunoglobulin
,7834398,serum half-lives,"Mean calculated peak serum rCD4-IgG concentrations were 5.47 micrograms/ml with ZDV and 8.28 micrograms/ml without ZDV, with serum half-lives of 34.2 and 32.0 h, respectively.",Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834398/),h,32.0,175346,DB00028,Intravenous Immunoglobulin
higher,11384719,absolute bioavailability,"Bot venom is completely absorbed from its SC injection site, since the absolute bioavailability is higher than 95%; the maximum plasma venom concentration is reached between 30 and 60 min after venom injection.",Effects of antivenom on Buthus occitanus tunetanus (Bot) scorpion venom pharmacokinetics: towards an optimization of antivenom immunotherapy in a rabbit model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11384719/),%,95,179388,DB00028,Intravenous Immunoglobulin
,3166511,CD4/CD8 ratio,The mean CD4/CD8 ratio was 0.18; 11 patients had CD4 counts below 0.2 x 10(9) per liter.,Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),,0.18,185222,DB00028,Intravenous Immunoglobulin
,3166511,plasma drug concentrations,"The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM.",Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),μM,1.9,185223,DB00028,Intravenous Immunoglobulin
,3166511,plasma drug concentrations,"The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM.",Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),μM,2.8,185224,DB00028,Intravenous Immunoglobulin
,3166511,plasma drug concentrations,"The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM.",Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),μM,3.1,185225,DB00028,Intravenous Immunoglobulin
,3166511,plasma drug concentrations,"The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM.",Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),μM,4.5,185226,DB00028,Intravenous Immunoglobulin
,3166511,steady-state cerebrospinal fluid:plasma ratio,The steady-state cerebrospinal fluid:plasma ratio was 0.24 +/- 0.07.,Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),,0.24,185227,DB00028,Intravenous Immunoglobulin
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],30.1,186660,DB00028,Intravenous Immunoglobulin
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],31.1,186661,DB00028,Intravenous Immunoglobulin
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],37.7,186662,DB00028,Intravenous Immunoglobulin
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],35.7,186663,DB00028,Intravenous Immunoglobulin
,31758502,terminal half-life,"Risankizumab exhibits linear pharmacokinetics when administered intravenously (0.01 mg/kg-1200 mg) or subcutaneously (0.25 mg/kg-300 mg), with a long terminal half-life of approximately 28 days.",Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758502/),d,28,187155,DB00028,Intravenous Immunoglobulin
,31758502,bioavailability,"Following subcutaneous administration, peak plasma concentration was reached approximately 3-14 days after dosing, with an estimated bioavailability of 89%.",Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758502/),%,89,187156,DB00028,Intravenous Immunoglobulin
,24912797,elimination,"Typical elimination and distribution clearances, central and peripheral volumes of distribution are 0.222 L/day, 0.518 L/day, 3.08 L, and 1.94 L, resulting in a terminal half-life of 16.8 days.",Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),[l] / [d],0.222,187819,DB00028,Intravenous Immunoglobulin
,24912797,distribution clearances,"Typical elimination and distribution clearances, central and peripheral volumes of distribution are 0.222 L/day, 0.518 L/day, 3.08 L, and 1.94 L, resulting in a terminal half-life of 16.8 days.",Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),[l] / [d],0.222,187820,DB00028,Intravenous Immunoglobulin
,24912797,distribution clearances,"Typical elimination and distribution clearances, central and peripheral volumes of distribution are 0.222 L/day, 0.518 L/day, 3.08 L, and 1.94 L, resulting in a terminal half-life of 16.8 days.",Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),[l] / [d],0.518,187821,DB00028,Intravenous Immunoglobulin
,24912797,distribution clearances,"Typical elimination and distribution clearances, central and peripheral volumes of distribution are 0.222 L/day, 0.518 L/day, 3.08 L, and 1.94 L, resulting in a terminal half-life of 16.8 days.",Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),l,3.08,187822,DB00028,Intravenous Immunoglobulin
,24912797,central,"Typical elimination and distribution clearances, central and peripheral volumes of distribution are 0.222 L/day, 0.518 L/day, 3.08 L, and 1.94 L, resulting in a terminal half-life of 16.8 days.",Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),[l] / [d],0.518,187823,DB00028,Intravenous Immunoglobulin
,24912797,central,"Typical elimination and distribution clearances, central and peripheral volumes of distribution are 0.222 L/day, 0.518 L/day, 3.08 L, and 1.94 L, resulting in a terminal half-life of 16.8 days.",Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),l,3.08,187824,DB00028,Intravenous Immunoglobulin
,24912797,peripheral volumes of distribution,"Typical elimination and distribution clearances, central and peripheral volumes of distribution are 0.222 L/day, 0.518 L/day, 3.08 L, and 1.94 L, resulting in a terminal half-life of 16.8 days.",Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),l,1.94,187825,DB00028,Intravenous Immunoglobulin
,24912797,terminal half-life,"Typical elimination and distribution clearances, central and peripheral volumes of distribution are 0.222 L/day, 0.518 L/day, 3.08 L, and 1.94 L, resulting in a terminal half-life of 16.8 days.",Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),d,16.8,187826,DB00028,Intravenous Immunoglobulin
,24912797,Bioavailability,Bioavailability (0.432-0.721) and absorption half-life (94.3-157 h) after SC administration are smaller with larger doses.,Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),,0.432-0.721,187827,DB00028,Intravenous Immunoglobulin
,24912797,absorption half-life,Bioavailability (0.432-0.721) and absorption half-life (94.3-157 h) after SC administration are smaller with larger doses.,Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24912797/),h,94.3-157,187828,DB00028,Intravenous Immunoglobulin
,22622405,maximum serum concentrations,"The 3- and 10-mg/kg groups had respective maximum serum concentrations of 52,811-88,660 and 121,857-285,454 ng/mL, with mean elimination half-lives of 8.1 and 9.3 days.","Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622405/),[ng] / [ml],"52,811-88,660",188528,DB00028,Intravenous Immunoglobulin
,22622405,maximum serum concentrations,"The 3- and 10-mg/kg groups had respective maximum serum concentrations of 52,811-88,660 and 121,857-285,454 ng/mL, with mean elimination half-lives of 8.1 and 9.3 days.","Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622405/),[ng] / [ml],"121,857-285,454",188529,DB00028,Intravenous Immunoglobulin
,22622405,elimination half-lives,"The 3- and 10-mg/kg groups had respective maximum serum concentrations of 52,811-88,660 and 121,857-285,454 ng/mL, with mean elimination half-lives of 8.1 and 9.3 days.","Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622405/),d,8.1,188530,DB00028,Intravenous Immunoglobulin
,22622405,elimination half-lives,"The 3- and 10-mg/kg groups had respective maximum serum concentrations of 52,811-88,660 and 121,857-285,454 ng/mL, with mean elimination half-lives of 8.1 and 9.3 days.","Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622405/),d,9.3,188531,DB00028,Intravenous Immunoglobulin
,22622405,endotracheal aspirate/serum concentration ratios,"Respective mean endotracheal aspirate/serum concentration ratios were 0.092 and 0.085 for the 3- and 10-mg/kg groups, who developed Pseudomonas aeruginosa pneumonia less frequently (33% and 31%, respectively) than placebo recipients (60%).","Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622405/),,0.092,188532,DB00028,Intravenous Immunoglobulin
,22622405,endotracheal aspirate/serum concentration ratios,"Respective mean endotracheal aspirate/serum concentration ratios were 0.092 and 0.085 for the 3- and 10-mg/kg groups, who developed Pseudomonas aeruginosa pneumonia less frequently (33% and 31%, respectively) than placebo recipients (60%).","Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622405/),,0.085,188533,DB00028,Intravenous Immunoglobulin
,18954531,concentration at a steady state,Serum rhEndostatin reached a steady-state level after 7 d of successive administration with the average concentration at a steady state of 272.44+/-91.98 ng/mL.,"Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18954531/),[ng] / [ml],272.44,188554,DB00028,Intravenous Immunoglobulin
,21748299,area under the curve,"This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg·min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-naïve, advanced NSCLC.",Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21748299/),[mg·min] / [ml],6,188919,DB00028,Intravenous Immunoglobulin
,12131216,half-life,Pharmacokinetic properties of this product were similar to other immune globulin products with a median half-life of 28 days in women and 30 days in infants.,Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131216/),d,28,189358,DB00028,Intravenous Immunoglobulin
,12131216,half-life,Pharmacokinetic properties of this product were similar to other immune globulin products with a median half-life of 28 days in women and 30 days in infants.,Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131216/),d,30,189359,DB00028,Intravenous Immunoglobulin
,27363843,maximum mean serum atezolizumab concentration,"The maximum mean serum atezolizumab concentration was 220 μg/mL (SD ± 21.9), with 10-mg/kg dosing and 536 μg/mL (SD ± 49.4) with 20-mg/kg dosing.","Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363843/),[μg] / [ml],220,190190,DB00028,Intravenous Immunoglobulin
,27363843,maximum mean serum atezolizumab concentration,"The maximum mean serum atezolizumab concentration was 220 μg/mL (SD ± 21.9), with 10-mg/kg dosing and 536 μg/mL (SD ± 49.4) with 20-mg/kg dosing.","Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363843/),[μg] / [ml],536,190191,DB00028,Intravenous Immunoglobulin
>,27363843,progression-free survival,"Three patients were still on treatment, and three of the six had achieved a progression-free survival of >12 months.","Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363843/),month,12,190192,DB00028,Intravenous Immunoglobulin
,3183495,half-life,"For total IgG, the half-life found was 25.8 days; for IgG1 it was 29.7 days; for IgG2 it was 26.9 days; and for IgG3 it was 15.7 days.",The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183495/),d,25.8,190263,DB00028,Intravenous Immunoglobulin
,3183495,half-life,"For total IgG, the half-life found was 25.8 days; for IgG1 it was 29.7 days; for IgG2 it was 26.9 days; and for IgG3 it was 15.7 days.",The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183495/),d,29.7,190264,DB00028,Intravenous Immunoglobulin
,3183495,half-life,"For total IgG, the half-life found was 25.8 days; for IgG1 it was 29.7 days; for IgG2 it was 26.9 days; and for IgG3 it was 15.7 days.",The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183495/),d,26.9,190265,DB00028,Intravenous Immunoglobulin
,3183495,half-life,"For total IgG, the half-life found was 25.8 days; for IgG1 it was 29.7 days; for IgG2 it was 26.9 days; and for IgG3 it was 15.7 days.",The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183495/),d,15.7,190266,DB00028,Intravenous Immunoglobulin
,21398296,maximal concentration,"In 13 patients receiving three doses, the maximal concentration after the third infusion was 33.9 ± 8.0 μg/mL, total area under the serum concentration-time curve was 5397 ± 1993 μg h/mL and elimination half-life was 102.3 ± 47.8 h.",Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21398296/),[μg] / [ml],33.9,192176,DB00028,Intravenous Immunoglobulin
,21398296,total area under the serum concentration-time curve,"In 13 patients receiving three doses, the maximal concentration after the third infusion was 33.9 ± 8.0 μg/mL, total area under the serum concentration-time curve was 5397 ± 1993 μg h/mL and elimination half-life was 102.3 ± 47.8 h.",Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21398296/),[h·μg] / [ml],5397,192177,DB00028,Intravenous Immunoglobulin
,21398296,elimination half-life,"In 13 patients receiving three doses, the maximal concentration after the third infusion was 33.9 ± 8.0 μg/mL, total area under the serum concentration-time curve was 5397 ± 1993 μg h/mL and elimination half-life was 102.3 ± 47.8 h.",Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21398296/),h,102.3,192178,DB00028,Intravenous Immunoglobulin
,16594642,clearance,"In addition, AMI pretreatment induced a 57% increase in 7E3 clearance (1.13 +/- 0.13 mL h(-1) kg(-1) vs 0.72 +/- 0.08 mL h(-1) kg(-1), P < .05).",Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16594642/),[ml] / [h·kg],1.13,192473,DB00028,Intravenous Immunoglobulin
,16594642,clearance,"In addition, AMI pretreatment induced a 57% increase in 7E3 clearance (1.13 +/- 0.13 mL h(-1) kg(-1) vs 0.72 +/- 0.08 mL h(-1) kg(-1), P < .05).",Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16594642/),[ml] / [h·kg],0.72,192474,DB00028,Intravenous Immunoglobulin
,19268719,half-life (beta),The half-life (beta) of pagibaximab was approximately 33 days.,Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19268719/),d,33,192803,DB00028,Intravenous Immunoglobulin
,22212346,trough immunoglobulin G concentration,"There was no significant within-patient difference in the average trough immunoglobulin G concentration between Intragam P and Intragam 10 NF (8.76 g/L, 8.55 g/L respectively) (geometrical mean ratio 1.034; 95% confidence interval 0.996-1.073; P = 0.079).","Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22212346/),[g] / [l],8.76,193083,DB00028,Intravenous Immunoglobulin
,22212346,trough immunoglobulin G concentration,"There was no significant within-patient difference in the average trough immunoglobulin G concentration between Intragam P and Intragam 10 NF (8.76 g/L, 8.55 g/L respectively) (geometrical mean ratio 1.034; 95% confidence interval 0.996-1.073; P = 0.079).","Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22212346/),[g] / [l],8.55,193084,DB00028,Intravenous Immunoglobulin
,22212346,Time to maximum concentration,"Time to maximum concentration occurred earlier with Intragam 10 NF compared with Intragam P, with a shorter infusion time (mean 1.75 h vs 2.52 h respectively; P < 0.05).","Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22212346/),h,1.75,193085,DB00028,Intravenous Immunoglobulin
,22212346,Time to maximum concentration,"Time to maximum concentration occurred earlier with Intragam 10 NF compared with Intragam P, with a shorter infusion time (mean 1.75 h vs 2.52 h respectively; P < 0.05).","Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22212346/),h,2.52,193086,DB00028,Intravenous Immunoglobulin
,27410490,apparent bioavailability,The apparent bioavailability was 36.3%-56.7% across single subcutaneous doses.,"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27410490/),%,36.3,193611,DB00028,Intravenous Immunoglobulin
,27410490,t1/2,"Similar to single-dose treatment, ASP2408 concentrations peaked 2 to 3 days postdose, with a median t1/2 of approximately 8 days.","Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27410490/),d,8,193612,DB00028,Intravenous Immunoglobulin
,21771770,AUC,"Estimated contributions of IVIG [calculated as mean AUC (IVIG group) minus mean AUC (control group)] were 4890.8 g h/l pre-pregnancy, 5591.4 g h/l first trimester and 4755.1 g h/l second trimester (P> 0.05, non-significant).",A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771770/),[g·h] / [l],4890.8,195652,DB00028,Intravenous Immunoglobulin
,21771770,AUC,"Estimated contributions of IVIG [calculated as mean AUC (IVIG group) minus mean AUC (control group)] were 4890.8 g h/l pre-pregnancy, 5591.4 g h/l first trimester and 4755.1 g h/l second trimester (P> 0.05, non-significant).",A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771770/),[g·h] / [l],5591.4,195653,DB00028,Intravenous Immunoglobulin
,21771770,AUC,"Estimated contributions of IVIG [calculated as mean AUC (IVIG group) minus mean AUC (control group)] were 4890.8 g h/l pre-pregnancy, 5591.4 g h/l first trimester and 4755.1 g h/l second trimester (P> 0.05, non-significant).",A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21771770/),[g·h] / [l],4755.1,195654,DB00028,Intravenous Immunoglobulin
,25644368,absolute bioavailability,"After sc administration, initial plasma pharmacokinetics and lymphatic exposure were also similar between PEG-trastuzumab and trastuzumab, but the absolute bioavailability of PEG-trastuzumab was 100% when compared to 86.1% bioavailability for trastuzumab.",PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25644368/),%,100,196816,DB00028,Intravenous Immunoglobulin
,25644368,absolute bioavailability,"After sc administration, initial plasma pharmacokinetics and lymphatic exposure were also similar between PEG-trastuzumab and trastuzumab, but the absolute bioavailability of PEG-trastuzumab was 100% when compared to 86.1% bioavailability for trastuzumab.",PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25644368/),%,86.1,196817,DB00028,Intravenous Immunoglobulin
,25644368,bioavailability,"After sc administration, initial plasma pharmacokinetics and lymphatic exposure were also similar between PEG-trastuzumab and trastuzumab, but the absolute bioavailability of PEG-trastuzumab was 100% when compared to 86.1% bioavailability for trastuzumab.",PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25644368/),%,86.1,196818,DB00028,Intravenous Immunoglobulin
,31145415,overall objective response rate,Responses were seen in 5 patients receiving PF-06801591 intravenously and in 2 patients treated subcutaneously for an overall objective response rate of 18.4%.,Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145415/),%,18.4,197041,DB00028,Intravenous Immunoglobulin
,31145415,overall survival,Median overall survival was not reached with intravenous dosing vs 10.7 months with subcutaneous administration.,Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145415/),month,10.7,197042,DB00028,Intravenous Immunoglobulin
,31145415,time to maximum observed serum concentration,Median time to maximum observed serum concentration was 8 days after subcutaneous administration.,Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145415/),d,8,197043,DB00028,Intravenous Immunoglobulin
,914999,intrinsic association constant,Selected antiserum from sheep immunized and boosted with a digoxin-serum albumin conjugate contained antibodies that cross-reacted with digitoxin with an average intrinsic association constant of 1.4 x 10(10) M(-1) as determined by equilibrium dialysis.,Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),1/[M],1.4 x 10(10),199371,DB00028,Intravenous Immunoglobulin
,914999,k(f),Rapid second-order association kinetics (k(f) = 3.7 x 10(6) M(-1) per s) and slow dissociation kinetics (k(r) = 1.9 x 10(-4) per s) were documented for the antibody-digitoxin complex.,Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),1/[M·s],3.7 x 10(6),199372,DB00028,Intravenous Immunoglobulin
,914999,k(r),Rapid second-order association kinetics (k(f) = 3.7 x 10(6) M(-1) per s) and slow dissociation kinetics (k(r) = 1.9 x 10(-4) per s) were documented for the antibody-digitoxin complex.,Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),1/[s],1.9 x 10(-4),199373,DB00028,Intravenous Immunoglobulin
,914999,elimination half-life,"Unlike common laboratory animals previously studied, the rhesus monkey was found to have a prolonged elimination half-life, estimated at 135 and 118 h by radioimmunoassay and [(3)H]digitoxin measurements, respectively, similar to man and thus providing a clinically relevant experimental model.",Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),h,135,199374,DB00028,Intravenous Immunoglobulin
,914999,elimination half-life,"Unlike common laboratory animals previously studied, the rhesus monkey was found to have a prolonged elimination half-life, estimated at 135 and 118 h by radioimmunoassay and [(3)H]digitoxin measurements, respectively, similar to man and thus providing a clinically relevant experimental model.",Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),h,118,199375,DB00028,Intravenous Immunoglobulin
,914999,t((1/2)),Intravenous administration of 2 mol of specific Fab fragments per mole of digitoxin 6 h after 0.2 mg of digitoxin produced a rapid 4.3-fold increase in plasma total digitoxin concentration followed by a rapid fall (t((1/2)) 4 h) accompanied by a 14-fold enhancement of urinary digitoxin excretion over control values during the 6-h period after Fab was given.,Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),h,4,199376,DB00028,Intravenous Immunoglobulin
,27582171,annual,"The rate of validated serious bacterial infections was 0.012 event/patient-year (p < 0.0001 compared with the historical control), and the annualized rate of infection was 2.41 events/patient.","Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27582171/),[events] / [patient],2.41,199455,DB00028,Intravenous Immunoglobulin
>,27582171,trough levels,Median IgG trough levels were >14.5 g/l.,"Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27582171/),[g] / [l],14.5,199456,DB00028,Intravenous Immunoglobulin
,27582171,maximum infusion rate,"The median maximum infusion rate was 60 ml/h/site (range 4.4-180), resulting in a median infusion duration of 0.95 h.","Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27582171/),[ml] / [h·site],60,199457,DB00028,Intravenous Immunoglobulin
,11160623,half-life,"The pharmacokinetics of BLyS following i.v. injection are monophasic with a half-life of 160 min, a clearance of 0.22 ml/min-kg, and a volume of distribution of 53 ml/kg.",Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160623/),min,160,199910,DB00028,Intravenous Immunoglobulin
,11160623,clearance,"The pharmacokinetics of BLyS following i.v. injection are monophasic with a half-life of 160 min, a clearance of 0.22 ml/min-kg, and a volume of distribution of 53 ml/kg.",Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160623/),[ml] / [min-kg],0.22,199911,DB00028,Intravenous Immunoglobulin
,11160623,volume of distribution,"The pharmacokinetics of BLyS following i.v. injection are monophasic with a half-life of 160 min, a clearance of 0.22 ml/min-kg, and a volume of distribution of 53 ml/kg.",Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160623/),[ml] / [kg],53,199912,DB00028,Intravenous Immunoglobulin
,11160623,bioavailability,"The i.v. and s.c. routes of administration were pharmacologically equivalent, even though s.c. bioavailability of BLyS is only 25%.",Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160623/),%,25,199913,DB00028,Intravenous Immunoglobulin
,11160623,t(1/2),"BLyS (s.c.) dramatically elevated serum IgG and IgA levels, and the duration of the responses after cessation of treatment (t(1/2) = 4.4 and 1.3 days, respectively) are similar to the half-lives of endogenous IgG and IgA in mice.",Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160623/),d,4.4,199914,DB00028,Intravenous Immunoglobulin
,11160623,t(1/2),"BLyS (s.c.) dramatically elevated serum IgG and IgA levels, and the duration of the responses after cessation of treatment (t(1/2) = 4.4 and 1.3 days, respectively) are similar to the half-lives of endogenous IgG and IgA in mice.",Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160623/),d,1.3,199915,DB00028,Intravenous Immunoglobulin
,11160623,t(1/2),The IgM response is more modest than that of IgG and IgA but lasts longer (t(1/2) = 7.0 days) than the half-life of endogenous IgM.,Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160623/),d,7.0,199916,DB00028,Intravenous Immunoglobulin
,31664766,time to maximum concentration (Tmax ),"BOS161721 administered subcutaneously was absorbed slowly, with a median time to maximum concentration (Tmax ) of 144 hours across doses (range 1-15 days) and a mean apparent terminal elimination half-life of 80-87 days for doses ≥ 30 mg.","A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31664766/),h,144,201515,DB00028,Intravenous Immunoglobulin
,31664766,apparent terminal elimination half-life,"BOS161721 administered subcutaneously was absorbed slowly, with a median time to maximum concentration (Tmax ) of 144 hours across doses (range 1-15 days) and a mean apparent terminal elimination half-life of 80-87 days for doses ≥ 30 mg.","A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31664766/),d,80-87,201516,DB00028,Intravenous Immunoglobulin
,31664766,Subcutaneous bioavailability,Subcutaneous bioavailability was 64%.,"A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31664766/),%,64,201517,DB00028,Intravenous Immunoglobulin
,19745765,area under the curve,"Patients received paclitaxel 200 mg/m2, carboplatin (area under the curve of 6), and F (0.05-20 mg/kg) q3 weeks for up to six cycles.","Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19745765/),,6,202814,DB00028,Intravenous Immunoglobulin
,15496641,clearance (CL,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.072,203962,DB00028,Intravenous Immunoglobulin
,15496641,volume of distribution in the central compartment (V(c),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),l,5.97,203963,DB00028,Intravenous Immunoglobulin
,15496641,volume of distribution in the peripheral compartment (V(p),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),l,2.05,203964,DB00028,Intravenous Immunoglobulin
,15496641,intercompartment clearance (Q,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.0645,203965,DB00028,Intravenous Immunoglobulin
,15496641,first-order absorption rate constant (k(a),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[1] / [h],0.0282,203966,DB00028,Intravenous Immunoglobulin
,15496641,absolute bioavailability,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),,0.626,203967,DB00028,Intravenous Immunoglobulin
,15496641,clearance,"Based on the bioequivalence criteria, the Bayesian-estimated clearance for patients receiving etanercept alone (mean: 0.070 L/h) was comparable to that for patients receiving a combination of etanercept and methotrexate (mean = 0.066 L/h).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.070,203968,DB00028,Intravenous Immunoglobulin
,15496641,clearance,"Based on the bioequivalence criteria, the Bayesian-estimated clearance for patients receiving etanercept alone (mean: 0.070 L/h) was comparable to that for patients receiving a combination of etanercept and methotrexate (mean = 0.066 L/h).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.066,203969,DB00028,Intravenous Immunoglobulin
,9062345,Time of recovery to 50%,Time of recovery to 50% of baseline IgE correlated with the dose of administered antibody and ranged from a mean of 1.3 d for the 3 mg to 39 d for the 100 mg dose.,"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062345/),d,1.3,204449,DB00028,Intravenous Immunoglobulin
,9062345,Time of recovery to 50%,Time of recovery to 50% of baseline IgE correlated with the dose of administered antibody and ranged from a mean of 1.3 d for the 3 mg to 39 d for the 100 mg dose.,"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062345/),d,39,204450,DB00028,Intravenous Immunoglobulin
,9062345,terminal half-life,Complexed IgE was eliminated at a rate comparable with the terminal half-life of free CGP 51901 (11-13 d at all doses).,"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062345/),d,11-13,204451,DB00028,Intravenous Immunoglobulin
,15163895,serious infection rate,The calculated serious infection rate for the intent-to-treat population was 0.061/subject/year.,"Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15163895/),1/[subject·year],0.061,206213,DB00028,Intravenous Immunoglobulin
,15163895,half-life,The half-life of total IgG was 37 days.,"Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15163895/),d,37,206214,DB00028,Intravenous Immunoglobulin
,9203648,half-life,"Using 200 mg/kg, mean half-life and volume of distribution (Vd) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),d,15,206279,DB00028,Intravenous Immunoglobulin
,9203648,volume of distribution (Vd),"Using 200 mg/kg, mean half-life and volume of distribution (Vd) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),[ml] / [kg],72,206280,DB00028,Intravenous Immunoglobulin
,9203648,volume of distribution (Vd),"Using 200 mg/kg, mean half-life and volume of distribution (Vd) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),d,32,206281,DB00028,Intravenous Immunoglobulin
,9203648,volume of distribution (Vd),"Using 200 mg/kg, mean half-life and volume of distribution (Vd) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),[ml] / [kg],154,206282,DB00028,Intravenous Immunoglobulin
,9203648,volume of distribution (Vd),"Using 200 mg/kg, mean half-life and volume of distribution (Vd) in women were 15 days and 72 mL/kg, respectively, after one and 32 days and 154 mL/kg after three monthly infusions, with stable 4 mL/kg/day clearance.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),m,4,206283,DB00028,Intravenous Immunoglobulin
,9203648,half-life,"Newborn single-dose half-life, Vd, and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),d,30,206284,DB00028,Intravenous Immunoglobulin
,9203648,Vd,"Newborn single-dose half-life, Vd, and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),[ml] / [kg],143,206285,DB00028,Intravenous Immunoglobulin
,9203648,Vd,"Newborn single-dose half-life, Vd, and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),[ml] / [d·kg],4,206286,DB00028,Intravenous Immunoglobulin
,9203648,clearance,"Newborn single-dose half-life, Vd, and clearance were 30 days, 143 mL/kg, and 4 mL/kg/day, respectively.",Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203648/),[ml] / [d·kg],4,206287,DB00028,Intravenous Immunoglobulin
,27613250,rate of,"The rate of validated acute bacterial infections (VASBIs) was significantly lower than 1 per year (0·022/patient-year, P < 0·0001); the rate of all infections was 4·38/patient-year.","Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613250/),1/[patient-year],4·38,206304,DB00028,Intravenous Immunoglobulin
≥,27613250,trough IgG concentrations,Median trough IgG concentrations were ≥ 8 g/l.,"Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613250/),[g] / [l],8,206305,DB00028,Intravenous Immunoglobulin
,27613250,infusion duration,The median infusion duration was 0·95 (range = 0·3-4·1) h using mainly one to two administration sites [median = 2 sites (range = 1-5)].,"Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613250/),h,0·95,206306,DB00028,Intravenous Immunoglobulin
,21604075,linear clearance,"For a typical 80-kg, 40-year subject, linear clearance was 35.0 mL/hr, central and peripheral volumes of distribution were 1.78 and 5.03 L, respectively, and SC bioavailability was 24.3%.",Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604075/),[ml] / [h],35.0,206630,DB00028,Intravenous Immunoglobulin
,21604075,central,"For a typical 80-kg, 40-year subject, linear clearance was 35.0 mL/hr, central and peripheral volumes of distribution were 1.78 and 5.03 L, respectively, and SC bioavailability was 24.3%.",Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604075/),l,1.78,206631,DB00028,Intravenous Immunoglobulin
,21604075,peripheral volumes of distribution,"For a typical 80-kg, 40-year subject, linear clearance was 35.0 mL/hr, central and peripheral volumes of distribution were 1.78 and 5.03 L, respectively, and SC bioavailability was 24.3%.",Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604075/),l,5.03,206632,DB00028,Intravenous Immunoglobulin
,21604075,bioavailability,"For a typical 80-kg, 40-year subject, linear clearance was 35.0 mL/hr, central and peripheral volumes of distribution were 1.78 and 5.03 L, respectively, and SC bioavailability was 24.3%.",Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21604075/),%,24.3,206633,DB00028,Intravenous Immunoglobulin
,8550076,initial blood clearance (t1/2 early phase,Pharmacokinetic studies in vivo involving intravenous injection of radiolabelled rsFc epsilon RI in mice revealed the receptor to have a rapid initial blood clearance (t1/2 early phase of 15 min) and to accumulate in the liver before being detected in urine.,Expression of recombinant soluble Fc epsilon RI: function and tissue distribution studies. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8550076/),min,15,207243,DB00028,Intravenous Immunoglobulin
,9493805,half-life,The mean half-life of 20 days was comparable with that of other immunoglobulin G preparations.,"Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),d,20,210165,DB00028,Intravenous Immunoglobulin
,9493805,trough serum concentrations,"Mean trough serum concentrations 30 days after Infusion 1 were 6.8, 36.1 and 60.6 microg/ml for the 3-, 10- and 15-mg/kg dose groups, respectively.","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],6.8,210166,DB00028,Intravenous Immunoglobulin
,9493805,trough serum concentrations,"Mean trough serum concentrations 30 days after Infusion 1 were 6.8, 36.1 and 60.6 microg/ml for the 3-, 10- and 15-mg/kg dose groups, respectively.","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],36.1,210167,DB00028,Intravenous Immunoglobulin
,9493805,trough serum concentrations,"Mean trough serum concentrations 30 days after Infusion 1 were 6.8, 36.1 and 60.6 microg/ml for the 3-, 10- and 15-mg/kg dose groups, respectively.","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],60.6,210168,DB00028,Intravenous Immunoglobulin
,9493805,trough concentrations,"After Infusion 2 the trough concentrations were 11.9, 45.2 and 70.7 microg/ml.","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],11.9,210169,DB00028,Intravenous Immunoglobulin
,9493805,trough concentrations,"After Infusion 2 the trough concentrations were 11.9, 45.2 and 70.7 microg/ml.","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],45.2,210170,DB00028,Intravenous Immunoglobulin
,9493805,trough concentrations,"After Infusion 2 the trough concentrations were 11.9, 45.2 and 70.7 microg/ml.","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],70.7,210171,DB00028,Intravenous Immunoglobulin
,9493805,trough,"After subsequent doses the mean trough values ranged from 14 to 18 microg/ml in those given 3 mg/kg and were > 40 microg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 microg/ml and 88 to 96 microg/ml, respectively).","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],14 to 18,210172,DB00028,Intravenous Immunoglobulin
>,9493805,trough,"After subsequent doses the mean trough values ranged from 14 to 18 microg/ml in those given 3 mg/kg and were > 40 microg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 microg/ml and 88 to 96 microg/ml, respectively).","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],40,210173,DB00028,Intravenous Immunoglobulin
,9493805,trough,"After subsequent doses the mean trough values ranged from 14 to 18 microg/ml in those given 3 mg/kg and were > 40 microg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 microg/ml and 88 to 96 microg/ml, respectively).","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],46 to 72,210174,DB00028,Intravenous Immunoglobulin
,9493805,trough,"After subsequent doses the mean trough values ranged from 14 to 18 microg/ml in those given 3 mg/kg and were > 40 microg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 microg/ml and 88 to 96 microg/ml, respectively).","Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493805/),[μg] / [ml],88 to 96,210175,DB00028,Intravenous Immunoglobulin
,15113381,elimination half-life,"In both the treatment groups, the mean elimination half-life was about 18 days and thus similar to that described for plasma-derived anti-D IgG.",Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113381/),d,18,213125,DB00028,Intravenous Immunoglobulin
,15113381,bioavailability,The bioavailability of MonoRho after intramuscular administration was estimated as 46%.,Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113381/),%,46,213126,DB00028,Intravenous Immunoglobulin
,22340283,terminal half-life,PK data demonstrated an approximately proportional increase in concentration with increasing dose and a terminal half-life of 20 hours.,"A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22340283/),h,20,214123,DB00028,Intravenous Immunoglobulin
,1761689,half-life,"Injected intravenously, 20 mg of Candida mannan antigen was cleared from the serum with a half-life of approximately 2 h.",Rapid clearance of Candida albicans mannan antigens by liver and spleen in contrast to prolonged circulation of Cryptococcus neoformans antigens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761689/),h,2,215670,DB00028,Intravenous Immunoglobulin
,1761689,half-life,"In contrast, 20 micrograms of Cryptococcus glucuronoxylomannan antigen had a half-life in serum of approximately 24 h.",Rapid clearance of Candida albicans mannan antigens by liver and spleen in contrast to prolonged circulation of Cryptococcus neoformans antigens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761689/),h,24,215671,DB00028,Intravenous Immunoglobulin
,1571545,maximal rate of lysis,"Continuous intravenous infusion of rscu-PA/MA-FU1-74 (1:1.2 molar ratio) over 2 hours showed a fivefold increased thrombolytic potency (lysis per unit dose) over that of unconjugated rscu-PA, as evidenced both by a higher maximal rate of lysis (380% +/- 68% v 78% +/- 25% lysis per mg u-PA equivalent of compound administered per kg body weight, P less than .001), and by a lower dose at which the maximal rate of lysis occurs (0.19 +/- 0.03 v 0.82 +/- 0.10 mg compound per kg body weight, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),%,380,216064,DB00028,Intravenous Immunoglobulin
,1571545,maximal rate of lysis,"Continuous intravenous infusion of rscu-PA/MA-FU1-74 (1:1.2 molar ratio) over 2 hours showed a fivefold increased thrombolytic potency (lysis per unit dose) over that of unconjugated rscu-PA, as evidenced both by a higher maximal rate of lysis (380% +/- 68% v 78% +/- 25% lysis per mg u-PA equivalent of compound administered per kg body weight, P less than .001), and by a lower dose at which the maximal rate of lysis occurs (0.19 +/- 0.03 v 0.82 +/- 0.10 mg compound per kg body weight, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),%,78,216065,DB00028,Intravenous Immunoglobulin
,1571545,maximal rate of lysis,"Continuous intravenous infusion of rscu-PA/MA-FU1-74 (1:1.2 molar ratio) over 2 hours showed a fivefold increased thrombolytic potency (lysis per unit dose) over that of unconjugated rscu-PA, as evidenced both by a higher maximal rate of lysis (380% +/- 68% v 78% +/- 25% lysis per mg u-PA equivalent of compound administered per kg body weight, P less than .001), and by a lower dose at which the maximal rate of lysis occurs (0.19 +/- 0.03 v 0.82 +/- 0.10 mg compound per kg body weight, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),mg,0.19,216066,DB00028,Intravenous Immunoglobulin
,1571545,maximal rate of lysis,"Continuous intravenous infusion of rscu-PA/MA-FU1-74 (1:1.2 molar ratio) over 2 hours showed a fivefold increased thrombolytic potency (lysis per unit dose) over that of unconjugated rscu-PA, as evidenced both by a higher maximal rate of lysis (380% +/- 68% v 78% +/- 25% lysis per mg u-PA equivalent of compound administered per kg body weight, P less than .001), and by a lower dose at which the maximal rate of lysis occurs (0.19 +/- 0.03 v 0.82 +/- 0.10 mg compound per kg body weight, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),mg,0.82,216067,DB00028,Intravenous Immunoglobulin
,1571545,maximal rate of lysis,"The specific thrombolytic activity (percent lysis per unit steady-state plasma u-PA antigen level) was lower for rscu-PA/MA-FU1-74 than for rscu-PA, as shown by both a lower maximal rate of lysis (60% +/- 13% v 220% +/- 22% lysis per microgram/mL u-PA antigen level in plasma, P less than .001) and a higher plasma antigen level at which maximal lysis is achieved (1.2 +/- 0.17 v 0.20 +/- 0.01 microgram/mL, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),%,60,216068,DB00028,Intravenous Immunoglobulin
,1571545,maximal rate of lysis,"The specific thrombolytic activity (percent lysis per unit steady-state plasma u-PA antigen level) was lower for rscu-PA/MA-FU1-74 than for rscu-PA, as shown by both a lower maximal rate of lysis (60% +/- 13% v 220% +/- 22% lysis per microgram/mL u-PA antigen level in plasma, P less than .001) and a higher plasma antigen level at which maximal lysis is achieved (1.2 +/- 0.17 v 0.20 +/- 0.01 microgram/mL, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),%,220,216069,DB00028,Intravenous Immunoglobulin
,1571545,maximal lysis,"The specific thrombolytic activity (percent lysis per unit steady-state plasma u-PA antigen level) was lower for rscu-PA/MA-FU1-74 than for rscu-PA, as shown by both a lower maximal rate of lysis (60% +/- 13% v 220% +/- 22% lysis per microgram/mL u-PA antigen level in plasma, P less than .001) and a higher plasma antigen level at which maximal lysis is achieved (1.2 +/- 0.17 v 0.20 +/- 0.01 microgram/mL, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),,1,216070,DB00028,Intravenous Immunoglobulin
,1571545,maximal lysis,"The specific thrombolytic activity (percent lysis per unit steady-state plasma u-PA antigen level) was lower for rscu-PA/MA-FU1-74 than for rscu-PA, as shown by both a lower maximal rate of lysis (60% +/- 13% v 220% +/- 22% lysis per microgram/mL u-PA antigen level in plasma, P less than .001) and a higher plasma antigen level at which maximal lysis is achieved (1.2 +/- 0.17 v 0.20 +/- 0.01 microgram/mL, P less than .001).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),,0,216071,DB00028,Intravenous Immunoglobulin
,1571545,initial half-life,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),min,3.3,216072,DB00028,Intravenous Immunoglobulin
,1571545,initial half-life,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),min,13,216073,DB00028,Intravenous Immunoglobulin
,1571545,plasma clearances,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),[ml] / [min],340,216074,DB00028,Intravenous Immunoglobulin
,1571545,plasma clearances,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),[ml] / [min],10,216075,DB00028,Intravenous Immunoglobulin
,1571545,plasma clearances,"After the end of the infusions, u-PA-related antigen disappeared from plasma in a biphasic manner, with an initial half-life of 3.3 +/- 0.4 minutes for rscu-PA, 13 +/- 1 minutes for rscu-PA/MA-FU1-74, and 13 +/- 1 minutes for rscu-PA/MA-UK1-3, with corresponding plasma clearances of 340 +/- 28, 10 +/- 1, and 37 +/- 4 mL/min, respectively (mean +/- SEM).",Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1571545/),[ml] / [min],37,216076,DB00028,Intravenous Immunoglobulin
,31403867,progression-free survival time,"By the cutoff date, among 29 patients with chemotherapy-naïve mucosal melanoma, 14 patients (48.3%; 95% CI, 29.4% to 67.5%) achieved objective response, and the median progression-free survival time was 7.5 months (95% CI, 3.7 months to not reached) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.","Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31403867/),month,7.5,216576,DB00028,Intravenous Immunoglobulin
,25953213,infusion rate,"In Part A, patients (n = 30) received 3 infusions of BT090 at their pretrial dose and dosing interval; the infusion rate of BT090 was increased from 0·3 to 1·4 to 2·0 ml/kg/h for each infusion in each patient initially at 30-min intervals.","An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25953213/),[ml] / [h·kg],0,216612,DB00028,Intravenous Immunoglobulin
,25953213,infusion rate,"In Part A, patients (n = 30) received 3 infusions of BT090 at their pretrial dose and dosing interval; the infusion rate of BT090 was increased from 0·3 to 1·4 to 2·0 ml/kg/h for each infusion in each patient initially at 30-min intervals.","An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25953213/),[ml] / [h·kg],1,216613,DB00028,Intravenous Immunoglobulin
,25953213,infusion rate,"In Part A, patients (n = 30) received 3 infusions of BT090 at their pretrial dose and dosing interval; the infusion rate of BT090 was increased from 0·3 to 1·4 to 2·0 ml/kg/h for each infusion in each patient initially at 30-min intervals.","An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25953213/),[ml] / [h·kg],2,216614,DB00028,Intravenous Immunoglobulin
<,25953213,maximum tolerated infusion rates,"At subsequent infusions, all patients tolerated their individually defined maximum infusion rate: 17 patients (68·0%) tolerated infusion rates of 6·0 or 8·0 ml/kg/h and four patients (16%) had maximum tolerated infusion rates of <4·0 ml/kg/h at subsequent infusions.","An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25953213/),[ml] / [h·kg],4·0,216615,DB00028,Intravenous Immunoglobulin
,25953213,infusion time,Escalation of infusion rates shortened infusion time from a median of around 2·5 h to around 1·6 h.,"An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25953213/),h,2·5,216616,DB00028,Intravenous Immunoglobulin
,25953213,infusion time,Escalation of infusion rates shortened infusion time from a median of around 2·5 h to around 1·6 h.,"An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25953213/),h,1·6,216617,DB00028,Intravenous Immunoglobulin
,33085033,clearance (CL),Mean clearance (CL) after a single IV infusion ranged between 2.28 and 3.09 mL/kg/day.,"Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33085033/),[ml] / [d·kg],2.28 and 3.09,218153,DB00028,Intravenous Immunoglobulin
≥,33085033,Absolute bioavailability,Absolute bioavailability after a single SC injection was ≥ 80.0%.,"Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33085033/),%,80.0,218154,DB00028,Intravenous Immunoglobulin
,33085033,terminal elimination half-life (t1/2),Mean terminal elimination half-life (t1/2) was similar after IV (20.7 to 24.6 days) and SC administration (22.6 days).,"Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33085033/),d,20.7 to 24.6,218155,DB00028,Intravenous Immunoglobulin
,33085033,terminal elimination half-life (t1/2),Mean terminal elimination half-life (t1/2) was similar after IV (20.7 to 24.6 days) and SC administration (22.6 days).,"Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33085033/),d,22.6,218156,DB00028,Intravenous Immunoglobulin
,33085033,steady-state CL,"Mean steady-state CL and t1/2 were 4.73 mL/kg/day and 14.8 days, respectively.","Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33085033/),[ml] / [d·kg],4.73,218157,DB00028,Intravenous Immunoglobulin
,33085033,t1/2,"Mean steady-state CL and t1/2 were 4.73 mL/kg/day and 14.8 days, respectively.","Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33085033/),d,14.8,218158,DB00028,Intravenous Immunoglobulin
,22446296,maximum serum concentration,The maximum serum concentration of 460 μg/ml was achieved following 1h infusion of the highest dose of 20 mg/kg.,"Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446296/),[μg] / [ml],460,218653,DB00028,Intravenous Immunoglobulin
,22446296,systemic clearance,The systemic clearance was low (0.4 to 0.5 ml/hkg).,"Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446296/),[ml] / [hkg],0.4 to 0.5,218654,DB00028,Intravenous Immunoglobulin
,22446296,terminal elimination half-life,Mean terminal elimination half-life was 12 to 15 days.,"Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446296/),d,12 to 15,218655,DB00028,Intravenous Immunoglobulin
,26062668,elimination half-life,"Subsequently, it gradually decreased with an elimination half-life of 21.9 days (±20.4 SD) but was still detectable in serum even a few weeks after allogeneic hematopoietic stem cell transplantation.",Pharmacokinetics of 8 mg/kg anti-human T-lymphocyte rabbit immunoglobulin conditioning for hematopoietic stem cell transplantation in Japanese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26062668/),d,21.9,221152,DB00028,Intravenous Immunoglobulin
,28399040,sensitivity,This method was developed and validated within the acceptance criteria in compliance with the Guidelines for a biological method validation: the sensitivity of the method was 0.095 ng/mL.,"A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),[ng] / [ml],0.095,221220,DB00028,Intravenous Immunoglobulin
,28399040,total ATLG levels,"The median total ATLG levels pre-IVand post-IV were 0 and 118 mcg/mL on day -5; 85.9 and 199.2 mcg/mL on day -4; 153 and 270.9 mcg/mL on day -3, respectively.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),[mcg] / [ml],0,221221,DB00028,Intravenous Immunoglobulin
,28399040,total ATLG levels,"The median total ATLG levels pre-IVand post-IV were 0 and 118 mcg/mL on day -5; 85.9 and 199.2 mcg/mL on day -4; 153 and 270.9 mcg/mL on day -3, respectively.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),[mcg] / [ml],118,221222,DB00028,Intravenous Immunoglobulin
,28399040,total ATLG levels,"The median total ATLG levels pre-IVand post-IV were 0 and 118 mcg/mL on day -5; 85.9 and 199.2 mcg/mL on day -4; 153 and 270.9 mcg/mL on day -3, respectively.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),[mcg] / [ml],85.9,221223,DB00028,Intravenous Immunoglobulin
,28399040,total ATLG levels,"The median total ATLG levels pre-IVand post-IV were 0 and 118 mcg/mL on day -5; 85.9 and 199.2 mcg/mL on day -4; 153 and 270.9 mcg/mL on day -3, respectively.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),[mcg] / [ml],199.2,221224,DB00028,Intravenous Immunoglobulin
,28399040,total ATLG levels,"The median total ATLG levels pre-IVand post-IV were 0 and 118 mcg/mL on day -5; 85.9 and 199.2 mcg/mL on day -4; 153 and 270.9 mcg/mL on day -3, respectively.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),[mcg] / [ml],153,221225,DB00028,Intravenous Immunoglobulin
,28399040,total ATLG levels,"The median total ATLG levels pre-IVand post-IV were 0 and 118 mcg/mL on day -5; 85.9 and 199.2 mcg/mL on day -4; 153 and 270.9 mcg/mL on day -3, respectively.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),[mcg] / [ml],270.9,221226,DB00028,Intravenous Immunoglobulin
,28399040,CL,"The median PK values of CL was 0.0029 (range: 0.0028-0.0057) L·kg·d, Vd was 0.088 (range: 0.025-0.448) L/kg and t1/2 was 20.2 (range: 5.8-50.2) days.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),d·kg·l,0.0029,221227,DB00028,Intravenous Immunoglobulin
,28399040,Vd,"The median PK values of CL was 0.0029 (range: 0.0028-0.0057) L·kg·d, Vd was 0.088 (range: 0.025-0.448) L/kg and t1/2 was 20.2 (range: 5.8-50.2) days.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),[l] / [kg],0.088,221228,DB00028,Intravenous Immunoglobulin
,28399040,t1/2,"The median PK values of CL was 0.0029 (range: 0.0028-0.0057) L·kg·d, Vd was 0.088 (range: 0.025-0.448) L/kg and t1/2 was 20.2 (range: 5.8-50.2) days.","A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399040/),d,20.2,221229,DB00028,Intravenous Immunoglobulin
,25392325,elimination half-life,GNbAC1 pharmacokinetics is dose-linear with mean elimination half-life of 27-37 d.,"A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392325/),d,27-37,221476,DB00028,Intravenous Immunoglobulin
,18690878,volume of distribution,"Trastuzumab pharmacokinetics are characterized by a low systemic clearance, a low volume of distribution (4l) and a very long half-life (28 days) comparable to that of endogenous immunoglobulins G.",Clinical pharmacology of trastuzumab. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18690878/),l,4,223477,DB00028,Intravenous Immunoglobulin
,18690878,half-life,"Trastuzumab pharmacokinetics are characterized by a low systemic clearance, a low volume of distribution (4l) and a very long half-life (28 days) comparable to that of endogenous immunoglobulins G.",Clinical pharmacology of trastuzumab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18690878/),d,28,223478,DB00028,Intravenous Immunoglobulin
,15116285,VL,"Eleven males were enrolled; median CD4+T-cell count and VL were 96 cells/microL and 126,200 copies/mL, respectively.","A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116285/),,126,224476,DB00028,Intravenous Immunoglobulin
,15116285,terminal elimination half-life (t(1/2)),"The mean terminal elimination half-life (t(1/2)) was 136.6 +/- 44.6 hours (range, 52.6-198 h).","A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116285/),h,136.6,224477,DB00028,Intravenous Immunoglobulin
,29890876,recurrence rate,The recurrence rate of NH in a subsequent infant of a mother with an affected infant is 70-90%.,The Japanese experience and pharmacokinetics of antenatal maternal high-dose immunoglobulin treatment as a prophylaxis for neonatal hemochromatosis in siblings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29890876/),%,70-90,226782,DB00028,Intravenous Immunoglobulin
,29890876,trough,"A simulation study showed that the estimated trough and peak levels of IgG concentrations during IVIG were 2000-3000 and 4000-5000 mg/dl, respectively.",The Japanese experience and pharmacokinetics of antenatal maternal high-dose immunoglobulin treatment as a prophylaxis for neonatal hemochromatosis in siblings. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29890876/),[mg] / [dl],2000-3000,226783,DB00028,Intravenous Immunoglobulin
,29890876,peak levels,"A simulation study showed that the estimated trough and peak levels of IgG concentrations during IVIG were 2000-3000 and 4000-5000 mg/dl, respectively.",The Japanese experience and pharmacokinetics of antenatal maternal high-dose immunoglobulin treatment as a prophylaxis for neonatal hemochromatosis in siblings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29890876/),[mg] / [dl],4000-5000,226784,DB00028,Intravenous Immunoglobulin
,9406699,T(1/2),"The plasma clearance curves were biexponential, with average T(1/2) values of 2-4 hours and 28-33 hours, respectively.",A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9406699/),h,2-4,227281,DB00028,Intravenous Immunoglobulin
,9406699,T(1/2),"The plasma clearance curves were biexponential, with average T(1/2) values of 2-4 hours and 28-33 hours, respectively.",A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9406699/),h,28-33,227282,DB00028,Intravenous Immunoglobulin
,28683953,trough level at steady state,"Bioequivalence was established with a mean average total IgG trough level at steady state being 8.05g/L with TEGELINE® and 9.17g/L with ClairYg® (i.e. geometric mean for the difference between ClairYg® and TEGELINE® was 1.136; [90% CI: 1.092-1.181] P<0.001), within the pre-specified margin to establish bioequivalence (0.80-1.25).","A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28683953/),[g] / [l],8.05,228053,DB00028,Intravenous Immunoglobulin
,28683953,trough level at steady state,"Bioequivalence was established with a mean average total IgG trough level at steady state being 8.05g/L with TEGELINE® and 9.17g/L with ClairYg® (i.e. geometric mean for the difference between ClairYg® and TEGELINE® was 1.136; [90% CI: 1.092-1.181] P<0.001), within the pre-specified margin to establish bioequivalence (0.80-1.25).","A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28683953/),[g] / [l],9.17,228054,DB00028,Intravenous Immunoglobulin
>,28683953,trough levels,Total IgG trough levels remained clinically adequate (>4-6g/L) throughout the study.,"A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28683953/),[g] / [l],4-6,228055,DB00028,Intravenous Immunoglobulin
,28683953,annualized infections rate,The median annualized infections rate per patient was similar for both products: 4.35 [0; 21.8] for TEGELINE® and 4.30 [0; 15.1] for ClairYg®.,"A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28683953/),,4.35,228056,DB00028,Intravenous Immunoglobulin
,28683953,annualized infections rate,The median annualized infections rate per patient was similar for both products: 4.35 [0; 21.8] for TEGELINE® and 4.30 [0; 15.1] for ClairYg®.,"A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28683953/),,4.30,228057,DB00028,Intravenous Immunoglobulin
>,28683953,trough levels,Infections were less common with higher IgG trough levels (>8.16g/L).,"A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28683953/),[g] / [l],8.16,228058,DB00028,Intravenous Immunoglobulin
,16850270,serum clearances,"For GPIbalpha-Ig/2V, the serum clearances were 2.62+/-0.27 ml/hr/kg in rats and 1.97+/-0.24 ml/hr/kg in dogs.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],2.62,229733,DB00028,Intravenous Immunoglobulin
,16850270,serum clearances,"For GPIbalpha-Ig/2V, the serum clearances were 2.62+/-0.27 ml/hr/kg in rats and 1.97+/-0.24 ml/hr/kg in dogs.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],1.97,229734,DB00028,Intravenous Immunoglobulin
,16850270,serum clearances,"The serum clearances of less potent GPIbalpha-Ig/1V were 1.08+/-0.08 and 0.97+/-0.19 ml/hr/kg in rats and dogs, respectively.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],1.08,229735,DB00028,Intravenous Immunoglobulin
,16850270,serum clearances,"The serum clearances of less potent GPIbalpha-Ig/1V were 1.08+/-0.08 and 0.97+/-0.19 ml/hr/kg in rats and dogs, respectively.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],0.97,229736,DB00028,Intravenous Immunoglobulin
,16850270,serum clearance,"In addition, the serum clearance of GPlbalpha-Ig/2V of 1.53 ml/hr/kg in vWF-deficient mice was lower than that in wild-type mice of 2.79 ml/hr/kg.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],1.53,229737,DB00028,Intravenous Immunoglobulin
,16850270,serum clearance,"In addition, the serum clearance of GPlbalpha-Ig/2V of 1.53 ml/hr/kg in vWF-deficient mice was lower than that in wild-type mice of 2.79 ml/hr/kg.",Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16850270/),[ml] / [h·kg],2.79,229738,DB00028,Intravenous Immunoglobulin
,27424629,elimination half-life,The mean elimination half-life was 15 days.,"Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27424629/),d,15,229760,DB00028,Intravenous Immunoglobulin
,27424629,accumulation ratios,The average accumulation ratios of the area under the time-concentration curve and the maximum concentration after the fourth administration of SM03 were 2.0 and 1.5.,"Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27424629/),,2.0,229761,DB00028,Intravenous Immunoglobulin
,27424629,accumulation ratios,The average accumulation ratios of the area under the time-concentration curve and the maximum concentration after the fourth administration of SM03 were 2.0 and 1.5.,"Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27424629/),,1.5,229762,DB00028,Intravenous Immunoglobulin
,15550588,alpha half-life,The pharmacokinetic evaluation revealed a short alpha half-life of 13 min and linear kinetics on dose levels > or =1600 ng/kg.,Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550588/),min,13,230224,DB00028,Intravenous Immunoglobulin
,22540283,clearance of permeation,The kinetics of adalimumab permeation to the synovial fluid (0.00422 L/h clearance of permeation) versus the rate of TNFα turnover in the affected joints (1.84 pmol/h synthesis rate and 0.877 h(-1) degradation rate constant) are apparently the major parameters that determine the time course of TNFα concentrations in the synovial fluid and the TNFα-neutralizing effects of adalimumab in RA patients.,Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22540283/),[l] / [h],0.00422,230343,DB00028,Intravenous Immunoglobulin
,22540283,synthesis rate,The kinetics of adalimumab permeation to the synovial fluid (0.00422 L/h clearance of permeation) versus the rate of TNFα turnover in the affected joints (1.84 pmol/h synthesis rate and 0.877 h(-1) degradation rate constant) are apparently the major parameters that determine the time course of TNFα concentrations in the synovial fluid and the TNFα-neutralizing effects of adalimumab in RA patients.,Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22540283/),[pM] / [h],1.84,230344,DB00028,Intravenous Immunoglobulin
,22540283,degradation rate constant,The kinetics of adalimumab permeation to the synovial fluid (0.00422 L/h clearance of permeation) versus the rate of TNFα turnover in the affected joints (1.84 pmol/h synthesis rate and 0.877 h(-1) degradation rate constant) are apparently the major parameters that determine the time course of TNFα concentrations in the synovial fluid and the TNFα-neutralizing effects of adalimumab in RA patients.,Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22540283/),1/[h],0.877,230345,DB00028,Intravenous Immunoglobulin
,22955257,clearance,"In the final model, estimated values of clearance and volume of distribution of the central compartment were 0.00784 l/h and 3.00 l, respectively.","Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22955257/),[l] / [h],0.00784,230416,DB00028,Intravenous Immunoglobulin
,22955257,volume of distribution of the central compartment,"In the final model, estimated values of clearance and volume of distribution of the central compartment were 0.00784 l/h and 3.00 l, respectively.","Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22955257/),l,3.00,230417,DB00028,Intravenous Immunoglobulin
,20064211,half-life,The half-life of CAT-354 was 12-17 days and was dose-independent.,"A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20064211/),d,12-17,233786,DB00028,Intravenous Immunoglobulin
,20064211,Clearance,Clearance (2.2-2.6 mL/day/kg) and volume of distribution (44-57 mL/kg) were both low and dose-independent.,"A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20064211/),[ml] / [d·kg],2.2-2.6,233787,DB00028,Intravenous Immunoglobulin
,20064211,volume of distribution,Clearance (2.2-2.6 mL/day/kg) and volume of distribution (44-57 mL/kg) were both low and dose-independent.,"A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20064211/),[ml] / [kg],44-57,233788,DB00028,Intravenous Immunoglobulin
,20064211,accumulation ratio,"The observed maximum serum concentration after each dose increased slightly from dose 1 through dose 3 at all dose levels, consistent with an accumulation ratio of 1.4 to 1.7 for area under the curve.","A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20064211/),,1.4,233789,DB00028,Intravenous Immunoglobulin
,20064211,accumulation ratio,"The observed maximum serum concentration after each dose increased slightly from dose 1 through dose 3 at all dose levels, consistent with an accumulation ratio of 1.4 to 1.7 for area under the curve.","A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20064211/),,1,233790,DB00028,Intravenous Immunoglobulin
less,1655138,trough levels,Allogeneic recipients in the group with trough levels less than 1200 mg/dl required more platelet transfusions.,Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1655138/),[mg] / [dl],1200,235314,DB00028,Intravenous Immunoglobulin
less,1655138,trough levels,"Although there was no significant difference in fungal infection rates or bacteremia, sepsis was noted in only two recipients (one allogeneic, one autologous), both with serum IgG trough levels less than 1200 mg/dl.",Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1655138/),[mg] / [dl],1200,235315,DB00028,Intravenous Immunoglobulin
,26873229,Clearance (CL),"Clearance (CL) was 0.212 L/day and the central volume of distribution was 3.92 L, scaled by [body weight (kg)/68] with exponents of 0.87 and 1.12, respectively.",Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873229/),[l] / [d],0.212,235344,DB00028,Intravenous Immunoglobulin
,26873229,central volume of distribution,"Clearance (CL) was 0.212 L/day and the central volume of distribution was 3.92 L, scaled by [body weight (kg)/68] with exponents of 0.87 and 1.12, respectively.",Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873229/),l,3.92,235345,DB00028,Intravenous Immunoglobulin
,26873229,peripheral volume of distribution,The peripheral volume of distribution was 2.42 L.,Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873229/),l,2.42,235346,DB00028,Intravenous Immunoglobulin
,26873229,Absorption lag time,"Absorption lag time, mean absorption time, and absolute bioavailability (100-300 mg SC) were 1.61 h, 7.2 days, and 88 %, respectively.",Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873229/),h,1.61,235347,DB00028,Intravenous Immunoglobulin
,26873229,mean absorption time,"Absorption lag time, mean absorption time, and absolute bioavailability (100-300 mg SC) were 1.61 h, 7.2 days, and 88 %, respectively.",Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873229/),d,7.2,235348,DB00028,Intravenous Immunoglobulin
,26873229,absolute bioavailability,"Absorption lag time, mean absorption time, and absolute bioavailability (100-300 mg SC) were 1.61 h, 7.2 days, and 88 %, respectively.",Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873229/),%,88,235349,DB00028,Intravenous Immunoglobulin
,26873229,terminal half-life,The daclizumab HYP terminal half-life was 21 days.,Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26873229/),d,21,235350,DB00028,Intravenous Immunoglobulin
,19940229,maximum observed serum golimumab concentration (C(max)),"Following IV administration, the mean maximum observed serum golimumab concentration (C(max)) and the mean area under the concentration versus time curves from time zero to infinity (AUC(0-infinity)) were 29.5 +/- 5.8 microg/mL and 195.9 +/- 48.9 microg x d/mL, respectively.",Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940229/),[μg] / [ml],29.5,236451,DB00028,Intravenous Immunoglobulin
,19940229,area under the concentration versus time curves from time zero to infinity (AUC(0-infinity)),"Following IV administration, the mean maximum observed serum golimumab concentration (C(max)) and the mean area under the concentration versus time curves from time zero to infinity (AUC(0-infinity)) were 29.5 +/- 5.8 microg/mL and 195.9 +/- 48.9 microg x d/mL, respectively.",Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940229/),[d·μg] / [ml],195.9,236452,DB00028,Intravenous Immunoglobulin
,19940229,C(max),"After SC administration, the mean values of C(max) and AUC(0-infinity) were 6.3 +/- 2.8 microg/mL and 100.1 +/- 29.2 microg x d/mL, respectively.",Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940229/),[μg] / [ml],6.3,236453,DB00028,Intravenous Immunoglobulin
,19940229,AUC(0-infinity),"After SC administration, the mean values of C(max) and AUC(0-infinity) were 6.3 +/- 2.8 microg/mL and 100.1 +/- 29.2 microg x d/mL, respectively.",Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940229/),[d·μg] / [ml],100.1,236454,DB00028,Intravenous Immunoglobulin
,19940229,terminal half-life,"The median terminal half-life was similar for SC and IV administration (10.9 and 11.8 days, respectively).",Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940229/),d,10.9,236455,DB00028,Intravenous Immunoglobulin
,19940229,terminal half-life,"The median terminal half-life was similar for SC and IV administration (10.9 and 11.8 days, respectively).",Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940229/),d,11.8,236456,DB00028,Intravenous Immunoglobulin
,17636457,clearance,"These data showed that high dose intravenous immunoglobulin (IVIG), 1g/kg, increased 7E3 clearance in control mice from 5.2 +/- 0.3 to 14.4 +/- 1.4 ml/d/kg; however, IVIG failed to increase the clearance of 7E3 in KO mice (72.5 +/- 4.0 vs. 61.0 +/- 3.6 ml/d/kg).",Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17636457/),[ml] / [d·kg],5.2,239528,DB00028,Intravenous Immunoglobulin
,17636457,clearance,"These data showed that high dose intravenous immunoglobulin (IVIG), 1g/kg, increased 7E3 clearance in control mice from 5.2 +/- 0.3 to 14.4 +/- 1.4 ml/d/kg; however, IVIG failed to increase the clearance of 7E3 in KO mice (72.5 +/- 4.0 vs. 61.0 +/- 3.6 ml/d/kg).",Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17636457/),[ml] / [d·kg],14.4,239529,DB00028,Intravenous Immunoglobulin
,17636457,clearance,"These data showed that high dose intravenous immunoglobulin (IVIG), 1g/kg, increased 7E3 clearance in control mice from 5.2 +/- 0.3 to 14.4 +/- 1.4 ml/d/kg; however, IVIG failed to increase the clearance of 7E3 in KO mice (72.5 +/- 4.0 vs. 61.0 +/- 3.6 ml/d/kg).",Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17636457/),[ml] / [d·kg],72.5,239530,DB00028,Intravenous Immunoglobulin
,17636457,clearance,"These data showed that high dose intravenous immunoglobulin (IVIG), 1g/kg, increased 7E3 clearance in control mice from 5.2 +/- 0.3 to 14.4 +/- 1.4 ml/d/kg; however, IVIG failed to increase the clearance of 7E3 in KO mice (72.5 +/- 4.0 vs. 61.0 +/- 3.6 ml/d/kg).",Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17636457/),[ml] / [d·kg],61.0,239531,DB00028,Intravenous Immunoglobulin
,17636457,AUC ratios,"The model accurately predicted 7E3 tissue concentrations, with mean predicted vs. observed AUC ratios of 1.04 +/- 0.2 and 0.86 +/- 0.3 in control and FcRn-KO mice.",Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17636457/),,1.04,239532,DB00028,Intravenous Immunoglobulin
,17636457,AUC ratios,"The model accurately predicted 7E3 tissue concentrations, with mean predicted vs. observed AUC ratios of 1.04 +/- 0.2 and 0.86 +/- 0.3 in control and FcRn-KO mice.",Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17636457/),,0.86,239533,DB00028,Intravenous Immunoglobulin
,3706572,cerebrovascular permeability-surface area (PA;,"The mean cerebrovascular permeability-surface area (PA; permeability X capillary surface area) to immunoglobulin M (IgM) MAb (mol wt 1,000,000) 10 min after infusion was 0.40 X 10(-6) S-1.",Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706572/),1/[s],0.40 X 10(-6),239685,DB00028,Intravenous Immunoglobulin
,3706572,permeability X capillary surface area,"The mean cerebrovascular permeability-surface area (PA; permeability X capillary surface area) to immunoglobulin M (IgM) MAb (mol wt 1,000,000) 10 min after infusion was 0.40 X 10(-6) S-1.",Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706572/),1/[s],0.40 X 10(-6),239686,DB00028,Intravenous Immunoglobulin
,3706572,PA,"When osmotic blood-brain barrier (BBB) disruption is utilized, the PA increased to 8.36 X 10(-6) S-1.",Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706572/),1/[s],8.36 X 10(-6),239687,DB00028,Intravenous Immunoglobulin
,3706572,maximum concentration,After BBB opening and intracarotid MAb the maximum concentration in brain at 1 h was 0.72% per gram of the total administered dose.,Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706572/),[%] / [gram],0.72,239688,DB00028,Intravenous Immunoglobulin
,26230385,bioavailability,"Although lymphoid tissue was expected to accumulate drug due to the high levels of CCL21 present, bioavailability following subcutaneous administration in monkeys was 52%.","Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26230385/),%,52,240869,DB00028,Intravenous Immunoglobulin
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],622,241008,DB00028,Intravenous Immunoglobulin
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],3428,241009,DB00028,Intravenous Immunoglobulin
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],8416,241010,DB00028,Intravenous Immunoglobulin
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],"10,347",241011,DB00028,Intravenous Immunoglobulin
,13679816,serum half-life,The serum half-life of the IDEC-152 antibody increased from 2 to 10 days with increasing doses.,"Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13679816/),d,2,242736,DB00028,Intravenous Immunoglobulin
,13679816,serum half-life,The serum half-life of the IDEC-152 antibody increased from 2 to 10 days with increasing doses.,"Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13679816/),d,10,242737,DB00028,Intravenous Immunoglobulin
,23979731,elimination half-life,"The elimination half-life of AIGIV in rabbits, nonhuman primates (NHPs), and humans following intravenous infusion was estimated to be approximately 4, 12, and 24 days, respectively, and dose proportionality was observed.",Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23979731/),d,4,243379,DB00028,Intravenous Immunoglobulin
,23979731,elimination half-life,"The elimination half-life of AIGIV in rabbits, nonhuman primates (NHPs), and humans following intravenous infusion was estimated to be approximately 4, 12, and 24 days, respectively, and dose proportionality was observed.",Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23979731/),d,12,243380,DB00028,Intravenous Immunoglobulin
,23979731,elimination half-life,"The elimination half-life of AIGIV in rabbits, nonhuman primates (NHPs), and humans following intravenous infusion was estimated to be approximately 4, 12, and 24 days, respectively, and dose proportionality was observed.",Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23979731/),d,24,243381,DB00028,Intravenous Immunoglobulin
,12670369,half-lives (t1/2),"IGIV-C, 10% was bioequivalent to IGIV-SD, 10%, with half-lives (t1/2) of 35 and 34 days, respectively.","Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670369/),d,35,244321,DB00028,Intravenous Immunoglobulin
,12670369,half-lives (t1/2),"IGIV-C, 10% was bioequivalent to IGIV-SD, 10%, with half-lives (t1/2) of 35 and 34 days, respectively.","Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670369/),d,34,244322,DB00028,Intravenous Immunoglobulin
,12670369,t1/2,"IGIV-C, 5%, was bioequivalent to IGIV-C, 10%, with t1/2 of 35 and 36 days, respectively.","Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670369/),d,35,244323,DB00028,Intravenous Immunoglobulin
,12670369,t1/2,"IGIV-C, 5%, was bioequivalent to IGIV-C, 10%, with t1/2 of 35 and 36 days, respectively.","Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670369/),d,36,244324,DB00028,Intravenous Immunoglobulin
,15552588,clearance,Preliminary pharmacokinetic investigations of AMI allowed estimation of AMI clearance to be 0.017 mL kg(-1) min(-1) in the rat and 0.043 mL kg(-1) min(-1) in the mouse.,Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552588/),[ml] / [kg·min],0.017,244425,DB00028,Intravenous Immunoglobulin
,15552588,clearance,Preliminary pharmacokinetic investigations of AMI allowed estimation of AMI clearance to be 0.017 mL kg(-1) min(-1) in the rat and 0.043 mL kg(-1) min(-1) in the mouse.,Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552588/),[ml] / [kg·min],0.043,244426,DB00028,Intravenous Immunoglobulin
,15552588,clearance,"AMF clearance was estimated to be 0.038 and 1.93 mL kg(-1) min(-1) in the mouse and rat, respectively.",Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552588/),[ml] / [kg·min],0.038,244427,DB00028,Intravenous Immunoglobulin
,15552588,clearance,"AMF clearance was estimated to be 0.038 and 1.93 mL kg(-1) min(-1) in the mouse and rat, respectively.",Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552588/),[ml] / [kg·min],1.93,244428,DB00028,Intravenous Immunoglobulin
,23370434,areas under the concentration vs. time curves (AUC0-10 days),"Plasma areas under the concentration vs. time curves (AUC0-10 days) ±SD for MWReg30 were: 5.24±0.68, 5.51±0.24, and 5.39±1.05 nM×d at 0.04mg/kg, and 12.7±0.5, 13.6±1.1, and 14.5±2.0nM×d at 0.1mg/kg in control, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370434/),d·nM,5.24,246614,DB00028,Intravenous Immunoglobulin
,23370434,areas under the concentration vs. time curves (AUC0-10 days),"Plasma areas under the concentration vs. time curves (AUC0-10 days) ±SD for MWReg30 were: 5.24±0.68, 5.51±0.24, and 5.39±1.05 nM×d at 0.04mg/kg, and 12.7±0.5, 13.6±1.1, and 14.5±2.0nM×d at 0.1mg/kg in control, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370434/),d·nM,5.51,246615,DB00028,Intravenous Immunoglobulin
,23370434,areas under the concentration vs. time curves (AUC0-10 days),"Plasma areas under the concentration vs. time curves (AUC0-10 days) ±SD for MWReg30 were: 5.24±0.68, 5.51±0.24, and 5.39±1.05 nM×d at 0.04mg/kg, and 12.7±0.5, 13.6±1.1, and 14.5±2.0nM×d at 0.1mg/kg in control, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370434/),d·nM,5.39,246616,DB00028,Intravenous Immunoglobulin
,23370434,areas under the concentration vs. time curves (AUC0-10 days),"Plasma areas under the concentration vs. time curves (AUC0-10 days) ±SD for MWReg30 were: 5.24±0.68, 5.51±0.24, and 5.39±1.05 nM×d at 0.04mg/kg, and 12.7±0.5, 13.6±1.1, and 14.5±2.0nM×d at 0.1mg/kg in control, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370434/),d·nM,12.7,246617,DB00028,Intravenous Immunoglobulin
,23370434,areas under the concentration vs. time curves (AUC0-10 days),"Plasma areas under the concentration vs. time curves (AUC0-10 days) ±SD for MWReg30 were: 5.24±0.68, 5.51±0.24, and 5.39±1.05 nM×d at 0.04mg/kg, and 12.7±0.5, 13.6±1.1, and 14.5±2.0nM×d at 0.1mg/kg in control, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370434/),d·nM,13.6,246618,DB00028,Intravenous Immunoglobulin
,23370434,areas under the concentration vs. time curves (AUC0-10 days),"Plasma areas under the concentration vs. time curves (AUC0-10 days) ±SD for MWReg30 were: 5.24±0.68, 5.51±0.24, and 5.39±1.05 nM×d at 0.04mg/kg, and 12.7±0.5, 13.6±1.1, and 14.5±2.0nM×d at 0.1mg/kg in control, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice.","Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370434/),d·nM,14.5,246619,DB00028,Intravenous Immunoglobulin
,22203367,nonspecific clearance,The nonspecific clearance in monkey was estimated to be 14 mL/day/kg.,"Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203367/),[ml] / [d·kg],14,246644,DB00028,Intravenous Immunoglobulin
,22203367,nonspecific clearance,The predicted nonspecific clearance range in humans was 6-10 mL/day/kg.,"Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203367/),[ml] / [d·kg],6-10,246645,DB00028,Intravenous Immunoglobulin
,19828386,half-life,Pharmacokinetic analysis showed a half-life of 27 days and extensive exposure to the study drug.,"Efficacy, safety, and pharmacokinetics of intramuscular hepatitis B immune globulin, Igantibe, for the prophylaxis of viral B hepatitis after liver transplantation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19828386/),d,27,246921,DB00028,Intravenous Immunoglobulin
,20849955,time to peak plasma [F(ab')(2)],"The time to peak plasma [F(ab')(2)] was 45 (33, 74) h.",Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849955/),h,45,247864,DB00028,Intravenous Immunoglobulin
,20849955,"AUC(im,∞)","The most significant antivenom pharmacokinetic parameters determined were: AUC(im,∞)=803 (605, 1463) mg·h·L(-1); V(c)=8.8 (2.8, 23.6) L; V(ss,im)=55 (47, 64) L; MRT(im)=776(326, 1335) h; CL(t)=3.7 (0.6, 1.9) mL·min(-1); f(im,)V(ss)=0.300 (0.153, 0.466).",Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849955/),[h·mg] / [l],803,247865,DB00028,Intravenous Immunoglobulin
,20849955,V(c),"The most significant antivenom pharmacokinetic parameters determined were: AUC(im,∞)=803 (605, 1463) mg·h·L(-1); V(c)=8.8 (2.8, 23.6) L; V(ss,im)=55 (47, 64) L; MRT(im)=776(326, 1335) h; CL(t)=3.7 (0.6, 1.9) mL·min(-1); f(im,)V(ss)=0.300 (0.153, 0.466).",Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849955/),l,8.8,247866,DB00028,Intravenous Immunoglobulin
,20849955,"V(ss,im)","The most significant antivenom pharmacokinetic parameters determined were: AUC(im,∞)=803 (605, 1463) mg·h·L(-1); V(c)=8.8 (2.8, 23.6) L; V(ss,im)=55 (47, 64) L; MRT(im)=776(326, 1335) h; CL(t)=3.7 (0.6, 1.9) mL·min(-1); f(im,)V(ss)=0.300 (0.153, 0.466).",Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849955/),l,55,247867,DB00028,Intravenous Immunoglobulin
,20849955,MRT(im),"The most significant antivenom pharmacokinetic parameters determined were: AUC(im,∞)=803 (605, 1463) mg·h·L(-1); V(c)=8.8 (2.8, 23.6) L; V(ss,im)=55 (47, 64) L; MRT(im)=776(326, 1335) h; CL(t)=3.7 (0.6, 1.9) mL·min(-1); f(im,)V(ss)=0.300 (0.153, 0.466).",Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849955/),h,776,247868,DB00028,Intravenous Immunoglobulin
,20849955,CL(t),"The most significant antivenom pharmacokinetic parameters determined were: AUC(im,∞)=803 (605, 1463) mg·h·L(-1); V(c)=8.8 (2.8, 23.6) L; V(ss,im)=55 (47, 64) L; MRT(im)=776(326, 1335) h; CL(t)=3.7 (0.6, 1.9) mL·min(-1); f(im,)V(ss)=0.300 (0.153, 0.466).",Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849955/),[ml] / [min],3.7,247869,DB00028,Intravenous Immunoglobulin
,20849955,"f(im,)V(ss)","The most significant antivenom pharmacokinetic parameters determined were: AUC(im,∞)=803 (605, 1463) mg·h·L(-1); V(c)=8.8 (2.8, 23.6) L; V(ss,im)=55 (47, 64) L; MRT(im)=776(326, 1335) h; CL(t)=3.7 (0.6, 1.9) mL·min(-1); f(im,)V(ss)=0.300 (0.153, 0.466).",Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20849955/),,0.300,247870,DB00028,Intravenous Immunoglobulin
,17893153,time to the resolution of fever,"Compared to the control patients, the Altastaph recipients had a shorter median time to the resolution of fever (2 days and 7 days, respectively; P = 0.09) and a shorter length of hospital stay (9 days and 14 days, respectively; P = 0.03).","Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17893153/),d,2,248641,DB00028,Intravenous Immunoglobulin
,17893153,time to the resolution of fever,"Compared to the control patients, the Altastaph recipients had a shorter median time to the resolution of fever (2 days and 7 days, respectively; P = 0.09) and a shorter length of hospital stay (9 days and 14 days, respectively; P = 0.03).","Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17893153/),d,7,248642,DB00028,Intravenous Immunoglobulin
,17893153,length of hospital stay,"Compared to the control patients, the Altastaph recipients had a shorter median time to the resolution of fever (2 days and 7 days, respectively; P = 0.09) and a shorter length of hospital stay (9 days and 14 days, respectively; P = 0.03).","Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17893153/),d,9,248643,DB00028,Intravenous Immunoglobulin
,17893153,length of hospital stay,"Compared to the control patients, the Altastaph recipients had a shorter median time to the resolution of fever (2 days and 7 days, respectively; P = 0.09) and a shorter length of hospital stay (9 days and 14 days, respectively; P = 0.03).","Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17893153/),d,14,248644,DB00028,Intravenous Immunoglobulin
,9435168,rate of CSF bulk flow,"We found that an IgM mAb was cleared from rat CSF at the rate of CSF bulk flow (0.0041 ml/min), but an IgG mAb was cleared at a faster rate (0.011 ml/min).",Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435168/),[ml] / [min],0.0041,249742,DB00028,Intravenous Immunoglobulin
,23425116,bioavailability,AMG 181 had an s.c. bioavailability of 80%.,"Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23425116/),%,80,250392,DB00028,Intravenous Immunoglobulin
,23425116,linear elimination half-life,"The linear elimination half-life was 12 days, with a volume of distribution close to the intravascular plasma space.","Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23425116/),d,12,250393,DB00028,Intravenous Immunoglobulin
,4043204,plasma turnover,"Furthermore, as plasma survival studies of 125I-labeled pIgA yielded a plasma turnover of pIgA averaging 20.6 mg/kg/day, it can be approximated that the hepatobiliary pathway contributes for only 38% to the elimination of intravascular pIgA from mouse plasma, a figure to be compared to 89.8% in the rat and approximately 8.9% in man.",Hepatobiliary transport of plasma IgA in the mouse: contribution to clearance of intravascular IgA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043204/),[mg] / [d·kg],20.6,250394,DB00028,Intravenous Immunoglobulin
,11408538,apparent affinity (K(A)),"The apparent affinity (K(A)) of 7E3-rat platelet binding was 1.2 +/- 0.2 x 10(7) M(-1), with 3.3 +/- 0.3 x 10(4) binding sites per platelet.","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),1/[M],1.2,250803,DB00028,Intravenous Immunoglobulin
,11408538,apparent affinity (K(A)),"The apparent affinity (K(A)) of 7E3-rat platelet binding was 1.2 +/- 0.2 x 10(7) M(-1), with 3.3 +/- 0.3 x 10(4) binding sites per platelet.","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),,3.3,250804,DB00028,Intravenous Immunoglobulin
,11408538,terminal half-life,"Following intravenous 7E3 administration (0.8, 4, and 8 mg/kg), plasma concentrations declined in a bi-exponential manner, with a terminal half-life of 61 +/- 5 h and a steady-state volume of distribution of 62 +/- 15 ml/kg.","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),h,61,250805,DB00028,Intravenous Immunoglobulin
,11408538,steady-state volume of distribution,"Following intravenous 7E3 administration (0.8, 4, and 8 mg/kg), plasma concentrations declined in a bi-exponential manner, with a terminal half-life of 61 +/- 5 h and a steady-state volume of distribution of 62 +/- 15 ml/kg.","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),[ml] / [kg],62,250806,DB00028,Intravenous Immunoglobulin
,11408538,Clearance,"Clearance was dose-dependent, with values ranging from 0.64 +/- 0.08 ml/h/kg (8 mg/kg) to 1.01 +/- 0.08 ml/h/kg (0.8 mg/kg).","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),[ml] / [h·kg],0.64,250807,DB00028,Intravenous Immunoglobulin
,11408538,Clearance,"Clearance was dose-dependent, with values ranging from 0.64 +/- 0.08 ml/h/kg (8 mg/kg) to 1.01 +/- 0.08 ml/h/kg (0.8 mg/kg).","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),[ml] / [h·kg],1.01,250808,DB00028,Intravenous Immunoglobulin
,11408538,Nadir,"Nadir platelet counts were 79 +/- 33, 25 +/- 6, and 17 +/- 2 x 10(6)/ml, for 7E3 doses of 0.8, 4, and 8 mg/kg, respectively.","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),1/[ml],79,250809,DB00028,Intravenous Immunoglobulin
,11408538,platelet counts,"Nadir platelet counts were 79 +/- 33, 25 +/- 6, and 17 +/- 2 x 10(6)/ml, for 7E3 doses of 0.8, 4, and 8 mg/kg, respectively.","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),1/[ml],79,250810,DB00028,Intravenous Immunoglobulin
,11408538,platelet counts,"Nadir platelet counts were 79 +/- 33, 25 +/- 6, and 17 +/- 2 x 10(6)/ml, for 7E3 doses of 0.8, 4, and 8 mg/kg, respectively.","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),1/[ml],25,250811,DB00028,Intravenous Immunoglobulin
,11408538,platelet counts,"Nadir platelet counts were 79 +/- 33, 25 +/- 6, and 17 +/- 2 x 10(6)/ml, for 7E3 doses of 0.8, 4, and 8 mg/kg, respectively.","Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),1/[ml],17,250812,DB00028,Intravenous Immunoglobulin
,11408538,Bleeding times,Bleeding times after a 10-mm tail incision ranged from 5 +/- 3 min in control animals to 15 +/- 0 min (the maximum allowed time in this study) in animals receiving 8 mg/kg.,"Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),min,5,250813,DB00028,Intravenous Immunoglobulin
,11408538,Bleeding times,Bleeding times after a 10-mm tail incision ranged from 5 +/- 3 min in control animals to 15 +/- 0 min (the maximum allowed time in this study) in animals receiving 8 mg/kg.,"Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),min,15,250814,DB00028,Intravenous Immunoglobulin
,11408538,maximum allowed time,Bleeding times after a 10-mm tail incision ranged from 5 +/- 3 min in control animals to 15 +/- 0 min (the maximum allowed time in this study) in animals receiving 8 mg/kg.,"Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),min,15,250815,DB00028,Intravenous Immunoglobulin
,11408538,Blood volumes lost,Blood volumes lost during bleeding experiments ranged from 30 +/- 24 microl (control) to 349 +/- 358 microl (8 mg/kg).,"Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),μl,30,250816,DB00028,Intravenous Immunoglobulin
,11408538,Blood volumes lost,Blood volumes lost during bleeding experiments ranged from 30 +/- 24 microl (control) to 349 +/- 358 microl (8 mg/kg).,"Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408538/),μl,349,250817,DB00028,Intravenous Immunoglobulin
,9572296,Ka,"One was a murine monoclonal IgG1 (Ka = 3.8 x 10(7) M(-1)) at an IgG/IMI molar ratio of 1,000 (IgG1,000), and the other was a sheep polyclonal IgG (TAb; Ka = 1.3 x 10(10) M(-1)) at IgG/IMI molar ratios of 1, 10, and 100 (TAb1, TAb10, and TAb100).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),1/[M],3.8 x 10(7),252008,DB00028,Intravenous Immunoglobulin
,9572296,Ka,"One was a murine monoclonal IgG1 (Ka = 3.8 x 10(7) M(-1)) at an IgG/IMI molar ratio of 1,000 (IgG1,000), and the other was a sheep polyclonal IgG (TAb; Ka = 1.3 x 10(10) M(-1)) at IgG/IMI molar ratios of 1, 10, and 100 (TAb1, TAb10, and TAb100).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),1/[M],1.3 x 10(10),252009,DB00028,Intravenous Immunoglobulin
,9572296,Cmax,"In the control rats, IMI was rapidly taken up by the brain (Cmax at 5 min) with no significant differences among the brain regions (4.1 +/- 0.4 to 5.4 +/- 0.6 pmol/ g), and brain IMI then declined monoexponentially with a half-life of 44.2 min (cerebellum) to 77.3 min (hippocampus).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),,4,252010,DB00028,Intravenous Immunoglobulin
,9572296,half-life,"In the control rats, IMI was rapidly taken up by the brain (Cmax at 5 min) with no significant differences among the brain regions (4.1 +/- 0.4 to 5.4 +/- 0.6 pmol/ g), and brain IMI then declined monoexponentially with a half-life of 44.2 min (cerebellum) to 77.3 min (hippocampus).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),min,44.2,252011,DB00028,Intravenous Immunoglobulin
,9572296,half-life,"In the control rats, IMI was rapidly taken up by the brain (Cmax at 5 min) with no significant differences among the brain regions (4.1 +/- 0.4 to 5.4 +/- 0.6 pmol/ g), and brain IMI then declined monoexponentially with a half-life of 44.2 min (cerebellum) to 77.3 min (hippocampus).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),min,77.3,252012,DB00028,Intravenous Immunoglobulin
,9572296,fraction,"The fraction of IMI removed from the brain was 58-74%, and the redistribution half-life was 7.9-15.6 min; the mean residence time was reduced by 66-75% (11.8-23.9 min).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),%,58-74,252013,DB00028,Intravenous Immunoglobulin
,9572296,redistribution half-life,"The fraction of IMI removed from the brain was 58-74%, and the redistribution half-life was 7.9-15.6 min; the mean residence time was reduced by 66-75% (11.8-23.9 min).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),min,7.9-15.6,252014,DB00028,Intravenous Immunoglobulin
,12529736,clearance,"IVIG increased the clearance of 7E3 in mice with functioning FcRn receptors, with an average clearance value of 14.4 +/- 1.4 ml/d/kg in IVIG treated mice vs. 5.2 +/- 0.3 ml/d/kg in controls (P <0.001).",Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12529736/),[ml] / [d·kg],14.4,252990,DB00028,Intravenous Immunoglobulin
,12529736,clearance,"IVIG increased the clearance of 7E3 in mice with functioning FcRn receptors, with an average clearance value of 14.4 +/- 1.4 ml/d/kg in IVIG treated mice vs. 5.2 +/- 0.3 ml/d/kg in controls (P <0.001).",Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12529736/),[ml] / [d·kg],5.2,252991,DB00028,Intravenous Immunoglobulin
,12529736,clearance,"In mice lacking expression of FcRn, IVIG treatment did not increase 7E3 clearance (61.0 +/- 3.6 ml/d/kg vs. 71.5 +/- 4.0 ml/d/kg in controls).",Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12529736/),[ml] / [d·kg],61.0,252992,DB00028,Intravenous Immunoglobulin
,12529736,clearance,"In mice lacking expression of FcRn, IVIG treatment did not increase 7E3 clearance (61.0 +/- 3.6 ml/d/kg vs. 71.5 +/- 4.0 ml/d/kg in controls).",Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12529736/),[ml] / [d·kg],71.5,252993,DB00028,Intravenous Immunoglobulin
,29522908,maximum concentration,The maximum concentration of total IgG (mean ± SD) was 21.82 ± 5.83 g/L in patients treated 3-weekly and 17.42 ± 3.34 g/L in patients treated 4-weekly.,"Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522908/),[g] / [l],21.82,253943,DB00028,Intravenous Immunoglobulin
,29522908,maximum concentration,The maximum concentration of total IgG (mean ± SD) was 21.82 ± 5.83 g/L in patients treated 3-weekly and 17.42 ± 3.34 g/L in patients treated 4-weekly.,"Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522908/),[g] / [l],17.42,253944,DB00028,Intravenous Immunoglobulin
,29522908,trough IgG concentrations,"Median trough IgG concentrations were nearly constant over the course of the study, remaining between 11.0 and 12.2 g/L for patients on the 3-week schedule and between 8.10 and 8.65 g/L for patients on the 4-week schedule.","Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522908/),[g] / [l],11.0 and 12.2,253945,DB00028,Intravenous Immunoglobulin
,29522908,trough IgG concentrations,"Median trough IgG concentrations were nearly constant over the course of the study, remaining between 11.0 and 12.2 g/L for patients on the 3-week schedule and between 8.10 and 8.65 g/L for patients on the 4-week schedule.","Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522908/),[g] / [l],8.10 and 8.65,253946,DB00028,Intravenous Immunoglobulin
,29522908,terminal half-life,"The median terminal half-life of total IgG was 36.1 (range 18.5-65.9) days, with generally similar values for the IgG subclasses (26.7-38.0 days).","Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522908/),d,36.1,253947,DB00028,Intravenous Immunoglobulin
,29522908,terminal half-life,"The median terminal half-life of total IgG was 36.1 (range 18.5-65.9) days, with generally similar values for the IgG subclasses (26.7-38.0 days).","Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522908/),d,26.7-38.0,253948,DB00028,Intravenous Immunoglobulin
,29522908,half-lives,"Median half-lives for specific antibodies ranged between 21.3 and 51.2 days for anti-cytomegalovirus, anti-Haemophilus influenzae, anti-measles, anti-tetanus toxoid, anti-varicella zoster virus antibodies, and anti-Streptococcus pneumoniae subtype antibodies.","Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522908/),d,21.3 and 51.2,253949,DB00028,Intravenous Immunoglobulin
≥,21553933,serum trough concentration (C(trough)),Eligible patients were males or females aged 6-75 years with a primary immunodeficiency (common variable immunodeficiency or X-linked agammaglobulinaemia) who had received regular treatment with IgPro10 for at least 3 months prior to entering this study and had achieved serum trough concentration (C(trough)) values ≥5 g/L.,Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21553933/),[g] / [l],5,256316,DB00028,Intravenous Immunoglobulin
,21553933,AUCs,The resulting mean AUCs were 105.6 g · day/L for IgPro20 versus 103.2 g · day/L for IgPro10 (geometric mean ratio 1.002; lower one-sided 95% confidence limit [CL] 0.951).,Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21553933/),[d·g] / [l],105.6,256317,DB00028,Intravenous Immunoglobulin
,21553933,AUCs,The resulting mean AUCs were 105.6 g · day/L for IgPro20 versus 103.2 g · day/L for IgPro10 (geometric mean ratio 1.002; lower one-sided 95% confidence limit [CL] 0.951).,Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21553933/),[d·g] / [l],103.2,256318,DB00028,Intravenous Immunoglobulin
,21553933,AU,"At these AUCs, which were considered equivalent, the mean IgPro20 : IgPro10 TLR, determined by the developed algorithm, was 1.29 (range 1.18-1.73).",Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21553933/),,1.29,256319,DB00028,Intravenous Immunoglobulin
,21553933,TLR,"At these AUCs, which were considered equivalent, the mean IgPro20 : IgPro10 TLR, determined by the developed algorithm, was 1.29 (range 1.18-1.73).",Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21553933/),,1.29,256320,DB00028,Intravenous Immunoglobulin
,2480576,elimination half-life,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),d,19.6,256630,DB00028,Intravenous Immunoglobulin
,2480576,elimination half-life,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),d,28.7,256631,DB00028,Intravenous Immunoglobulin
,2480576,elimination half-life,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),d,22.1,256632,DB00028,Intravenous Immunoglobulin
,2480576,clearance,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[ml] / [d·kg],5.2,256633,DB00028,Intravenous Immunoglobulin
,2480576,clearance,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[ml] / [d·kg],5.6,256634,DB00028,Intravenous Immunoglobulin
,2480576,clearance,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[ml] / [d·kg],3.7,256635,DB00028,Intravenous Immunoglobulin
,2480576,volume of distribution,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[ml] / [kg],151,256636,DB00028,Intravenous Immunoglobulin
,2480576,volume of distribution,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[ml] / [kg],255,256637,DB00028,Intravenous Immunoglobulin
,2480576,volume of distribution,"Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[ml] / [kg],130,256638,DB00028,Intravenous Immunoglobulin
,2480576,peak IgG concentrations,"Mean peak IgG concentrations in serum were 1826, 1476 and 1257 mg/dl for the large, intermediate and small dose groups, respectively.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[mg] / [dl],1826,256639,DB00028,Intravenous Immunoglobulin
,2480576,peak IgG concentrations,"Mean peak IgG concentrations in serum were 1826, 1476 and 1257 mg/dl for the large, intermediate and small dose groups, respectively.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[mg] / [dl],1476,256640,DB00028,Intravenous Immunoglobulin
,2480576,peak IgG concentrations,"Mean peak IgG concentrations in serum were 1826, 1476 and 1257 mg/dl for the large, intermediate and small dose groups, respectively.",Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2480576/),[mg] / [dl],1257,256641,DB00028,Intravenous Immunoglobulin
,2503283,clearance (antigen),"Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes.",Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503283/),[ml] / [min],620,257366,DB00028,Intravenous Immunoglobulin
,2503283,volume of distribution at steady state,"Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes.",Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503283/),l,8.1,257367,DB00028,Intravenous Immunoglobulin
,2503283,initial volume of distribution,"Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes.",Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503283/),l,4.4,257368,DB00028,Intravenous Immunoglobulin
,2503283,dominant half-life,"Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes.",Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503283/),min,4.4,257369,DB00028,Intravenous Immunoglobulin
,16052545,terminal half-life,"The mean terminal half-life of AMF was found to be 10.9 +/- 3.3 h and was not dose-dependent, and s.c. bioavailability was 28% +/- 7% at 2.2 g/kg.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),h,10.9,258074,DB00028,Intravenous Immunoglobulin
,16052545,bioavailability,"The mean terminal half-life of AMF was found to be 10.9 +/- 3.3 h and was not dose-dependent, and s.c. bioavailability was 28% +/- 7% at 2.2 g/kg.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),%,28,258075,DB00028,Intravenous Immunoglobulin
,16052545,survival times,"Median survival times for saline-treated control animals and animals receiving i.p. MTX (1.9, 2.8, 3.8 mg/kg) were 9, 12, 10, and 7 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,9,258076,DB00028,Intravenous Immunoglobulin
,16052545,survival times,"Median survival times for saline-treated control animals and animals receiving i.p. MTX (1.9, 2.8, 3.8 mg/kg) were 9, 12, 10, and 7 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,12,258077,DB00028,Intravenous Immunoglobulin
,16052545,survival times,"Median survival times for saline-treated control animals and animals receiving i.p. MTX (1.9, 2.8, 3.8 mg/kg) were 9, 12, 10, and 7 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,10,258078,DB00028,Intravenous Immunoglobulin
,16052545,survival times,"Median survival times for saline-treated control animals and animals receiving i.p. MTX (1.9, 2.8, 3.8 mg/kg) were 9, 12, 10, and 7 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,7,258079,DB00028,Intravenous Immunoglobulin
,16052545,survival time,"AMF, median survival time increased to 17 and 14 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,17,258080,DB00028,Intravenous Immunoglobulin
,16052545,survival time,"AMF, median survival time increased to 17 and 14 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,14,258081,DB00028,Intravenous Immunoglobulin
,8196081,Total plasma clearance,Total plasma clearance of E09 ranged from 3.2 to 24 L/min.,Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196081/),[l] / [min],3.2 to 24,260956,DB00028,Intravenous Immunoglobulin
,8196081,MTD,The MTD of E09 was determined to be 27 mg/m2.,Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196081/),[mg] / [m2],27,260957,DB00028,Intravenous Immunoglobulin
,16189088,steady-state levels,"Following administration of the 500- and 750-mg/kg doses, the estimated average steady-state levels of anti-ClfA were 6.1 U/ml and 9.2 U/ml, respectively, and those of anti-SdrG were 5.2 U/ml and 7.7 U/ml, respectively.","Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189088/),[u] / [ml],6.1,261470,DB00028,Intravenous Immunoglobulin
,16189088,steady-state levels,"Following administration of the 500- and 750-mg/kg doses, the estimated average steady-state levels of anti-ClfA were 6.1 U/ml and 9.2 U/ml, respectively, and those of anti-SdrG were 5.2 U/ml and 7.7 U/ml, respectively.","Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189088/),[u] / [ml],9.2,261471,DB00028,Intravenous Immunoglobulin
,16189088,steady-state levels,"Following administration of the 500- and 750-mg/kg doses, the estimated average steady-state levels of anti-ClfA were 6.1 U/ml and 9.2 U/ml, respectively, and those of anti-SdrG were 5.2 U/ml and 7.7 U/ml, respectively.","Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189088/),[u] / [ml],5.2,261472,DB00028,Intravenous Immunoglobulin
,16189088,steady-state levels,"Following administration of the 500- and 750-mg/kg doses, the estimated average steady-state levels of anti-ClfA were 6.1 U/ml and 9.2 U/ml, respectively, and those of anti-SdrG were 5.2 U/ml and 7.7 U/ml, respectively.","Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189088/),[u] / [ml],7.7,261473,DB00028,Intravenous Immunoglobulin
,16189088,elimination half-lives,"The elimination half-lives for anti-ClfA and anti-SdrG were 719 h and 701 h, respectively, and the clearances were 0.18 ml/h and 0.21 ml/h, respectively.","Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189088/),h,719,261474,DB00028,Intravenous Immunoglobulin
,16189088,elimination half-lives,"The elimination half-lives for anti-ClfA and anti-SdrG were 719 h and 701 h, respectively, and the clearances were 0.18 ml/h and 0.21 ml/h, respectively.","Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189088/),h,701,261475,DB00028,Intravenous Immunoglobulin
,16189088,clearances,"The elimination half-lives for anti-ClfA and anti-SdrG were 719 h and 701 h, respectively, and the clearances were 0.18 ml/h and 0.21 ml/h, respectively.","Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189088/),[ml] / [h],0.18,261476,DB00028,Intravenous Immunoglobulin
,16189088,clearances,"The elimination half-lives for anti-ClfA and anti-SdrG were 719 h and 701 h, respectively, and the clearances were 0.18 ml/h and 0.21 ml/h, respectively.","Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16189088/),[ml] / [h],0.21,261477,DB00028,Intravenous Immunoglobulin
,26659791,clearance (CL),"The estimated typical clearance (CL) and central volume of distribution (V1 ) were 184 ml day(-1) and 2.82 l with 24% and 16% between-subject variability (BSV), respectively.",Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26659791/),[ml] / [day],184,261595,DB00028,Intravenous Immunoglobulin
,26659791,central volume of distribution (V1 ),"The estimated typical clearance (CL) and central volume of distribution (V1 ) were 184 ml day(-1) and 2.82 l with 24% and 16% between-subject variability (BSV), respectively.",Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26659791/),l,2.82,261596,DB00028,Intravenous Immunoglobulin
,27513815,plasma bioavailability,The HIRMAb is readily absorbed into the systemic circulation following SQ injection with a 42% plasma bioavailability.,Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513815/),%,42,264967,DB00028,Intravenous Immunoglobulin
,27513815,rate of plasma clearance,"The rate of plasma clearance of the antibody, 0.04-0.06 mL/min/kg, is the same following either IV or SQ administration.",Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513815/),[ml] / [kg·min],0.04-0.06,264968,DB00028,Intravenous Immunoglobulin
,16783465,trough serum IgG levels,"Mean trough serum IgG levels increased from 786 to 1040 mg/dL during the study, a mean increase of 39%.",Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783465/),[mg] / [dl],786 to 1040,264969,DB00028,Intravenous Immunoglobulin
,16635071,terminal half-life,The median terminal half-life of total IgG following administration of the new preparation was 30.1 days.,"Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16635071/),d,30.1,265184,DB00028,Intravenous Immunoglobulin
,16635071,terminal half-lives,"Median terminal half-lives for IgG subclasses IgG(1), IgG(2), IgG(3) and IgG(4) were 28.3, 31.3, 20.9 and 24.2 days, respectively.","Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16635071/),d,28.3,265185,DB00028,Intravenous Immunoglobulin
,16635071,terminal half-lives,"Median terminal half-lives for IgG subclasses IgG(1), IgG(2), IgG(3) and IgG(4) were 28.3, 31.3, 20.9 and 24.2 days, respectively.","Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16635071/),d,31.3,265186,DB00028,Intravenous Immunoglobulin
,16635071,terminal half-lives,"Median terminal half-lives for IgG subclasses IgG(1), IgG(2), IgG(3) and IgG(4) were 28.3, 31.3, 20.9 and 24.2 days, respectively.","Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16635071/),d,20.9,265187,DB00028,Intravenous Immunoglobulin
,16635071,terminal half-lives,"Median terminal half-lives for IgG subclasses IgG(1), IgG(2), IgG(3) and IgG(4) were 28.3, 31.3, 20.9 and 24.2 days, respectively.","Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16635071/),d,24.2,265188,DB00028,Intravenous Immunoglobulin
,16635071,steady-state trough level,The median total serum IgG steady-state trough level was 8.51 g/l.,"Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16635071/),[g] / [l],8.51,265189,DB00028,Intravenous Immunoglobulin
,16635071,rate of mild or moderate infection episodes,The median rate of mild or moderate infection episodes was 0.48 per month.,"Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16635071/),1/[month],0.48,265190,DB00028,Intravenous Immunoglobulin
,16635071,maximum infusion rates,The mean dose per infusion was 0.41 g/kg body weight and the maximum infusion rates recorded were 8 ml/kg/h.,"Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16635071/),[ml] / [h·kg],8,265191,DB00028,Intravenous Immunoglobulin
,2694604,Vdss,"Pharmacokinetic analysis suggests a Vdss of 42 ml/kg, Cl of 3.0 ml/kg/day, a biphasic elimination curve, and a terminal elimination half-life of 24.2 days.",Pharmacokinetics of intravenous immunoglobulin in neonates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2694604/),[ml] / [kg],42,266580,DB00028,Intravenous Immunoglobulin
,2694604,Cl,"Pharmacokinetic analysis suggests a Vdss of 42 ml/kg, Cl of 3.0 ml/kg/day, a biphasic elimination curve, and a terminal elimination half-life of 24.2 days.",Pharmacokinetics of intravenous immunoglobulin in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2694604/),[ml] / [d·kg],3.0,266581,DB00028,Intravenous Immunoglobulin
,2694604,terminal elimination half-life,"Pharmacokinetic analysis suggests a Vdss of 42 ml/kg, Cl of 3.0 ml/kg/day, a biphasic elimination curve, and a terminal elimination half-life of 24.2 days.",Pharmacokinetics of intravenous immunoglobulin in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2694604/),d,24.2,266582,DB00028,Intravenous Immunoglobulin
,20550549,steady-state trough concentration,"The overall mean steady-state trough concentration of plasma total IgG with subcutaneous IGIV-C was 11·4 mg/ml, 18·8% higher than intravenous IGIV-C (9·6 mg/ml).","Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20550549/),[mg] / [ml],11·4,267033,DB00028,Intravenous Immunoglobulin
,20550549,steady-state trough concentration,"The overall mean steady-state trough concentration of plasma total IgG with subcutaneous IGIV-C was 11·4 mg/ml, 18·8% higher than intravenous IGIV-C (9·6 mg/ml).","Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20550549/),[mg] / [ml],9·6,267034,DB00028,Intravenous Immunoglobulin
,32045493,maximum observed serum concentration (Cmax ),"Following an i.v. infusion of 0.06 mg kg-1 TAK-079, maximum observed serum concentration (Cmax ) was 100.4 (%CV: 52) ng mL-1 , time to Cmax was the end of infusion and natural killer (NK_ cells were reduced 93.8 (±8.5) % from baseline levels.","Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32045493/),[ng] / [ml],100.4,268387,DB00028,Intravenous Immunoglobulin
,32045493,Cmax,"Following a s.c. injection of 0.6 mg kg-1 TAK-079, Cmax was 23.0 (%CV: 67) ng mL-1 with time to Cmax of 24 (range 7.98-96.02) hours, and plasmablasts were subsequently reduced 93.4 (±8.8) % from predose levels.","Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32045493/),[ng] / [ml],23.0,268388,DB00028,Intravenous Immunoglobulin
,32045493,time to Cmax,"Following a s.c. injection of 0.6 mg kg-1 TAK-079, Cmax was 23.0 (%CV: 67) ng mL-1 with time to Cmax of 24 (range 7.98-96.02) hours, and plasmablasts were subsequently reduced 93.4 (±8.8) % from predose levels.","Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32045493/),h,24,268389,DB00028,Intravenous Immunoglobulin
,25764208,half-life,Single-dose intravenous and subcutaneous pharmacokinetics studies indicate that ABT-981 has a half-life of 8.0 to 10.4 d in cynomolgus monkey and 10.0 to 20.3 d in rodents.,"Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25764208/),d,8.0 to 10.4,270110,DB00028,Intravenous Immunoglobulin
,25764208,half-life,Single-dose intravenous and subcutaneous pharmacokinetics studies indicate that ABT-981 has a half-life of 8.0 to 10.4 d in cynomolgus monkey and 10.0 to 20.3 d in rodents.,"Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25764208/),d,10.0 to 20.3,270111,DB00028,Intravenous Immunoglobulin
,12095038,time to maximum concentration,The mean time to maximum concentration was 10.5 d (range 4-20 d) and the mean half-life was 20 d (range 13.5-23.5 d).,A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12095038/),d,10.5,270884,DB00028,Intravenous Immunoglobulin
,12095038,half-life,The mean time to maximum concentration was 10.5 d (range 4-20 d) and the mean half-life was 20 d (range 13.5-23.5 d).,A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12095038/),d,20,270885,DB00028,Intravenous Immunoglobulin
,18980631,systemic availability,The mean systemic availability of oral hydroxyzine was 72%.,Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,72,272329,DB00028,Intravenous Immunoglobulin
,18980631,peak concentration,"After oral administration of hydroxyzine, the mean peak concentration of cetirizine was approximately 2.2 microg mL(-1) and that of hydroxyzine 0.16 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),[μg] / [ml],2.2,272330,DB00028,Intravenous Immunoglobulin
,18980631,peak concentration,"After oral administration of hydroxyzine, the mean peak concentration of cetirizine was approximately 2.2 microg mL(-1) and that of hydroxyzine 0.16 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),[μg] / [ml],0.16,272331,DB00028,Intravenous Immunoglobulin
,18980631,terminal half-life,The terminal half-life for cetirizine varied between 10 and 11 h after intravenous and oral administration of hydroxyzine.,Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),h,10 and 11,272332,DB00028,Intravenous Immunoglobulin
,18980631,Maximum inhibition,"Maximum inhibition (82% and 69% for histamine and anticanine IgE-mediated skin reactions, respectively) was observed during the first 8 h, which correlated with a plasma concentration of cetirizine greater than 1.5 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,82,272333,DB00028,Intravenous Immunoglobulin
,18980631,Maximum inhibition,"Maximum inhibition (82% and 69% for histamine and anticanine IgE-mediated skin reactions, respectively) was observed during the first 8 h, which correlated with a plasma concentration of cetirizine greater than 1.5 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,69,272334,DB00028,Intravenous Immunoglobulin
,3395101,serum half-life,The serum half-life of the antibody was approximately 10 h at doses of 0.1 to 7.5 mg/kg and approximately 18 h at a dose of 15 mg/kg.,Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395101/),h,10,272558,DB00028,Intravenous Immunoglobulin
,3395101,serum half-life,The serum half-life of the antibody was approximately 10 h at doses of 0.1 to 7.5 mg/kg and approximately 18 h at a dose of 15 mg/kg.,Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395101/),h,18,272559,DB00028,Intravenous Immunoglobulin
,30156758,Absolute subcutaneous bioavailability,"Absolute subcutaneous bioavailability was ∼80%, and the time to Cmax (tmax ) occurred 6 to 8 days after subcutaneous administration.","Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156758/),%,∼80,273264,DB00028,Intravenous Immunoglobulin
,30156758,time to Cmax (tmax ),"Absolute subcutaneous bioavailability was ∼80%, and the time to Cmax (tmax ) occurred 6 to 8 days after subcutaneous administration.","Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156758/),d,6 to 8,273265,DB00028,Intravenous Immunoglobulin
,30156758,elimination half-life (t½ ),The terminal-phase harmonic mean elimination half-life (t½ ) ranged from 5.5 to 11 days following intravenous and subcutaneous administration.,"Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156758/),d,5.5 to 11,273266,DB00028,Intravenous Immunoglobulin
,30156758,Cmax,"Following the fourth dose, Cmax was 7.69 μg/mL, and tmax occurred ∼4 days after dosing; t½ was ∼16 days.","Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156758/),[μg] / [ml],7.69,273267,DB00028,Intravenous Immunoglobulin
,30156758,t½,"Following the fourth dose, Cmax was 7.69 μg/mL, and tmax occurred ∼4 days after dosing; t½ was ∼16 days.","Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156758/),d,∼16,273268,DB00028,Intravenous Immunoglobulin
,27886407,terminal half-life,Serum PRX002 exposure was dose proportional; the average terminal half-life across all doses was 18.2 days.,"First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886407/),d,18.2,273483,DB00028,Intravenous Immunoglobulin
,7725671,half-life,"The 5S-IVIG had a half-life with a median of 0.24 (distribution) and 2.0 (terminal) days, respectively.",Pharmacokinetics of single and multiple infusions of 5S intravenous immunoglobulin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7725671/),d,0.24,273694,DB00028,Intravenous Immunoglobulin
,7725671,half-life,"The 5S-IVIG had a half-life with a median of 0.24 (distribution) and 2.0 (terminal) days, respectively.",Pharmacokinetics of single and multiple infusions of 5S intravenous immunoglobulin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7725671/),d,2.0,273695,DB00028,Intravenous Immunoglobulin
